Background  ||| S:24 E:43 ||| NN
A  ||| S:43 E:45 ||| DT
plethora  ||| S:45 E:54 ||| NN
of  ||| S:54 E:57 ||| IN
circumstantial  ||| S:57 E:72 ||| JJ
evidence  ||| S:72 E:81 ||| NN
implicates  ||| S:81 E:100 ||| NN
downregulation  ||| S:100 E:115 ||| NN
of  ||| S:115 E:118 ||| IN
the  ||| S:118 E:122 ||| DT
cyclin-dependent  ||| S:122 E:139 ||| JJ
kinase  ||| S:139 E:146 ||| NNS
( ||| S:146 E:147 ||| -LRB-
CDK ||| S:147 E:150 ||| NNP
)  ||| S:150 E:160 ||| -RRB-
inhibitor  ||| S:160 E:170 ||| JJ
p27  ||| S:170 E:174 ||| NN
in  ||| S:174 E:177 ||| IN
prostate  ||| S:177 E:186 ||| JJ
cancer ||| S:186 E:192 ||| NN
.  ||| S:192 E:194 ||| .
While  ||| S:194 E:200 ||| IN
greater  ||| S:200 E:208 ||| JJR
than  ||| S:208 E:213 ||| IN
85 ||| S:213 E:215 ||| CD
%  ||| S:215 E:217 ||| NN
of  ||| S:217 E:228 ||| IN
terminally  ||| S:228 E:239 ||| JJ
differentiated  ||| S:239 E:254 ||| JJ
secretory  ||| S:254 E:264 ||| JJ
cells  ||| S:264 E:270 ||| NNS
in  ||| S:270 E:273 ||| IN
normal  ||| S:273 E:280 ||| JJ
human  ||| S:280 E:294 ||| JJ
prostate  ||| S:294 E:303 ||| NNS
display  ||| S:303 E:311 ||| VBP
strong  ||| S:311 E:318 ||| JJ
nuclear  ||| S:318 E:326 ||| JJ
staining  ||| S:326 E:335 ||| NN
for  ||| S:335 E:339 ||| IN
p27 ||| S:339 E:342 ||| NNP
,  ||| S:342 E:344 ||| ,
all  ||| S:344 E:348 ||| DT
cases  ||| S:348 E:362 ||| NNS
of  ||| S:362 E:365 ||| IN
high-grade  ||| S:365 E:376 ||| JJ
prostatic  ||| S:376 E:386 ||| JJ
intraepithelial  ||| S:386 E:402 ||| JJ
neoplasia ||| S:402 E:411 ||| NN
,  ||| S:411 E:413 ||| ,
invasive  ||| S:413 E:430 ||| JJ
carcinoma ||| S:430 E:439 ||| NN
,  ||| S:439 E:441 ||| ,
and  ||| S:441 E:445 ||| CC
pelvic  ||| S:445 E:452 ||| JJ
lymph  ||| S:452 E:458 ||| NN
node  ||| S:458 E:463 ||| NNS
metastases  ||| S:463 E:474 ||| VBP
studied  ||| S:474 E:482 ||| VBN
by  ||| S:482 E:493 ||| IN
DeMarzo  ||| S:493 E:510 ||| NNP
et  ||| S:510 E:513 ||| NNP
al.  ||| S:513 E:517 ||| NNP
showed  ||| S:517 E:524 ||| VBD
down-regulation  ||| S:524 E:540 ||| JJ
of  ||| S:540 E:543 ||| IN
p27  ||| S:543 E:555 ||| NNP
[  ||| S:555 E:557 ||| -LRB-
1  ||| S:557 E:559 ||| LS
]  ||| S:559 E:561 ||| -RRB-
.  ||| S:561 E:563 ||| .
In  ||| S:563 E:566 ||| IN
addition ||| S:566 E:574 ||| NN
,  ||| S:574 E:576 ||| ,
low  ||| S:576 E:580 ||| JJ
p27  ||| S:580 E:584 ||| CD
expression  ||| S:584 E:595 ||| NN
correlates  ||| S:595 E:606 ||| NN
with  ||| S:606 E:619 ||| IN
higher  ||| S:619 E:626 ||| JJR
mean  ||| S:626 E:631 ||| JJ
Gleason  ||| S:631 E:639 ||| JJ
scores ||| S:639 E:645 ||| NNS
,  ||| S:645 E:647 ||| ,
a  ||| S:647 E:649 ||| DT
number  ||| S:649 E:656 ||| NN
of  ||| S:656 E:659 ||| IN
prognostic  ||| S:659 E:678 ||| JJ
morphological  ||| S:678 E:692 ||| JJ
features ||| S:692 E:700 ||| NNS
,  ||| S:700 E:702 ||| ,
and  ||| S:702 E:706 ||| CC
decreased  ||| S:706 E:716 ||| JJ
survival  ||| S:716 E:725 ||| NN
[  ||| S:725 E:727 ||| -LRB-
2  ||| S:727 E:729 ||| CD
3  ||| S:729 E:731 ||| CD
4  ||| S:731 E:733 ||| CD
]  ||| S:733 E:735 ||| -RRB-
.  ||| S:735 E:745 ||| .
Thus ||| S:745 E:749 ||| RB
,  ||| S:749 E:751 ||| ,
p27  ||| S:751 E:755 ||| NNP
may  ||| S:755 E:759 ||| MD
be  ||| S:759 E:762 ||| VB
a  ||| S:762 E:764 ||| DT
prostate  ||| S:764 E:773 ||| JJ
tumor  ||| S:773 E:779 ||| NN
suppressor ||| S:779 E:789 ||| NN
.  ||| S:789 E:799 ||| .
In  ||| S:799 E:802 ||| IN
support  ||| S:802 E:810 ||| NN
of  ||| S:810 E:813 ||| IN
this  ||| S:813 E:818 ||| DT
notion ||| S:818 E:824 ||| NN
,  ||| S:824 E:826 ||| ,
the  ||| S:826 E:830 ||| DT
p27  ||| S:830 E:834 ||| JJ
protein  ||| S:834 E:842 ||| NN
has  ||| S:842 E:846 ||| VBZ
been  ||| S:846 E:859 ||| VBN
identified  ||| S:859 E:870 ||| VBN
as  ||| S:870 E:873 ||| IN
a  ||| S:873 E:875 ||| DT
target  ||| S:875 E:882 ||| NN
of  ||| S:882 E:885 ||| IN
viral  ||| S:885 E:891 ||| JJ
oncoproteins  ||| S:891 E:904 ||| NNS
[  ||| S:904 E:906 ||| -LRB-
5  ||| S:906 E:908 ||| CD
6  ||| S:908 E:910 ||| CD
]  ||| S:910 E:912 ||| -RRB-
.  ||| S:912 E:922 ||| .
However ||| S:922 E:929 ||| RB
,  ||| S:929 E:931 ||| ,
unlike  ||| S:931 E:938 ||| IN
traditional  ||| S:938 E:950 ||| JJ
tumor  ||| S:950 E:956 ||| NN
suppressors ||| S:956 E:967 ||| NN
,  ||| S:967 E:969 ||| ,
the  ||| S:969 E:973 ||| DT
p27  ||| S:973 E:977 ||| JJ
gene  ||| S:977 E:990 ||| NN
rarely  ||| S:990 E:997 ||| RB
shows  ||| S:997 E:1003 ||| VBZ
homozygous  ||| S:1003 E:1014 ||| JJ
inactivation  ||| S:1014 E:1027 ||| NN
in  ||| S:1027 E:1030 ||| IN
cancer  ||| S:1030 E:1037 ||| NN
cells  ||| S:1037 E:1043 ||| NNS
[  ||| S:1043 E:1045 ||| -LRB-
7  ||| S:1045 E:1047 ||| CD
8  ||| S:1047 E:1057 ||| CD
9  ||| S:1057 E:1059 ||| CD
]  ||| S:1059 E:1061 ||| -RRB-
,  ||| S:1061 E:1063 ||| ,
a  ||| S:1063 E:1065 ||| DT
finding  ||| S:1065 E:1073 ||| NN
that  ||| S:1073 E:1078 ||| IN
points  ||| S:1078 E:1085 ||| NNS
towards  ||| S:1085 E:1093 ||| IN
alternative  ||| S:1093 E:1105 ||| JJ
mechanisms  ||| S:1105 E:1124 ||| NNS
of  ||| S:1124 E:1127 ||| IN
p27  ||| S:1127 E:1131 ||| FW
inactivation.  ||| S:1131 E:1153 ||| FW
p27  ||| S:1153 E:1157 ||| FW
specifically  ||| S:1157 E:1170 ||| FW
inhibits  ||| S:1170 E:1179 ||| FW
CDKs ||| S:1179 E:1183 ||| FW
,  ||| S:1183 E:1185 ||| ,
which  ||| S:1185 E:1191 ||| WDT
mediate  ||| S:1191 E:1199 ||| JJ
entry  ||| S:1199 E:1205 ||| NN
into  ||| S:1205 E:1218 ||| IN
S  ||| S:1218 E:1220 ||| NNP
phase  ||| S:1220 E:1226 ||| NN
[  ||| S:1226 E:1228 ||| -LRB-
10  ||| S:1228 E:1231 ||| CD
11  ||| S:1231 E:1234 ||| CD
]  ||| S:1234 E:1236 ||| -RRB-
.  ||| S:1236 E:1238 ||| .
The  ||| S:1238 E:1242 ||| DT
level  ||| S:1242 E:1248 ||| NN
of  ||| S:1248 E:1251 ||| IN
p27  ||| S:1251 E:1255 ||| NNP
is  ||| S:1255 E:1258 ||| VBZ
higher  ||| S:1258 E:1265 ||| JJR
in  ||| S:1265 E:1268 ||| IN
quiescent  ||| S:1268 E:1286 ||| NN
than  ||| S:1286 E:1291 ||| IN
in  ||| S:1291 E:1294 ||| IN
proliferating  ||| S:1294 E:1308 ||| VBG
cells ||| S:1308 E:1313 ||| NNS
,  ||| S:1313 E:1315 ||| ,
and  ||| S:1315 E:1319 ||| CC
this  ||| S:1319 E:1324 ||| DT
increase  ||| S:1324 E:1333 ||| NN
in  ||| S:1333 E:1336 ||| IN
p27  ||| S:1336 E:1348 ||| CD
abundance  ||| S:1348 E:1358 ||| NN
is  ||| S:1358 E:1361 ||| VBZ
required  ||| S:1361 E:1370 ||| VBN
for  ||| S:1370 E:1374 ||| IN
an  ||| S:1374 E:1377 ||| DT
effective  ||| S:1377 E:1387 ||| JJ
cell  ||| S:1387 E:1392 ||| NN
cycle  ||| S:1392 E:1398 ||| NN
exit  ||| S:1398 E:1403 ||| NN
[  ||| S:1403 E:1405 ||| -LRB-
12  ||| S:1405 E:1416 ||| CD
]  ||| S:1416 E:1418 ||| -RRB-
.  ||| S:1418 E:1420 ||| .
The  ||| S:1420 E:1424 ||| DT
cell  ||| S:1424 E:1429 ||| NN
cycle-dependent  ||| S:1429 E:1445 ||| JJ
variations  ||| S:1445 E:1456 ||| NNS
in  ||| S:1456 E:1459 ||| IN
p27  ||| S:1459 E:1463 ||| CD
levels  ||| S:1463 E:1470 ||| NNS
are  ||| S:1470 E:1482 ||| VBP
not  ||| S:1482 E:1486 ||| RB
reflected  ||| S:1486 E:1496 ||| VBN
by  ||| S:1496 E:1499 ||| IN
similar  ||| S:1499 E:1507 ||| JJ
changes  ||| S:1507 E:1515 ||| NNS
in  ||| S:1515 E:1518 ||| IN
p27  ||| S:1518 E:1522 ||| NNP
mRNA  ||| S:1522 E:1527 ||| NNP
[  ||| S:1527 E:1529 ||| -LRB-
13  ||| S:1529 E:1532 ||| CD
]  ||| S:1532 E:1534 ||| -RRB-
.  ||| S:1534 E:1536 ||| .
Many  ||| S:1536 E:1549 ||| JJ
aggressive  ||| S:1549 E:1560 ||| JJ
prostate  ||| S:1560 E:1569 ||| NN
cancers  ||| S:1569 E:1577 ||| NNS
display  ||| S:1577 E:1585 ||| VBP
decreased  ||| S:1585 E:1595 ||| VBN
p27  ||| S:1595 E:1599 ||| CD
protein  ||| S:1599 E:1615 ||| NN
levels  ||| S:1615 E:1622 ||| NNS
in  ||| S:1622 E:1625 ||| IN
the  ||| S:1625 E:1629 ||| DT
presence  ||| S:1629 E:1638 ||| NN
of  ||| S:1638 E:1641 ||| IN
high  ||| S:1641 E:1646 ||| JJ
p27  ||| S:1646 E:1650 ||| NNP
mRNA  ||| S:1650 E:1655 ||| NNP
[  ||| S:1655 E:1657 ||| -LRB-
14  ||| S:1657 E:1660 ||| CD
]  ||| S:1660 E:1662 ||| -RRB-
,  ||| S:1662 E:1664 ||| ,
suggesting  ||| S:1664 E:1683 ||| VBG
that  ||| S:1683 E:1688 ||| IN
p27  ||| S:1688 E:1692 ||| CD
depletion  ||| S:1692 E:1702 ||| NN
may  ||| S:1702 E:1706 ||| MD
result  ||| S:1706 E:1713 ||| VB
from  ||| S:1713 E:1718 ||| IN
ectopic  ||| S:1718 E:1726 ||| JJ
proteolysis ||| S:1726 E:1737 ||| NN
.  ||| S:1737 E:1739 ||| .
In  ||| S:1739 E:1750 ||| IN
fact ||| S:1750 E:1754 ||| NN
,  ||| S:1754 E:1756 ||| ,
p27  ||| S:1756 E:1760 ||| CD
depletion  ||| S:1760 E:1770 ||| NN
in  ||| S:1770 E:1773 ||| IN
several  ||| S:1773 E:1781 ||| JJ
cancers  ||| S:1781 E:1789 ||| NNS
was  ||| S:1789 E:1793 ||| VBD
shown  ||| S:1793 E:1799 ||| VBN
to  ||| S:1799 E:1802 ||| TO
result  ||| S:1802 E:1817 ||| VB
from  ||| S:1817 E:1822 ||| IN
increased  ||| S:1822 E:1832 ||| JJ
proteolysis  ||| S:1832 E:1844 ||| NN
via  ||| S:1844 E:1848 ||| IN
the  ||| S:1848 E:1852 ||| DT
ubiquitin ||| S:1852 E:1861 ||| JJ
/ ||| S:1861 E:1862 ||| CD
proteasome  ||| S:1862 E:1881 ||| JJ
system  ||| S:1881 E:1888 ||| NN
[  ||| S:1888 E:1890 ||| -LRB-
15  ||| S:1890 E:1893 ||| CD
16  ||| S:1893 E:1896 ||| CD
17  ||| S:1896 E:1899 ||| CD
18  ||| S:1899 E:1902 ||| CD
]  ||| S:1902 E:1904 ||| -RRB-
.  ||| S:1904 E:1914 ||| .
This  ||| S:1914 E:1919 ||| DT
system  ||| S:1919 E:1926 ||| NN
employs  ||| S:1926 E:1934 ||| VBZ
a  ||| S:1934 E:1936 ||| DT
cascade  ||| S:1936 E:1944 ||| NN
of  ||| S:1944 E:1947 ||| IN
enzymatic  ||| S:1947 E:1957 ||| JJ
reactions  ||| S:1957 E:1975 ||| NNS
that  ||| S:1975 E:1980 ||| IN
covalently  ||| S:1980 E:1991 ||| NNS
attach  ||| S:1991 E:1998 ||| VBP
a  ||| S:1998 E:2000 ||| DT
ubiquitin  ||| S:2000 E:2010 ||| JJ
chain  ||| S:2010 E:2016 ||| NN
to  ||| S:2016 E:2019 ||| TO
substrate  ||| S:2019 E:2037 ||| VB
proteins ||| S:2037 E:2045 ||| NNS
,  ||| S:2045 E:2047 ||| ,
thereby  ||| S:2047 E:2055 ||| RB
targeting  ||| S:2055 E:2065 ||| VBG
them  ||| S:2065 E:2070 ||| PRP
to  ||| S:2070 E:2073 ||| TO
the  ||| S:2073 E:2077 ||| DT
proteasome  ||| S:2077 E:2088 ||| NN
[  ||| S:2088 E:2090 ||| -LRB-
19  ||| S:2090 E:2093 ||| CD
]  ||| S:2093 E:2095 ||| -RRB-
.  ||| S:2095 E:2105 ||| .
The  ||| S:2105 E:2109 ||| DT
ubiquitin  ||| S:2109 E:2119 ||| JJ
transfer  ||| S:2119 E:2128 ||| NN
reaction  ||| S:2128 E:2137 ||| NN
involves  ||| S:2137 E:2146 ||| VBZ
three  ||| S:2146 E:2152 ||| CD
enzymes ||| S:2152 E:2159 ||| NNS
:  ||| S:2159 E:2161 ||| :
E1 ||| S:2161 E:2163 ||| CD
,  ||| S:2163 E:2173 ||| ,
which  ||| S:2173 E:2179 ||| WDT
mediates  ||| S:2179 E:2188 ||| VBZ
the  ||| S:2188 E:2192 ||| DT
ATP-dependent  ||| S:2192 E:2206 ||| JJ
activation  ||| S:2206 E:2217 ||| NN
of  ||| S:2217 E:2220 ||| IN
ubiquitin ||| S:2220 E:2229 ||| NN
,  ||| S:2229 E:2239 ||| ,
and  ||| S:2239 E:2243 ||| CC
E2 ||| S:2243 E:2245 ||| NNP
,  ||| S:2245 E:2247 ||| ,
or  ||| S:2247 E:2250 ||| CC
ubiquitin  ||| S:2250 E:2260 ||| FW
conjugating  ||| S:2260 E:2272 ||| FW
enzyme  ||| S:2272 E:2279 ||| FW
( ||| S:2279 E:2280 ||| -LRB-
UBC ||| S:2280 E:2283 ||| NNP
) ||| S:2283 E:2284 ||| -RRB-
,  ||| S:2284 E:2286 ||| ,
which ||| S:2286 E:2291 ||| WDT
,  ||| S:2291 E:2301 ||| ,
together  ||| S:2301 E:2310 ||| RB
with  ||| S:2310 E:2315 ||| IN
an  ||| S:2315 E:2318 ||| DT
E3  ||| S:2318 E:2321 ||| FW
ubiquitin  ||| S:2321 E:2331 ||| FW
ligase ||| S:2331 E:2337 ||| FW
,  ||| S:2337 E:2339 ||| ,
transfers  ||| S:2339 E:2349 ||| VBZ
ubiquitin  ||| S:2349 E:2367 ||| VBN
to  ||| S:2367 E:2370 ||| TO
the  ||| S:2370 E:2374 ||| DT
target  ||| S:2374 E:2381 ||| NN
protein ||| S:2381 E:2388 ||| NN
.  ||| S:2388 E:2398 ||| .
Biochemical  ||| S:2398 E:2410 ||| JJ
studies  ||| S:2410 E:2418 ||| NNS
identified  ||| S:2418 E:2429 ||| VBD
SCF  ||| S:2429 E:2433 ||| NNP
SKP2 ||| S:2433 E:2437 ||| NNP
,  ||| S:2437 E:2439 ||| ,
an  ||| S:2439 E:2442 ||| DT
E3  ||| S:2442 E:2445 ||| NN
that  ||| S:2445 E:2458 ||| IN
mediates  ||| S:2458 E:2467 ||| FW
p27  ||| S:2467 E:2471 ||| FW
ubiquitylation  ||| S:2471 E:2495 ||| FW
in  ||| S:2495 E:2498 ||| FW
vitro  ||| S:2498 E:2504 ||| FW
[  ||| S:2504 E:2506 ||| -LRB-
20  ||| S:2506 E:2509 ||| CD
21  ||| S:2509 E:2512 ||| CD
]  ||| S:2512 E:2514 ||| -RRB-
.  ||| S:2514 E:2516 ||| .
This  ||| S:2516 E:2521 ||| DT
complex  ||| S:2521 E:2537 ||| NN
consists  ||| S:2537 E:2546 ||| VBZ
of  ||| S:2546 E:2549 ||| IN
at  ||| S:2549 E:2552 ||| IN
least  ||| S:2552 E:2558 ||| JJS
four  ||| S:2558 E:2563 ||| CD
proteins ||| S:2563 E:2571 ||| NNS
:  ||| S:2571 E:2573 ||| :
SKP1 ||| S:2573 E:2577 ||| CD
,  ||| S:2577 E:2579 ||| ,
CUL1 ||| S:2579 E:2583 ||| NNP
,  ||| S:2583 E:2585 ||| ,
HRT1  ||| S:2585 E:2598 ||| NNP
( ||| S:2598 E:2599 ||| -LRB-
=RBX1 ||| S:2599 E:2604 ||| CD
/ ||| S:2604 E:2605 ||| CD
ROC1 ||| S:2605 E:2609 ||| CD
) ||| S:2609 E:2610 ||| -RRB-
,  ||| S:2610 E:2612 ||| ,
and  ||| S:2612 E:2616 ||| CC
SKP2 ||| S:2616 E:2620 ||| NNP
.  ||| S:2620 E:2622 ||| .
SKP2  ||| S:2622 E:2627 ||| NNP
contains  ||| S:2627 E:2636 ||| VBZ
a  ||| S:2636 E:2638 ||| DT
so-called  ||| S:2638 E:2648 ||| JJ
F-box ||| S:2648 E:2653 ||| NN
,  ||| S:2653 E:2663 ||| ,
which  ||| S:2663 E:2669 ||| WDT
mediates  ||| S:2669 E:2678 ||| VBP
binding  ||| S:2678 E:2686 ||| VBG
to  ||| S:2686 E:2689 ||| TO
SKP1 ||| S:2689 E:2693 ||| CD
,  ||| S:2693 E:2695 ||| ,
and  ||| S:2695 E:2699 ||| CC
C-terminal  ||| S:2699 E:2710 ||| JJ
leucine-rich  ||| S:2710 E:2731 ||| JJ
repeats  ||| S:2731 E:2739 ||| NNS
that  ||| S:2739 E:2744 ||| WDT
recognize  ||| S:2744 E:2754 ||| VBP
p27 ||| S:2754 E:2757 ||| CD
.  ||| S:2757 E:2759 ||| .
CUL1 ||| S:2759 E:2763 ||| NNP
,  ||| S:2763 E:2765 ||| ,
in  ||| S:2765 E:2768 ||| IN
turn  ||| S:2768 E:2773 ||| NN
binds  ||| S:2773 E:2779 ||| NN
to  ||| S:2779 E:2782 ||| TO
SKP1 ||| S:2782 E:2786 ||| CD
,  ||| S:2786 E:2796 ||| ,
and  ||| S:2796 E:2800 ||| CC
together  ||| S:2800 E:2809 ||| RB
with  ||| S:2809 E:2814 ||| IN
HRT1 ||| S:2814 E:2818 ||| NNP
,  ||| S:2818 E:2820 ||| ,
mediates  ||| S:2820 E:2829 ||| VBG
the  ||| S:2829 E:2833 ||| DT
interaction  ||| S:2833 E:2845 ||| NN
with  ||| S:2845 E:2850 ||| IN
the  ||| S:2850 E:2862 ||| DT
ubiquitin-conjugating  ||| S:2862 E:2884 ||| JJ
enzyme  ||| S:2884 E:2891 ||| NN
CDC34 ||| S:2891 E:2896 ||| CD
/ ||| S:2896 E:2897 ||| CD
UBC3 ||| S:2897 E:2901 ||| CD
.  ||| S:2901 E:2903 ||| .
CKS1 ||| S:2903 E:2907 ||| NNP
,  ||| S:2907 E:2909 ||| ,
a  ||| S:2909 E:2911 ||| DT
small  ||| S:2911 E:2925 ||| JJ
protein  ||| S:2925 E:2933 ||| NN
that  ||| S:2933 E:2938 ||| IN
associates  ||| S:2938 E:2949 ||| NNS
with  ||| S:2949 E:2954 ||| IN
CDKs  ||| S:2954 E:2959 ||| JJ
and  ||| S:2959 E:2963 ||| CC
greatly  ||| S:2963 E:2971 ||| RB
stimulates  ||| S:2971 E:2990 ||| CD
p27  ||| S:2990 E:2994 ||| CD
ubiquitylation ||| S:2994 E:3008 ||| NN
,  ||| S:3008 E:3010 ||| ,
was  ||| S:3010 E:3014 ||| VBD
recently  ||| S:3014 E:3023 ||| RB
identified  ||| S:3023 E:3034 ||| VBN
as  ||| S:3034 E:3037 ||| IN
a  ||| S:3037 E:3039 ||| DT
forth  ||| S:3039 E:3045 ||| JJ
SCF  ||| S:3045 E:3057 ||| NNP
SKP2component  ||| S:3057 E:3071 ||| NNP
[  ||| S:3071 E:3073 ||| -LRB-
22  ||| S:3073 E:3076 ||| CD
23  ||| S:3076 E:3079 ||| CD
]  ||| S:3079 E:3081 ||| -RRB-
.  ||| S:3081 E:3091 ||| .
Two  ||| S:3091 E:3095 ||| CD
rate-limiting  ||| S:3095 E:3109 ||| JJ
steps  ||| S:3109 E:3115 ||| NNS
for  ||| S:3115 E:3119 ||| IN
p27  ||| S:3119 E:3123 ||| CD
ubiquitylation  ||| S:3123 E:3138 ||| NNS
were  ||| S:3138 E:3151 ||| VBD
defined ||| S:3151 E:3158 ||| VBN
:  ||| S:3158 E:3160 ||| :
( ||| S:3160 E:3161 ||| -LRB-
1. ||| S:3161 E:3163 ||| CD
)  ||| S:3163 E:3165 ||| -RRB-
phosphorylation  ||| S:3165 E:3181 ||| NN
of  ||| S:3181 E:3184 ||| IN
p27  ||| S:3184 E:3188 ||| CD
by  ||| S:3188 E:3191 ||| IN
CDK2  ||| S:3191 E:3196 ||| CD
at  ||| S:3196 E:3199 ||| IN
threonine  ||| S:3199 E:3217 ||| CD
187  ||| S:3217 E:3221 ||| CD
[  ||| S:3221 E:3223 ||| -LRB-
24  ||| S:3223 E:3226 ||| CD
25  ||| S:3226 E:3229 ||| CD
26  ||| S:3229 E:3232 ||| CD
]  ||| S:3232 E:3234 ||| -RRB-
,  ||| S:3234 E:3236 ||| ,
and  ||| S:3236 E:3240 ||| CC
( ||| S:3240 E:3241 ||| -LRB-
2. ||| S:3241 E:3243 ||| NNP
)  ||| S:3243 E:3245 ||| -RRB-
binding  ||| S:3245 E:3253 ||| NN
of  ||| S:3253 E:3256 ||| IN
phosphorylated  ||| S:3256 E:3271 ||| CD
p27  ||| S:3271 E:3283 ||| CD
to  ||| S:3283 E:3286 ||| TO
SKP2  ||| S:3286 E:3291 ||| CD
[  ||| S:3291 E:3293 ||| -LRB-
20  ||| S:3293 E:3296 ||| CD
21  ||| S:3296 E:3299 ||| CD
]  ||| S:3299 E:3301 ||| -RRB-
.  ||| S:3301 E:3303 ||| .
SKP2  ||| S:3303 E:3308 ||| NNP
is  ||| S:3308 E:3311 ||| VBZ
down-regulated  ||| S:3311 E:3326 ||| JJ
in  ||| S:3326 E:3329 ||| IN
resting  ||| S:3329 E:3337 ||| JJ
cells  ||| S:3337 E:3351 ||| NNS
with  ||| S:3351 E:3356 ||| IN
stable  ||| S:3356 E:3363 ||| JJ
p27 ||| S:3363 E:3366 ||| NN
,  ||| S:3366 E:3368 ||| ,
but  ||| S:3368 E:3372 ||| CC
strongly  ||| S:3372 E:3381 ||| RB
up-regulated  ||| S:3381 E:3394 ||| JJ
in  ||| S:3394 E:3397 ||| IN
cells ||| S:3397 E:3402 ||| NNS
,  ||| S:3402 E:3404 ||| ,
which  ||| S:3404 E:3418 ||| WDT
progress  ||| S:3418 E:3427 ||| NN
into  ||| S:3427 E:3432 ||| IN
S  ||| S:3432 E:3434 ||| NNP
phase  ||| S:3434 E:3440 ||| NN
[  ||| S:3440 E:3442 ||| -LRB-
27  ||| S:3442 E:3445 ||| CD
28  ||| S:3445 E:3448 ||| CD
]  ||| S:3448 E:3450 ||| -RRB-
.  ||| S:3450 E:3452 ||| .
In  ||| S:3452 E:3455 ||| IN
some  ||| S:3455 E:3460 ||| DT
tissue  ||| S:3460 E:3467 ||| NN
culture  ||| S:3467 E:3483 ||| NN
cells ||| S:3483 E:3488 ||| NNS
,  ||| S:3488 E:3490 ||| ,
overexpression  ||| S:3490 E:3505 ||| VBG
of  ||| S:3505 E:3508 ||| IN
SKP2  ||| S:3508 E:3513 ||| NNP
is  ||| S:3513 E:3516 ||| VBZ
sufficient  ||| S:3516 E:3527 ||| JJ
to  ||| S:3527 E:3530 ||| TO
induce  ||| S:3530 E:3537 ||| VB
p27  ||| S:3537 E:3549 ||| CD
degradation  ||| S:3549 E:3561 ||| NNS
and  ||| S:3561 E:3565 ||| CC
S  ||| S:3565 E:3567 ||| NNP
phase  ||| S:3567 E:3573 ||| NN
entry  ||| S:3573 E:3579 ||| NN
[  ||| S:3579 E:3581 ||| -LRB-
29  ||| S:3581 E:3584 ||| CD
30  ||| S:3584 E:3587 ||| CD
31  ||| S:3587 E:3590 ||| CD
32  ||| S:3590 E:3593 ||| CD
]  ||| S:3593 E:3595 ||| -RRB-
,  ||| S:3595 E:3597 ||| ,
and  ||| S:3597 E:3601 ||| CC
can  ||| S:3601 E:3613 ||| MD
cooperate  ||| S:3613 E:3623 ||| VB
with  ||| S:3623 E:3637 ||| IN
ras  ||| S:3637 E:3641 ||| NN
in  ||| S:3641 E:3644 ||| IN
transformation  ||| S:3644 E:3659 ||| NN
[  ||| S:3659 E:3661 ||| -LRB-
33  ||| S:3661 E:3664 ||| CD
34  ||| S:3664 E:3667 ||| CD
]  ||| S:3667 E:3669 ||| -RRB-
.  ||| S:3669 E:3679 ||| .
Significantly ||| S:3679 E:3692 ||| RB
,  ||| S:3692 E:3694 ||| ,
overexpression  ||| S:3694 E:3709 ||| VBG
of  ||| S:3709 E:3712 ||| IN
SKP2  ||| S:3712 E:3717 ||| NNP
has  ||| S:3717 E:3721 ||| VBZ
been  ||| S:3721 E:3726 ||| VBN
observed  ||| S:3726 E:3735 ||| VBN
in  ||| S:3735 E:3746 ||| IN
many  ||| S:3746 E:3751 ||| JJ
cancer  ||| S:3751 E:3758 ||| NN
cell  ||| S:3758 E:3763 ||| NN
lines  ||| S:3763 E:3769 ||| NNS
[  ||| S:3769 E:3771 ||| -LRB-
28  ||| S:3771 E:3774 ||| CD
35  ||| S:3774 E:3777 ||| CD
]  ||| S:3777 E:3779 ||| -RRB-
as  ||| S:3779 E:3782 ||| IN
well  ||| S:3782 E:3787 ||| RB
as  ||| S:3787 E:3790 ||| RB
in  ||| S:3790 E:3793 ||| IN
primary  ||| S:3793 E:3809 ||| JJ
cancer  ||| S:3809 E:3816 ||| NN
specimens  ||| S:3816 E:3826 ||| NNS
and  ||| S:3826 E:3830 ||| CC
many  ||| S:3830 E:3835 ||| JJ
of  ||| S:3835 E:3838 ||| IN
these  ||| S:3838 E:3844 ||| DT
tumors  ||| S:3844 E:3851 ||| NNS
also  ||| S:3851 E:3856 ||| RB
display  ||| S:3856 E:3872 ||| VB
down-regulation  ||| S:3872 E:3888 ||| JJ
of  ||| S:3888 E:3891 ||| IN
p27  ||| S:3891 E:3895 ||| NNP
[  ||| S:3895 E:3897 ||| -LRB-
33  ||| S:3897 E:3900 ||| CD
36  ||| S:3900 E:3903 ||| CD
37  ||| S:3903 E:3906 ||| CD
38  ||| S:3906 E:3909 ||| CD
]  ||| S:3909 E:3911 ||| -RRB-
.  ||| S:3911 E:3921 ||| .
Here ||| S:3921 E:3925 ||| RB
,  ||| S:3925 E:3927 ||| ,
we  ||| S:3927 E:3930 ||| PRP
used  ||| S:3930 E:3935 ||| VBD
the  ||| S:3935 E:3939 ||| DT
androgen-sensitive  ||| S:3939 E:3958 ||| JJ
human  ||| S:3958 E:3964 ||| JJ
prostate  ||| S:3964 E:3981 ||| JJ
cancer  ||| S:3981 E:3988 ||| NN
cell  ||| S:3988 E:3993 ||| NN
line  ||| S:3993 E:3998 ||| NN
LNCaP  ||| S:3998 E:4004 ||| NNS
[  ||| S:4004 E:4006 ||| -LRB-
39  ||| S:4006 E:4009 ||| CD
]  ||| S:4009 E:4011 ||| -RRB-
as  ||| S:4011 E:4014 ||| IN
a  ||| S:4014 E:4016 ||| DT
model  ||| S:4016 E:4022 ||| NN
system  ||| S:4022 E:4029 ||| NN
to  ||| S:4029 E:4032 ||| TO
address  ||| S:4032 E:4048 ||| VB
the  ||| S:4048 E:4052 ||| DT
role  ||| S:4052 E:4057 ||| NN
of  ||| S:4057 E:4060 ||| IN
SKP2  ||| S:4060 E:4065 ||| CD
in  ||| S:4065 E:4068 ||| IN
androgen-mediated  ||| S:4068 E:4086 ||| JJ
cell  ||| S:4086 E:4091 ||| NN
cycle  ||| S:4091 E:4097 ||| NN
control ||| S:4097 E:4104 ||| NN
.  ||| S:4104 E:4114 ||| .
This  ||| S:4114 E:4119 ||| DT
cell  ||| S:4119 E:4124 ||| NN
line  ||| S:4124 E:4129 ||| NN
undergoes  ||| S:4129 E:4139 ||| VBD
reversible  ||| S:4139 E:4150 ||| CD
G1  ||| S:4150 E:4153 ||| CD
arrest  ||| S:4153 E:4160 ||| NN
in  ||| S:4160 E:4163 ||| IN
response  ||| S:4163 E:4180 ||| NN
to  ||| S:4180 E:4183 ||| TO
androgens  ||| S:4183 E:4193 ||| VB
[  ||| S:4193 E:4195 ||| -LRB-
40  ||| S:4195 E:4198 ||| CD
41  ||| S:4198 E:4201 ||| CD
42  ||| S:4201 E:4204 ||| CD
43  ||| S:4204 E:4207 ||| CD
44  ||| S:4207 E:4210 ||| CD
]  ||| S:4210 E:4212 ||| -RRB-
.  ||| S:4212 E:4214 ||| .
The  ||| S:4214 E:4218 ||| DT
G1  ||| S:4218 E:4221 ||| JJ
arrest  ||| S:4221 E:4228 ||| NN
is  ||| S:4228 E:4239 ||| VBZ
accompanied  ||| S:4239 E:4251 ||| VBN
by  ||| S:4251 E:4254 ||| IN
p27  ||| S:4254 E:4258 ||| CD
upregulation  ||| S:4258 E:4271 ||| NNS
[  ||| S:4271 E:4273 ||| -LRB-
42  ||| S:4273 E:4276 ||| CD
43  ||| S:4276 E:4279 ||| CD
45  ||| S:4279 E:4282 ||| CD
]  ||| S:4282 E:4284 ||| -RRB-
,  ||| S:4284 E:4286 ||| ,
however  ||| S:4286 E:4294 ||| RB
the  ||| S:4294 E:4306 ||| DT
pathway  ||| S:4306 E:4314 ||| NN
leading  ||| S:4314 E:4322 ||| VBG
to  ||| S:4322 E:4325 ||| TO
p27  ||| S:4325 E:4329 ||| CD
upregulation  ||| S:4329 E:4342 ||| NN
is  ||| S:4342 E:4345 ||| VBZ
unknown ||| S:4345 E:4352 ||| JJ
.  ||| S:4352 E:4354 ||| .
We  ||| S:4354 E:4357 ||| PRP
show  ||| S:4357 E:4370 ||| VBP
that  ||| S:4370 E:4375 ||| IN
androgen-induced  ||| S:4375 E:4392 ||| JJ
p27  ||| S:4392 E:4396 ||| CD
upregulation  ||| S:4396 E:4409 ||| NN
is  ||| S:4409 E:4412 ||| VBZ
paralleled  ||| S:4412 E:4423 ||| VBN
by  ||| S:4423 E:4426 ||| IN
p27  ||| S:4426 E:4438 ||| CD
stabilization  ||| S:4438 E:4452 ||| NN
and  ||| S:4452 E:4456 ||| CC
SKP2  ||| S:4456 E:4461 ||| CD
downregulation ||| S:4461 E:4475 ||| NNS
.  ||| S:4475 E:4477 ||| .
SKP2  ||| S:4477 E:4482 ||| NNP
overexpression  ||| S:4482 E:4505 ||| NN
is  ||| S:4505 E:4508 ||| VBZ
sufficient  ||| S:4508 E:4519 ||| JJ
to  ||| S:4519 E:4522 ||| TO
overcome  ||| S:4522 E:4531 ||| VB
androgen-mediated  ||| S:4531 E:4549 ||| JJ
p27  ||| S:4549 E:4561 ||| CD
accumulation ||| S:4561 E:4573 ||| NN
,  ||| S:4573 E:4575 ||| ,
indicating  ||| S:4575 E:4586 ||| VBG
that  ||| S:4586 E:4591 ||| IN
it  ||| S:4591 E:4594 ||| PRP
is  ||| S:4594 E:4597 ||| VBZ
a  ||| S:4597 E:4599 ||| DT
major  ||| S:4599 E:4605 ||| JJ
mediator  ||| S:4605 E:4614 ||| NN
of  ||| S:4614 E:4625 ||| IN
androgen-mediated  ||| S:4625 E:4643 ||| JJ
cell  ||| S:4643 E:4648 ||| NN
cycle  ||| S:4648 E:4654 ||| NN
control ||| S:4654 E:4661 ||| NN
.  ||| S:4661 E:4685 ||| .
Results  ||| S:4685 E:4712 ||| NNS
Androgen-induced  ||| S:4712 E:4729 ||| JJ
G1  ||| S:4729 E:4732 ||| CD
arrest  ||| S:4732 E:4739 ||| NN
correlates  ||| S:4739 E:4750 ||| NN
with  ||| S:4750 E:4765 ||| IN
inhibition  ||| S:4765 E:4776 ||| NN
of  ||| S:4776 E:4779 ||| IN
cyclin  ||| S:4779 E:4786 ||| JJ
E  ||| S:4786 E:4788 ||| NN
kinase  ||| S:4788 E:4795 ||| NN
activity  ||| S:4795 E:4814 ||| NN
Consistent  ||| S:4814 E:4825 ||| NNS
with  ||| S:4825 E:4830 ||| IN
our  ||| S:4830 E:4834 ||| PRP$
previous  ||| S:4834 E:4843 ||| JJ
studies ||| S:4843 E:4850 ||| NNS
,  ||| S:4850 E:4852 ||| ,
the  ||| S:4852 E:4856 ||| DT
synthetic  ||| S:4856 E:4876 ||| JJ
androgen  ||| S:4876 E:4885 ||| JJ
7α-17α-dimethyl-19-nortestosterone  ||| S:4885 E:4920 ||| NNP
( ||| S:4920 E:4921 ||| -LRB-
mibolerone ||| S:4921 E:4931 ||| UH
,  ||| S:4931 E:4943 ||| ,
MIB ||| S:4943 E:4946 ||| NNP
)  ||| S:4946 E:4948 ||| -RRB-
inhibits  ||| S:4948 E:4957 ||| VBZ
the  ||| S:4957 E:4961 ||| DT
proliferation  ||| S:4961 E:4975 ||| NN
and  ||| S:4975 E:4979 ||| CC
suppresses  ||| S:4979 E:4990 ||| VBG
the  ||| S:4990 E:5004 ||| DT
transformed  ||| S:5004 E:5016 ||| JJ
phenotype  ||| S:5016 E:5026 ||| NN
of  ||| S:5026 E:5029 ||| IN
LNCaP  ||| S:5029 E:5035 ||| JJ
cells  ||| S:5035 E:5041 ||| NNS
(  ||| S:5041 E:5043 ||| -LRB-
[  ||| S:5043 E:5045 ||| CD
46  ||| S:5045 E:5048 ||| CD
]  ||| S:5048 E:5050 ||| -RRB-
and  ||| S:5050 E:5054 ||| CC
Fig.  ||| S:5054 E:5069 ||| CD
1A ||| S:5069 E:5071 ||| CD
) ||| S:5071 E:5072 ||| -RRB-
.  ||| S:5072 E:5074 ||| .
No  ||| S:5074 E:5077 ||| DT
cytotoxic  ||| S:5077 E:5087 ||| NN
or  ||| S:5087 E:5090 ||| CC
apoptosis-inducing  ||| S:5090 E:5109 ||| JJ
activity  ||| S:5109 E:5118 ||| NN
was  ||| S:5118 E:5132 ||| VBD
associated  ||| S:5132 E:5143 ||| VBN
with  ||| S:5143 E:5148 ||| IN
this  ||| S:5148 E:5153 ||| DT
growth  ||| S:5153 E:5160 ||| NN
inhibition  ||| S:5160 E:5171 ||| NNS
(  ||| S:5171 E:5173 ||| -LRB-
[  ||| S:5173 E:5175 ||| CD
46  ||| S:5175 E:5178 ||| CD
]  ||| S:5178 E:5180 ||| -RRB-
,  ||| S:5180 E:5182 ||| ,
and  ||| S:5182 E:5196 ||| CC
data  ||| S:5196 E:5201 ||| NNS
not  ||| S:5201 E:5205 ||| RB
shown ||| S:5205 E:5210 ||| VBN
) ||| S:5210 E:5211 ||| -RRB-
.  ||| S:5211 E:5213 ||| .
To  ||| S:5213 E:5216 ||| TO
determine  ||| S:5216 E:5226 ||| VB
whether  ||| S:5226 E:5234 ||| IN
MIB  ||| S:5234 E:5238 ||| NNP
caused  ||| S:5238 E:5245 ||| VBD
arrest  ||| S:5245 E:5262 ||| NN
in  ||| S:5262 E:5265 ||| IN
a  ||| S:5265 E:5267 ||| DT
particular  ||| S:5267 E:5278 ||| JJ
phase  ||| S:5278 E:5284 ||| NN
of  ||| S:5284 E:5287 ||| IN
the  ||| S:5287 E:5291 ||| DT
cell  ||| S:5291 E:5296 ||| NN
cycle ||| S:5296 E:5301 ||| NN
,  ||| S:5301 E:5303 ||| ,
MIB  ||| S:5303 E:5307 ||| NNP
treated  ||| S:5307 E:5325 ||| VBD
cells  ||| S:5325 E:5331 ||| NNS
were  ||| S:5331 E:5336 ||| VBD
examined  ||| S:5336 E:5345 ||| VBN
by  ||| S:5345 E:5348 ||| IN
flow  ||| S:5348 E:5353 ||| NN
cytometry ||| S:5353 E:5362 ||| NN
.  ||| S:5362 E:5364 ||| .
MIB  ||| S:5364 E:5368 ||| NNP
induced  ||| S:5368 E:5376 ||| VBD
a  ||| S:5376 E:5388 ||| DT
time-dependent  ||| S:5388 E:5403 ||| JJ
accumulation  ||| S:5403 E:5416 ||| NN
of  ||| S:5416 E:5419 ||| IN
cells  ||| S:5419 E:5425 ||| NNS
in  ||| S:5425 E:5428 ||| IN
G1  ||| S:5428 E:5431 ||| CD
at  ||| S:5431 E:5434 ||| IN
the  ||| S:5434 E:5438 ||| DT
expense  ||| S:5438 E:5456 ||| NN
of  ||| S:5456 E:5459 ||| IN
both  ||| S:5459 E:5464 ||| DT
S  ||| S:5464 E:5466 ||| NNP
and  ||| S:5466 E:5470 ||| CC
G2 ||| S:5470 E:5472 ||| NNP
/ ||| S:5472 E:5473 ||| NNP
M  ||| S:5473 E:5475 ||| NNP
phases  ||| S:5475 E:5482 ||| NNS
( ||| S:5482 E:5483 ||| -LRB-
Fig.  ||| S:5483 E:5488 ||| NNP
1B ||| S:5488 E:5490 ||| NNP
) ||| S:5490 E:5491 ||| -RRB-
.  ||| S:5491 E:5493 ||| .
Consistent  ||| S:5493 E:5504 ||| JJ
with  ||| S:5504 E:5509 ||| IN
G1  ||| S:5509 E:5522 ||| CD
arrest ||| S:5522 E:5528 ||| NN
,  ||| S:5528 E:5530 ||| ,
MIB  ||| S:5530 E:5534 ||| NNP
induced  ||| S:5534 E:5542 ||| VBD
inhibition  ||| S:5542 E:5553 ||| VBN
of  ||| S:5553 E:5556 ||| IN
cyclin  ||| S:5556 E:5563 ||| FW
E-associated  ||| S:5563 E:5576 ||| FW
H1  ||| S:5576 E:5589 ||| FW
kinase  ||| S:5589 E:5596 ||| FW
activity  ||| S:5596 E:5605 ||| FW
( ||| S:5605 E:5606 ||| -LRB-
Fig.  ||| S:5606 E:5611 ||| NNP
1C ||| S:5611 E:5613 ||| NNP
) ||| S:5613 E:5614 ||| -RRB-
.  ||| S:5614 E:5616 ||| .
This  ||| S:5616 E:5621 ||| DT
inhibition  ||| S:5621 E:5632 ||| JJ
correlated  ||| S:5632 E:5653 ||| NN
with  ||| S:5653 E:5658 ||| IN
increased  ||| S:5658 E:5668 ||| JJ
recovery  ||| S:5668 E:5677 ||| NN
of  ||| S:5677 E:5680 ||| IN
the  ||| S:5680 E:5684 ||| DT
CDK2  ||| S:5684 E:5689 ||| CD
inhibitor  ||| S:5689 E:5699 ||| CD
p27  ||| S:5699 E:5703 ||| CD
in  ||| S:5703 E:5716 ||| IN
cyclin  ||| S:5716 E:5723 ||| JJ
E  ||| S:5723 E:5725 ||| NN
immunocomplexes  ||| S:5725 E:5741 ||| VBZ
isolated  ||| S:5741 E:5750 ||| VBN
from  ||| S:5750 E:5755 ||| IN
MIB-treated  ||| S:5755 E:5767 ||| JJ
LNCaP  ||| S:5767 E:5783 ||| JJ
cells  ||| S:5783 E:5789 ||| NNS
( ||| S:5789 E:5790 ||| -LRB-
Fig.  ||| S:5790 E:5795 ||| NNP
1D ||| S:5795 E:5797 ||| NNP
) ||| S:5797 E:5798 ||| -RRB-
.  ||| S:5798 E:5800 ||| .
Similar  ||| S:5800 E:5808 ||| JJ
finding  ||| S:5808 E:5816 ||| NN
were  ||| S:5816 E:5821 ||| VBD
previously  ||| S:5821 E:5832 ||| RB
obtained  ||| S:5832 E:5851 ||| VBN
with  ||| S:5851 E:5856 ||| IN
the  ||| S:5856 E:5860 ||| DT
synthetic  ||| S:5860 E:5870 ||| JJ
androgen  ||| S:5870 E:5879 ||| JJ
R1881  ||| S:5879 E:5885 ||| NN
and  ||| S:5885 E:5889 ||| CC
the  ||| S:5889 E:5893 ||| DT
natural  ||| S:5893 E:5911 ||| JJ
androgen  ||| S:5911 E:5920 ||| JJ
dihydrotestosterone  ||| S:5920 E:5940 ||| NNS
( ||| S:5940 E:5941 ||| -LRB-
DHT ||| S:5941 E:5944 ||| NNP
)  ||| S:5944 E:5946 ||| -RRB-
[  ||| S:5946 E:5948 ||| -LRB-
42  ||| S:5948 E:5951 ||| CD
43  ||| S:5951 E:5954 ||| CD
]  ||| S:5954 E:5956 ||| -RRB-
.  ||| S:5956 E:5958 ||| .
The  ||| S:5958 E:5962 ||| DT
latter  ||| S:5962 E:5979 ||| JJ
study  ||| S:5979 E:5985 ||| NN
also  ||| S:5985 E:5990 ||| RB
showed  ||| S:5990 E:5997 ||| VBD
that  ||| S:5997 E:6002 ||| IN
p27  ||| S:6002 E:6006 ||| NNP
is  ||| S:6006 E:6009 ||| VBZ
quantitatively  ||| S:6009 E:6024 ||| VBN
bound  ||| S:6024 E:6030 ||| VBN
to  ||| S:6030 E:6043 ||| TO
cyclin  ||| S:6043 E:6050 ||| VB
E  ||| S:6050 E:6052 ||| NN
complexes  ||| S:6052 E:6062 ||| NNS
in  ||| S:6062 E:6065 ||| IN
DHT-treated  ||| S:6065 E:6077 ||| JJ
cells ||| S:6077 E:6082 ||| NNS
,  ||| S:6082 E:6084 ||| ,
indicating  ||| S:6084 E:6095 ||| VBG
that  ||| S:6095 E:6110 ||| IN
p27  ||| S:6110 E:6114 ||| CD
upregulation  ||| S:6114 E:6127 ||| NNS
was  ||| S:6127 E:6131 ||| VBD
sufficient  ||| S:6131 E:6142 ||| JJ
to  ||| S:6142 E:6145 ||| TO
saturate  ||| S:6145 E:6154 ||| VB
and  ||| S:6154 E:6158 ||| CC
inhibit  ||| S:6158 E:6176 ||| VB
cyclinE ||| S:6176 E:6183 ||| JJ
/ ||| S:6183 E:6184 ||| CD
CDK2  ||| S:6184 E:6189 ||| CD
complexes  ||| S:6189 E:6199 ||| NNS
[  ||| S:6199 E:6201 ||| -LRB-
43  ||| S:6201 E:6204 ||| CD
]  ||| S:6204 E:6206 ||| -RRB-
.  ||| S:6206 E:6236 ||| .
MIB-induced  ||| S:6236 E:6248 ||| JJ
cell  ||| S:6248 E:6253 ||| NN
cycle  ||| S:6253 E:6259 ||| NN
arrest  ||| S:6259 E:6266 ||| NN
and  ||| S:6266 E:6270 ||| CC
CDK2  ||| S:6270 E:6275 ||| CD
inhibition  ||| S:6275 E:6296 ||| JJ
coincide  ||| S:6296 E:6305 ||| NN
with  ||| S:6305 E:6310 ||| IN
upregulation  ||| S:6310 E:6323 ||| NN
of  ||| S:6323 E:6326 ||| IN
p27  ||| S:6326 E:6330 ||| NNP
and  ||| S:6330 E:6334 ||| CC
downregulation  ||| S:6334 E:6349 ||| NN
of  ||| S:6349 E:6362 ||| IN
SKP2  ||| S:6362 E:6377 ||| NNP
Consistent  ||| S:6377 E:6388 ||| NNP
with  ||| S:6388 E:6393 ||| IN
increased  ||| S:6393 E:6403 ||| JJ
recovery  ||| S:6403 E:6412 ||| NN
of  ||| S:6412 E:6415 ||| IN
p27  ||| S:6415 E:6419 ||| CD
in  ||| S:6419 E:6422 ||| IN
cyclin  ||| S:6422 E:6429 ||| JJ
E  ||| S:6429 E:6441 ||| NN
complexes ||| S:6441 E:6450 ||| NNS
,  ||| S:6450 E:6452 ||| ,
MIB  ||| S:6452 E:6456 ||| NNP
caused  ||| S:6456 E:6463 ||| VBD
a  ||| S:6463 E:6465 ||| DT
concentration  ||| S:6465 E:6479 ||| NN
and  ||| S:6479 E:6483 ||| CC
time-dependent  ||| S:6483 E:6508 ||| JJ
increase  ||| S:6508 E:6517 ||| NN
in  ||| S:6517 E:6520 ||| IN
steady-state  ||| S:6520 E:6533 ||| JJ
p27  ||| S:6533 E:6537 ||| CD
protein  ||| S:6537 E:6545 ||| NN
levels  ||| S:6545 E:6552 ||| NNS
( ||| S:6552 E:6553 ||| -LRB-
Fig.  ||| S:6553 E:6558 ||| NNP
2A ||| S:6558 E:6560 ||| NNP
, ||| S:6560 E:6561 ||| ,
2B ||| S:6561 E:6563 ||| CD
) ||| S:6563 E:6564 ||| -RRB-
.  ||| S:6564 E:6576 ||| .
This  ||| S:6576 E:6581 ||| DT
increase  ||| S:6581 E:6590 ||| NN
was  ||| S:6590 E:6594 ||| VBD
reversible ||| S:6594 E:6604 ||| JJ
,  ||| S:6604 E:6606 ||| ,
as  ||| S:6606 E:6609 ||| IN
p27  ||| S:6609 E:6613 ||| CD
levels  ||| S:6613 E:6620 ||| NNS
were  ||| S:6620 E:6635 ||| VBD
gradually  ||| S:6635 E:6645 ||| RB
restored  ||| S:6645 E:6654 ||| VBN
to  ||| S:6654 E:6657 ||| TO
near  ||| S:6657 E:6662 ||| JJ
control  ||| S:6662 E:6670 ||| NN
levels  ||| S:6670 E:6677 ||| NNS
after  ||| S:6677 E:6683 ||| IN
removal  ||| S:6683 E:6701 ||| NN
of  ||| S:6701 E:6704 ||| IN
MIB  ||| S:6704 E:6708 ||| NNP
and  ||| S:6708 E:6712 ||| CC
addition  ||| S:6712 E:6721 ||| NN
of  ||| S:6721 E:6724 ||| IN
a  ||| S:6724 E:6726 ||| DT
500-fold  ||| S:6726 E:6735 ||| JJ
molar  ||| S:6735 E:6741 ||| JJ
excess  ||| S:6741 E:6748 ||| NN
of  ||| S:6748 E:6751 ||| IN
the  ||| S:6751 E:6765 ||| DT
antiandrogen  ||| S:6765 E:6778 ||| FW
cyproterone  ||| S:6778 E:6790 ||| FW
acetate  ||| S:6790 E:6798 ||| FW
( ||| S:6798 E:6799 ||| -LRB-
CA ||| S:6799 E:6801 ||| NNP
)  ||| S:6801 E:6803 ||| -RRB-
( ||| S:6803 E:6804 ||| -LRB-
Fig.  ||| S:6804 E:6809 ||| CD
2Cand  ||| S:6809 E:6815 ||| CD
2D ||| S:6815 E:6817 ||| CD
) ||| S:6817 E:6818 ||| -RRB-
.  ||| S:6818 E:6830 ||| .
Simultaneous  ||| S:6830 E:6843 ||| JJ
administration  ||| S:6843 E:6858 ||| NN
of  ||| S:6858 E:6861 ||| IN
MIB  ||| S:6861 E:6865 ||| NNP
and  ||| S:6865 E:6869 ||| CC
CA  ||| S:6869 E:6872 ||| NNP
partially  ||| S:6872 E:6892 ||| RB
prevented  ||| S:6892 E:6902 ||| VBD
p27  ||| S:6902 E:6906 ||| CD
accumulation ||| S:6906 E:6918 ||| NN
,  ||| S:6918 E:6920 ||| ,
indicating  ||| S:6920 E:6931 ||| VBG
that  ||| S:6931 E:6936 ||| IN
it  ||| S:6936 E:6939 ||| PRP
was  ||| S:6939 E:6953 ||| VBD
mediated  ||| S:6953 E:6962 ||| VBN
by  ||| S:6962 E:6965 ||| IN
the  ||| S:6965 E:6969 ||| DT
androgen  ||| S:6969 E:6978 ||| JJ
receptor  ||| S:6978 E:6987 ||| NN
( ||| S:6987 E:6988 ||| -LRB-
AR ||| S:6988 E:6990 ||| NNP
)  ||| S:6990 E:6992 ||| -RRB-
( ||| S:6992 E:6993 ||| -LRB-
Fig.  ||| S:6993 E:6998 ||| NNP
2D ||| S:6998 E:7000 ||| NNP
) ||| S:7000 E:7001 ||| -RRB-
.  ||| S:7001 E:7013 ||| .
Since  ||| S:7013 E:7019 ||| IN
the  ||| S:7019 E:7023 ||| DT
level  ||| S:7023 E:7029 ||| NN
of  ||| S:7029 E:7032 ||| IN
SKP2  ||| S:7032 E:7037 ||| NNP
is  ||| S:7037 E:7040 ||| VBZ
a  ||| S:7040 E:7042 ||| DT
rate-limiting  ||| S:7042 E:7056 ||| JJ
determinant  ||| S:7056 E:7078 ||| NN
of  ||| S:7078 E:7081 ||| IN
p27  ||| S:7081 E:7085 ||| CD
levels  ||| S:7085 E:7092 ||| NNS
[  ||| S:7092 E:7094 ||| -LRB-
20  ||| S:7094 E:7097 ||| CD
21  ||| S:7097 E:7100 ||| CD
29  ||| S:7100 E:7103 ||| CD
]  ||| S:7103 E:7105 ||| -RRB-
,  ||| S:7105 E:7107 ||| ,
we  ||| S:7107 E:7110 ||| PRP
examined  ||| S:7110 E:7119 ||| VBD
the  ||| S:7119 E:7123 ||| DT
effect  ||| S:7123 E:7130 ||| NN
of  ||| S:7130 E:7143 ||| IN
MIB  ||| S:7143 E:7147 ||| NNP
on  ||| S:7147 E:7150 ||| IN
SKP2  ||| S:7150 E:7155 ||| CD
protein  ||| S:7155 E:7163 ||| NN
levels ||| S:7163 E:7169 ||| NNS
.  ||| S:7169 E:7171 ||| .
SKP2  ||| S:7171 E:7176 ||| NNP
levels  ||| S:7176 E:7183 ||| NNS
were  ||| S:7183 E:7198 ||| VBD
down-regulated  ||| S:7198 E:7213 ||| JJ
nearly  ||| S:7213 E:7220 ||| RB
four-fold  ||| S:7220 E:7230 ||| RB
by  ||| S:7230 E:7233 ||| IN
MIB  ||| S:7233 E:7237 ||| NNP
at  ||| S:7237 E:7240 ||| IN
concentrations  ||| S:7240 E:7265 ||| NNS
and  ||| S:7265 E:7269 ||| CC
with  ||| S:7269 E:7274 ||| IN
kinetics  ||| S:7274 E:7283 ||| NNS
that  ||| S:7283 E:7288 ||| WDT
closely  ||| S:7288 E:7296 ||| RB
paralleled  ||| S:7296 E:7307 ||| CD
p27  ||| S:7307 E:7321 ||| CD
accumulation  ||| S:7321 E:7334 ||| NN
( ||| S:7334 E:7335 ||| -LRB-
Fig.  ||| S:7335 E:7340 ||| NNP
2A ||| S:7340 E:7342 ||| NNP
, ||| S:7342 E:7343 ||| ,
2B ||| S:7343 E:7345 ||| CD
) ||| S:7345 E:7346 ||| -RRB-
.  ||| S:7346 E:7348 ||| .
In  ||| S:7348 E:7351 ||| IN
addition ||| S:7351 E:7359 ||| NN
,  ||| S:7359 E:7361 ||| ,
downregulation  ||| S:7361 E:7376 ||| VBG
of  ||| S:7376 E:7389 ||| IN
RB1  ||| S:7389 E:7393 ||| NNP
and  ||| S:7393 E:7397 ||| CC
accumulation  ||| S:7397 E:7410 ||| NN
in  ||| S:7410 E:7413 ||| IN
the  ||| S:7413 E:7417 ||| DT
underphosphorylated  ||| S:7417 E:7437 ||| JJ
form  ||| S:7437 E:7452 ||| NN
paralleled  ||| S:7452 E:7463 ||| FW
SKP2  ||| S:7463 E:7468 ||| FW
down-regulation  ||| S:7468 E:7484 ||| FW
( ||| S:7484 E:7485 ||| -LRB-
Fig.  ||| S:7485 E:7490 ||| NNP
2A ||| S:7490 E:7492 ||| NNP
) ||| S:7492 E:7493 ||| -RRB-
.  ||| S:7493 E:7495 ||| .
In  ||| S:7495 E:7498 ||| IN
contrast ||| S:7498 E:7506 ||| NN
,  ||| S:7506 E:7518 ||| ,
only  ||| S:7518 E:7523 ||| RB
minor  ||| S:7523 E:7529 ||| JJ
changes  ||| S:7529 E:7537 ||| NNS
were  ||| S:7537 E:7542 ||| VBD
detected  ||| S:7542 E:7551 ||| VBN
in  ||| S:7551 E:7554 ||| IN
the  ||| S:7554 E:7558 ||| DT
expression  ||| S:7558 E:7569 ||| NN
of  ||| S:7569 E:7572 ||| IN
the  ||| S:7572 E:7586 ||| DT
SKP2-associated  ||| S:7586 E:7602 ||| NNP
SCF  ||| S:7602 E:7606 ||| NNP
SKP2subunits  ||| S:7606 E:7619 ||| NNP
HRT1 ||| S:7619 E:7623 ||| NNP
,  ||| S:7623 E:7625 ||| ,
CUL1 ||| S:7625 E:7629 ||| NNP
,  ||| S:7629 E:7631 ||| ,
and  ||| S:7631 E:7635 ||| CC
SKP1  ||| S:7635 E:7650 ||| NNP
( ||| S:7650 E:7651 ||| -LRB-
Fig.  ||| S:7651 E:7656 ||| NNP
2A ||| S:7656 E:7658 ||| NNP
) ||| S:7658 E:7659 ||| -RRB-
.  ||| S:7659 E:7661 ||| .
MIB-dependent  ||| S:7661 E:7675 ||| NNP
SKP2  ||| S:7675 E:7680 ||| NNP
down-regulation  ||| S:7680 E:7696 ||| NNP
was  ||| S:7696 E:7710 ||| VBD
efficiently  ||| S:7710 E:7722 ||| RB
counteracted  ||| S:7722 E:7735 ||| VBN
by  ||| S:7735 E:7738 ||| IN
CA  ||| S:7738 E:7741 ||| NNP
( ||| S:7741 E:7742 ||| -LRB-
Fig.  ||| S:7742 E:7747 ||| CD
2Cand  ||| S:7747 E:7753 ||| CD
2D ||| S:7753 E:7755 ||| CD
) ||| S:7755 E:7756 ||| -RRB-
,  ||| S:7756 E:7758 ||| ,
again  ||| S:7758 E:7774 ||| RB
indicating  ||| S:7774 E:7785 ||| VBG
an  ||| S:7785 E:7788 ||| DT
involvement  ||| S:7788 E:7800 ||| NN
of  ||| S:7800 E:7803 ||| IN
the  ||| S:7803 E:7807 ||| DT
AR ||| S:7807 E:7809 ||| NNP
.  ||| S:7809 E:7811 ||| .
Cyclin  ||| S:7811 E:7818 ||| NNP
A ||| S:7818 E:7819 ||| NNP
,  ||| S:7819 E:7821 ||| ,
but  ||| S:7821 E:7825 ||| CC
not  ||| S:7825 E:7839 ||| RB
cyclin  ||| S:7839 E:7846 ||| JJ
E  ||| S:7846 E:7848 ||| NN
levels  ||| S:7848 E:7855 ||| NNS
were  ||| S:7855 E:7860 ||| VBD
also  ||| S:7860 E:7865 ||| RB
suppressed  ||| S:7865 E:7876 ||| VBN
by  ||| S:7876 E:7879 ||| IN
MIB  ||| S:7879 E:7883 ||| NNP
in  ||| S:7883 E:7886 ||| IN
an  ||| S:7886 E:7899 ||| DT
AR-dependent  ||| S:7899 E:7912 ||| JJ
manner ||| S:7912 E:7918 ||| NN
,  ||| S:7918 E:7920 ||| ,
while  ||| S:7920 E:7926 ||| IN
the  ||| S:7926 E:7930 ||| DT
levels  ||| S:7930 E:7937 ||| NNS
of  ||| S:7937 E:7940 ||| IN
the  ||| S:7940 E:7954 ||| DT
COP9 ||| S:7954 E:7958 ||| FW
/ ||| S:7958 E:7959 ||| FW
signalosome  ||| S:7959 E:7971 ||| FW
subunit  ||| S:7971 E:7979 ||| FW
CSN5 ||| S:7979 E:7983 ||| FW
/ ||| S:7983 E:7984 ||| FW
JAB1  ||| S:7984 E:7989 ||| FW
and  ||| S:7989 E:7993 ||| CC
tubulin  ||| S:7993 E:8001 ||| NNS
remained  ||| S:8001 E:8020 ||| VBD
constant  ||| S:8020 E:8029 ||| JJ
( ||| S:8029 E:8030 ||| -LRB-
Fig.  ||| S:8030 E:8035 ||| NNP
2D ||| S:8035 E:8037 ||| NNP
) ||| S:8037 E:8038 ||| -RRB-
.  ||| S:8038 E:8040 ||| .
Finally ||| S:8040 E:8047 ||| RB
,  ||| S:8047 E:8049 ||| ,
consistent  ||| S:8049 E:8060 ||| JJ
with  ||| S:8060 E:8065 ||| IN
SKP2  ||| S:8065 E:8070 ||| NNP
and  ||| S:8070 E:8074 ||| CC
p27  ||| S:8074 E:8088 ||| RB
being  ||| S:8088 E:8094 ||| VBG
integral  ||| S:8094 E:8103 ||| JJ
components  ||| S:8103 E:8114 ||| NNS
of  ||| S:8114 E:8117 ||| IN
androgen-mediated  ||| S:8117 E:8135 ||| JJ
growth  ||| S:8135 E:8152 ||| NN
control  ||| S:8152 E:8160 ||| NN
of  ||| S:8160 E:8163 ||| IN
LNCaP  ||| S:8163 E:8169 ||| JJ
cells ||| S:8169 E:8174 ||| NNS
,  ||| S:8174 E:8176 ||| ,
CA  ||| S:8176 E:8179 ||| NNP
also  ||| S:8179 E:8184 ||| RB
efficiently  ||| S:8184 E:8196 ||| RB
reversed  ||| S:8196 E:8205 ||| VBD
the  ||| S:8205 E:8219 ||| DT
MIB-induced  ||| S:8219 E:8231 ||| JJ
G1  ||| S:8231 E:8234 ||| CD
cell  ||| S:8234 E:8239 ||| NN
cycle  ||| S:8239 E:8245 ||| NN
arrest  ||| S:8245 E:8252 ||| NN
( ||| S:8252 E:8253 ||| -LRB-
Fig.  ||| S:8253 E:8258 ||| NNP
2E ||| S:8258 E:8260 ||| NNP
) ||| S:8260 E:8261 ||| -RRB-
.  ||| S:8261 E:8273 ||| .
To  ||| S:8273 E:8276 ||| TO
confirm  ||| S:8276 E:8284 ||| VB
the  ||| S:8284 E:8288 ||| DT
effect  ||| S:8288 E:8295 ||| NN
of  ||| S:8295 E:8298 ||| IN
MIB  ||| S:8298 E:8302 ||| NNP
on  ||| S:8302 E:8305 ||| IN
p27  ||| S:8305 E:8309 ||| NNP
and  ||| S:8309 E:8313 ||| CC
SKP2  ||| S:8313 E:8318 ||| CD
at  ||| S:8318 E:8321 ||| IN
the  ||| S:8321 E:8335 ||| DT
level  ||| S:8335 E:8341 ||| NN
of  ||| S:8341 E:8344 ||| IN
individual  ||| S:8344 E:8355 ||| JJ
cells ||| S:8355 E:8360 ||| NNS
,  ||| S:8360 E:8362 ||| ,
we  ||| S:8362 E:8365 ||| PRP
performed  ||| S:8365 E:8385 ||| VBD
immunofluorescence  ||| S:8385 E:8404 ||| JJ
staining ||| S:8404 E:8412 ||| NN
.  ||| S:8412 E:8414 ||| .
In  ||| S:8414 E:8417 ||| IN
untreated  ||| S:8417 E:8427 ||| JJ
controls ||| S:8427 E:8435 ||| NNS
,  ||| S:8435 E:8437 ||| ,
most  ||| S:8437 E:8452 ||| JJS
cells  ||| S:8452 E:8458 ||| NNS
displayed  ||| S:8458 E:8468 ||| VBD
strong  ||| S:8468 E:8475 ||| JJ
staining  ||| S:8475 E:8484 ||| NN
for  ||| S:8484 E:8488 ||| IN
SKP2  ||| S:8488 E:8493 ||| CD
with  ||| S:8493 E:8498 ||| IN
few  ||| S:8498 E:8502 ||| JJ
cells  ||| S:8502 E:8518 ||| NNS
positive  ||| S:8518 E:8527 ||| JJ
for  ||| S:8527 E:8531 ||| IN
p27  ||| S:8531 E:8535 ||| NNP
( ||| S:8535 E:8536 ||| -LRB-
Fig.  ||| S:8536 E:8541 ||| NNP
2F ||| S:8541 E:8543 ||| NNP
) ||| S:8543 E:8544 ||| -RRB-
.  ||| S:8544 E:8546 ||| .
The  ||| S:8546 E:8550 ||| DT
nuclear  ||| S:8550 E:8558 ||| JJ
staining  ||| S:8558 E:8567 ||| JJ
patterns  ||| S:8567 E:8586 ||| NNS
of  ||| S:8586 E:8589 ||| IN
SKP2  ||| S:8589 E:8594 ||| NNP
and  ||| S:8594 E:8598 ||| CC
p27  ||| S:8598 E:8602 ||| NNP
appeared  ||| S:8602 E:8611 ||| VBD
mutually  ||| S:8611 E:8620 ||| RB
exclusive ||| S:8620 E:8629 ||| JJ
.  ||| S:8629 E:8631 ||| .
( ||| S:8631 E:8632 ||| -LRB-
Fig.  ||| S:8632 E:8637 ||| NNP
2F ||| S:8637 E:8639 ||| NNP
) ||| S:8639 E:8640 ||| -RRB-
.  ||| S:8640 E:8652 ||| .
In  ||| S:8652 E:8655 ||| IN
contrast ||| S:8655 E:8663 ||| NN
,  ||| S:8663 E:8665 ||| ,
the  ||| S:8665 E:8669 ||| DT
majority  ||| S:8669 E:8678 ||| NN
of  ||| S:8678 E:8681 ||| IN
MIB-treated  ||| S:8681 E:8693 ||| JJ
cells  ||| S:8693 E:8699 ||| NNS
showed  ||| S:8699 E:8716 ||| VBD
strong  ||| S:8716 E:8723 ||| JJ
p27  ||| S:8723 E:8727 ||| CD
expression ||| S:8727 E:8737 ||| NN
,  ||| S:8737 E:8739 ||| ,
while  ||| S:8739 E:8745 ||| IN
only  ||| S:8745 E:8750 ||| RB
few  ||| S:8750 E:8754 ||| JJ
cells  ||| S:8754 E:8760 ||| NNS
were  ||| S:8760 E:8765 ||| VBD
positive  ||| S:8765 E:8784 ||| JJ
for  ||| S:8784 E:8788 ||| IN
SKP2 ||| S:8788 E:8792 ||| CD
.  ||| S:8792 E:8822 ||| .
MIB-induced  ||| S:8822 E:8834 ||| NNP
p27  ||| S:8834 E:8838 ||| NNP
upregulation  ||| S:8838 E:8851 ||| VBD
correlates  ||| S:8851 E:8862 ||| VBN
with  ||| S:8862 E:8877 ||| IN
increased  ||| S:8877 E:8887 ||| JJ
p27  ||| S:8887 E:8891 ||| CD
protein  ||| S:8891 E:8899 ||| NN
stability  ||| S:8899 E:8909 ||| NN
and  ||| S:8909 E:8913 ||| CC
decreased  ||| S:8913 E:8933 ||| VBD
ubiquitylation  ||| S:8933 E:8958 ||| JJ
Northern  ||| S:8958 E:8967 ||| JJ
blot  ||| S:8967 E:8972 ||| JJ
analysis  ||| S:8972 E:8981 ||| NN
revealed  ||| S:8981 E:8990 ||| VBD
that  ||| S:8990 E:8995 ||| DT
MIB-induced  ||| S:8995 E:9007 ||| JJ
SKP2  ||| S:9007 E:9022 ||| CD
downregulation  ||| S:9022 E:9037 ||| NN
at  ||| S:9037 E:9040 ||| IN
the  ||| S:9040 E:9044 ||| DT
protein  ||| S:9044 E:9052 ||| NN
level  ||| S:9052 E:9058 ||| NN
is  ||| S:9058 E:9061 ||| VBZ
reflected  ||| S:9061 E:9071 ||| VBN
by  ||| S:9071 E:9084 ||| IN
quantitatively  ||| S:9084 E:9099 ||| JJ
similar  ||| S:9099 E:9107 ||| JJ
changes  ||| S:9107 E:9115 ||| NNS
in  ||| S:9115 E:9118 ||| IN
steady  ||| S:9118 E:9125 ||| JJ
state  ||| S:9125 E:9131 ||| NN
RNA  ||| S:9131 E:9135 ||| NNP
levels  ||| S:9135 E:9152 ||| NNS
( ||| S:9152 E:9153 ||| -LRB-
Fig  ||| S:9153 E:9157 ||| NNP
3A ||| S:9157 E:9159 ||| NNP
) ||| S:9159 E:9160 ||| -RRB-
.  ||| S:9160 E:9162 ||| .
In  ||| S:9162 E:9165 ||| IN
contrast ||| S:9165 E:9173 ||| NN
,  ||| S:9173 E:9175 ||| ,
p27  ||| S:9175 E:9179 ||| CD
mRNA  ||| S:9179 E:9184 ||| JJ
levels  ||| S:9184 E:9191 ||| NNS
were  ||| S:9191 E:9196 ||| VBD
upregulated  ||| S:9196 E:9218 ||| VBN
by  ||| S:9218 E:9221 ||| IN
MIB  ||| S:9221 E:9225 ||| NNP
only  ||| S:9225 E:9230 ||| RB
two-fold  ||| S:9230 E:9239 ||| JJ
( ||| S:9239 E:9240 ||| -LRB-
Fig.  ||| S:9240 E:9245 ||| NNP
3A ||| S:9245 E:9247 ||| NNP
) ||| S:9247 E:9248 ||| -RRB-
.  ||| S:9248 E:9250 ||| .
This  ||| S:9250 E:9255 ||| DT
suggested  ||| S:9255 E:9265 ||| VBN
that  ||| S:9265 E:9270 ||| IN
the  ||| S:9270 E:9284 ||| DT
effect  ||| S:9284 E:9291 ||| NN
of  ||| S:9291 E:9294 ||| IN
MIB  ||| S:9294 E:9298 ||| NNP
on  ||| S:9298 E:9301 ||| IN
p27  ||| S:9301 E:9305 ||| NNP
RNA  ||| S:9305 E:9309 ||| NNP
levels  ||| S:9309 E:9316 ||| NNS
can  ||| S:9316 E:9320 ||| MD
not  ||| S:9320 E:9324 ||| RB
fully  ||| S:9324 E:9330 ||| RB
account  ||| S:9330 E:9338 ||| VBP
for  ||| S:9338 E:9352 ||| IN
the  ||| S:9352 E:9356 ||| DT
accumulation  ||| S:9356 E:9369 ||| NN
of  ||| S:9369 E:9372 ||| IN
p27  ||| S:9372 E:9376 ||| CD
protein  ||| S:9376 E:9384 ||| NN
( ||| S:9384 E:9385 ||| -LRB-
compare  ||| S:9385 E:9393 ||| FW
Figs.  ||| S:9393 E:9399 ||| FW
2Band  ||| S:9399 E:9415 ||| FW
3A ||| S:9415 E:9417 ||| FW
)  ||| S:9417 E:9429 ||| -RRB-
We  ||| S:9429 E:9432 ||| PRP
therefore  ||| S:9432 E:9442 ||| RB
determined  ||| S:9442 E:9453 ||| VBN
the  ||| S:9453 E:9457 ||| DT
effect  ||| S:9457 E:9464 ||| NN
of  ||| S:9464 E:9467 ||| IN
MIB  ||| S:9467 E:9471 ||| NNP
on  ||| S:9471 E:9474 ||| IN
p27  ||| S:9474 E:9488 ||| CD
half-life ||| S:9488 E:9497 ||| NN
.  ||| S:9497 E:9499 ||| .
Protein  ||| S:9499 E:9507 ||| NN
synthesis  ||| S:9507 E:9517 ||| NN
was  ||| S:9517 E:9521 ||| VBD
inhibited  ||| S:9521 E:9531 ||| VBN
by  ||| S:9531 E:9544 ||| IN
cycloheximide  ||| S:9544 E:9558 ||| NN
in  ||| S:9558 E:9561 ||| IN
control  ||| S:9561 E:9569 ||| NN
cells  ||| S:9569 E:9575 ||| NNS
and  ||| S:9575 E:9579 ||| CC
in  ||| S:9579 E:9582 ||| IN
cells  ||| S:9582 E:9588 ||| NNS
pretreated  ||| S:9588 E:9609 ||| VBN
with  ||| S:9609 E:9614 ||| IN
MIB  ||| S:9614 E:9618 ||| NNP
for  ||| S:9618 E:9622 ||| IN
72  ||| S:9622 E:9625 ||| CD
h ||| S:9625 E:9626 ||| NNS
.  ||| S:9626 E:9628 ||| .
Cells  ||| S:9628 E:9634 ||| NNS
were  ||| S:9634 E:9639 ||| VBD
harvested  ||| S:9639 E:9649 ||| VBN
after  ||| S:9649 E:9655 ||| IN
various  ||| S:9655 E:9673 ||| JJ
times  ||| S:9673 E:9679 ||| NNS
and  ||| S:9679 E:9683 ||| CC
the  ||| S:9683 E:9687 ||| DT
effect  ||| S:9687 E:9694 ||| NN
on  ||| S:9694 E:9697 ||| IN
p27  ||| S:9697 E:9701 ||| CD
protein  ||| S:9701 E:9709 ||| NN
levels  ||| S:9709 E:9716 ||| NNS
was  ||| S:9716 E:9720 ||| VBD
assessed  ||| S:9720 E:9739 ||| VBN
by  ||| S:9739 E:9742 ||| IN
immunoblotting ||| S:9742 E:9756 ||| NN
.  ||| S:9756 E:9758 ||| .
Using  ||| S:9758 E:9764 ||| VBG
this  ||| S:9764 E:9769 ||| DT
assay ||| S:9769 E:9774 ||| NN
,  ||| S:9774 E:9776 ||| ,
we  ||| S:9776 E:9779 ||| PRP
determined  ||| S:9779 E:9790 ||| VBD
a  ||| S:9790 E:9792 ||| DT
p27  ||| S:9792 E:9806 ||| JJ
half-life  ||| S:9806 E:9816 ||| NN
of  ||| S:9816 E:9819 ||| IN
4  ||| S:9819 E:9821 ||| CD
h  ||| S:9821 E:9823 ||| NN
in  ||| S:9823 E:9826 ||| IN
control  ||| S:9826 E:9834 ||| NN
cells ||| S:9834 E:9839 ||| NNS
,  ||| S:9839 E:9841 ||| ,
which  ||| S:9841 E:9847 ||| WDT
was  ||| S:9847 E:9851 ||| VBD
increased  ||| S:9851 E:9861 ||| VBN
to  ||| S:9861 E:9874 ||| TO
more  ||| S:9874 E:9879 ||| JJR
than  ||| S:9879 E:9884 ||| IN
6  ||| S:9884 E:9886 ||| CD
h  ||| S:9886 E:9888 ||| NN
in  ||| S:9888 E:9891 ||| IN
MIB  ||| S:9891 E:9895 ||| NNP
treated  ||| S:9895 E:9903 ||| VBD
cells  ||| S:9903 E:9909 ||| NNS
( ||| S:9909 E:9910 ||| -LRB-
Fig.  ||| S:9910 E:9915 ||| NNP
3B ||| S:9915 E:9917 ||| NNP
) ||| S:9917 E:9918 ||| -RRB-
.  ||| S:9918 E:9920 ||| .
This  ||| S:9920 E:9935 ||| DT
experiment  ||| S:9935 E:9946 ||| NN
likely  ||| S:9946 E:9953 ||| RB
overestimates  ||| S:9953 E:9967 ||| CD
p27  ||| S:9967 E:9971 ||| CD
half-life  ||| S:9971 E:9981 ||| NN
in  ||| S:9981 E:9994 ||| IN
untreated  ||| S:9994 E:10004 ||| JJ
cells ||| S:10004 E:10009 ||| NNS
,  ||| S:10009 E:10011 ||| ,
as  ||| S:10011 E:10014 ||| IN
SKP2  ||| S:10014 E:10019 ||| NNP
was  ||| S:10019 E:10023 ||| VBD
itself  ||| S:10023 E:10030 ||| PRP
downregulated  ||| S:10030 E:10044 ||| VBD
by  ||| S:10044 E:10047 ||| IN
CHX  ||| S:10047 E:10061 ||| NNP
( ||| S:10061 E:10062 ||| -LRB-
data  ||| S:10062 E:10067 ||| NNS
not  ||| S:10067 E:10071 ||| RB
shown ||| S:10071 E:10076 ||| VBN
) ||| S:10076 E:10077 ||| -RRB-
.  ||| S:10077 E:10079 ||| .
Nevertheless ||| S:10079 E:10091 ||| RB
,  ||| S:10091 E:10093 ||| ,
the  ||| S:10093 E:10097 ||| DT
data  ||| S:10097 E:10102 ||| NNS
suggest  ||| S:10102 E:10110 ||| VBP
that  ||| S:10110 E:10115 ||| IN
p27  ||| S:10115 E:10129 ||| CD
upregulation  ||| S:10129 E:10142 ||| NN
in  ||| S:10142 E:10145 ||| IN
response  ||| S:10145 E:10154 ||| NN
to  ||| S:10154 E:10157 ||| TO
MIB  ||| S:10157 E:10161 ||| NNP
is  ||| S:10161 E:10164 ||| VBZ
partially  ||| S:10164 E:10174 ||| RB
mediated  ||| S:10174 E:10183 ||| VBN
by  ||| S:10183 E:10196 ||| IN
changes  ||| S:10196 E:10204 ||| NNS
in  ||| S:10204 E:10207 ||| IN
protein  ||| S:10207 E:10215 ||| NN
stability ||| S:10215 E:10224 ||| NN
.  ||| S:10224 E:10236 ||| .
To  ||| S:10236 E:10239 ||| TO
confirm  ||| S:10239 E:10247 ||| VB
this  ||| S:10247 E:10252 ||| DT
conjecture ||| S:10252 E:10262 ||| NN
,  ||| S:10262 E:10264 ||| ,
we  ||| S:10264 E:10267 ||| PRP
used  ||| S:10267 E:10272 ||| VBD
an  ||| S:10272 E:10286 ||| DT
in  ||| S:10286 E:10289 ||| IN
vitro  ||| S:10289 E:10295 ||| JJ
assay  ||| S:10295 E:10301 ||| NN
to  ||| S:10301 E:10304 ||| TO
determine  ||| S:10304 E:10314 ||| VB
p27  ||| S:10314 E:10328 ||| CD
ubiquitylation  ||| S:10328 E:10343 ||| JJ
activity  ||| S:10343 E:10352 ||| NN
in  ||| S:10352 E:10355 ||| IN
LNCaP  ||| S:10355 E:10361 ||| JJ
cell  ||| S:10361 E:10366 ||| NN
lysate ||| S:10366 E:10372 ||| NN
.  ||| S:10372 E:10374 ||| .
Similar  ||| S:10374 E:10382 ||| JJ
to  ||| S:10382 E:10395 ||| TO
previously  ||| S:10395 E:10406 ||| RB
described  ||| S:10406 E:10416 ||| VBN
protocols  ||| S:10416 E:10426 ||| NNS
[  ||| S:10426 E:10428 ||| -LRB-
21  ||| S:10428 E:10431 ||| CD
22  ||| S:10431 E:10434 ||| CD
30  ||| S:10434 E:10437 ||| CD
]  ||| S:10437 E:10439 ||| -RRB-
,  ||| S:10439 E:10441 ||| ,
cell  ||| S:10441 E:10456 ||| NN
lysates  ||| S:10456 E:10464 ||| NNS
were  ||| S:10464 E:10469 ||| VBD
prepared  ||| S:10469 E:10478 ||| VBN
by  ||| S:10478 E:10481 ||| IN
hypotonic  ||| S:10481 E:10491 ||| JJ
lysis  ||| S:10491 E:10497 ||| NN
of  ||| S:10497 E:10500 ||| IN
untreated  ||| S:10500 E:10520 ||| JJ
LNCaP  ||| S:10520 E:10526 ||| JJ
cells  ||| S:10526 E:10532 ||| NNS
or  ||| S:10532 E:10535 ||| CC
cells  ||| S:10535 E:10541 ||| NNS
treated  ||| S:10541 E:10549 ||| VBN
with  ||| S:10549 E:10554 ||| IN
MIB  ||| S:10554 E:10558 ||| NNP
for  ||| S:10558 E:10562 ||| IN
96  ||| S:10562 E:10565 ||| CD
h ||| S:10565 E:10566 ||| NNS
.  ||| S:10566 E:10578 ||| .
Ubiquitylation  ||| S:10578 E:10593 ||| JJ
substrate  ||| S:10593 E:10603 ||| NN
was  ||| S:10603 E:10607 ||| VBD
prepared  ||| S:10607 E:10616 ||| VBN
by  ||| S:10616 E:10630 ||| IN
in  ||| S:10630 E:10633 ||| IN
vitro  ||| S:10633 E:10639 ||| JJ
transcription  ||| S:10639 E:10653 ||| NN
and  ||| S:10653 E:10667 ||| CC
translation  ||| S:10667 E:10679 ||| NN
of  ||| S:10679 E:10682 ||| IN
p27  ||| S:10682 E:10686 ||| CD
in  ||| S:10686 E:10689 ||| IN
the  ||| S:10689 E:10693 ||| DT
presence  ||| S:10693 E:10702 ||| NN
of  ||| S:10702 E:10705 ||| IN
35S-methionine ||| S:10705 E:10719 ||| CD
.  ||| S:10719 E:10721 ||| .
A  ||| S:10721 E:10733 ||| DT
point  ||| S:10733 E:10739 ||| NN
mutant  ||| S:10739 E:10746 ||| NN
of  ||| S:10746 E:10749 ||| IN
p27  ||| S:10749 E:10753 ||| NNP
( ||| S:10753 E:10754 ||| -LRB-
p27T187A ||| S:10754 E:10762 ||| NNP
) ||| S:10762 E:10763 ||| -RRB-
,  ||| S:10763 E:10765 ||| ,
in  ||| S:10765 E:10768 ||| IN
which  ||| S:10768 E:10774 ||| WDT
the  ||| S:10774 E:10778 ||| DT
critical  ||| S:10778 E:10797 ||| JJ
CDK2  ||| S:10797 E:10802 ||| CD
phosphorylation  ||| S:10802 E:10818 ||| JJ
site  ||| S:10818 E:10823 ||| NN
in  ||| S:10823 E:10826 ||| IN
position  ||| S:10826 E:10835 ||| NN
187  ||| S:10835 E:10839 ||| CD
was  ||| S:10839 E:10843 ||| VBD
replaced  ||| S:10843 E:10852 ||| VBN
by  ||| S:10852 E:10865 ||| IN
alanine  ||| S:10865 E:10873 ||| NNS
[  ||| S:10873 E:10875 ||| -LRB-
24  ||| S:10875 E:10878 ||| CD
]  ||| S:10878 E:10880 ||| -RRB-
was  ||| S:10880 E:10884 ||| VBD
also  ||| S:10884 E:10889 ||| RB
prepared ||| S:10889 E:10897 ||| VBN
.  ||| S:10897 E:10899 ||| .
Both  ||| S:10899 E:10904 ||| DT
substrates  ||| S:10904 E:10915 ||| NN
were  ||| S:10915 E:10930 ||| VBD
incubated  ||| S:10930 E:10940 ||| VBN
with  ||| S:10940 E:10945 ||| IN
recombinant  ||| S:10945 E:10957 ||| JJ
cyclin  ||| S:10957 E:10964 ||| JJ
E ||| S:10964 E:10965 ||| NN
/ ||| S:10965 E:10966 ||| CD
CDK2  ||| S:10966 E:10971 ||| CD
complexes  ||| S:10971 E:10981 ||| NNS
in  ||| S:10981 E:10984 ||| IN
the  ||| S:10984 E:10998 ||| DT
presence  ||| S:10998 E:11007 ||| NN
of  ||| S:11007 E:11010 ||| IN
ATP ||| S:11010 E:11013 ||| NNP
,  ||| S:11013 E:11015 ||| ,
ubiquitin ||| S:11015 E:11024 ||| NN
,  ||| S:11024 E:11026 ||| ,
and  ||| S:11026 E:11030 ||| CC
LNCaP  ||| S:11030 E:11036 ||| JJ
cell  ||| S:11036 E:11041 ||| NN
lysate ||| S:11041 E:11047 ||| NN
.  ||| S:11047 E:11059 ||| .
Conversion  ||| S:11059 E:11070 ||| NN
of  ||| S:11070 E:11073 ||| IN
p27  ||| S:11073 E:11077 ||| CD
into  ||| S:11077 E:11082 ||| IN
polyubiquitylated  ||| S:11082 E:11100 ||| JJ
high  ||| S:11100 E:11105 ||| JJ
molecular  ||| S:11105 E:11125 ||| JJ
weight  ||| S:11125 E:11132 ||| NN
species  ||| S:11132 E:11140 ||| NNS
was  ||| S:11140 E:11144 ||| VBD
monitored  ||| S:11144 E:11154 ||| VBN
by  ||| S:11154 E:11157 ||| IN
autoradiography  ||| S:11157 E:11173 ||| NN
of  ||| S:11173 E:11186 ||| IN
35S-labeled  ||| S:11186 E:11198 ||| CD
p27  ||| S:11198 E:11202 ||| CD
following  ||| S:11202 E:11212 ||| JJ
gel  ||| S:11212 E:11216 ||| JJ
electrophoresis ||| S:11216 E:11231 ||| NN
.  ||| S:11231 E:11243 ||| .
Polyubiquitylation  ||| S:11243 E:11262 ||| NNP
of  ||| S:11262 E:11265 ||| IN
wildtype ||| S:11265 E:11273 ||| NN
,  ||| S:11273 E:11275 ||| ,
but  ||| S:11275 E:11279 ||| CC
not  ||| S:11279 E:11283 ||| RB
mutant  ||| S:11283 E:11290 ||| JJ
p27  ||| S:11290 E:11294 ||| NN
was  ||| S:11294 E:11308 ||| VBD
observed  ||| S:11308 E:11317 ||| VBN
in  ||| S:11317 E:11320 ||| IN
untreated  ||| S:11320 E:11330 ||| JJ
LNCaP  ||| S:11330 E:11336 ||| JJ
cell  ||| S:11336 E:11341 ||| NN
lysate  ||| S:11341 E:11348 ||| NNS
( ||| S:11348 E:11349 ||| -LRB-
Fig.  ||| S:11349 E:11354 ||| NNP
3C ||| S:11354 E:11356 ||| NNP
) ||| S:11356 E:11357 ||| -RRB-
.  ||| S:11357 E:11359 ||| .
This  ||| S:11359 E:11374 ||| DT
activity  ||| S:11374 E:11383 ||| NN
was  ||| S:11383 E:11387 ||| VBD
completely  ||| S:11387 E:11398 ||| RB
abolished  ||| S:11398 E:11408 ||| VBN
in  ||| S:11408 E:11411 ||| IN
MIB-treated  ||| S:11411 E:11423 ||| JJ
cells  ||| S:11423 E:11439 ||| NNS
( ||| S:11439 E:11440 ||| -LRB-
Fig.  ||| S:11440 E:11445 ||| NNP
3C ||| S:11445 E:11447 ||| NNP
) ||| S:11447 E:11448 ||| -RRB-
,  ||| S:11448 E:11450 ||| ,
suggesting  ||| S:11450 E:11461 ||| VBG
that  ||| S:11461 E:11466 ||| IN
p27  ||| S:11466 E:11470 ||| CD
accumulation  ||| S:11470 E:11483 ||| NN
results  ||| S:11483 E:11491 ||| NNS
from  ||| S:11491 E:11506 ||| IN
reduced  ||| S:11506 E:11514 ||| JJ
p27  ||| S:11514 E:11518 ||| CD
ubiquitylation ||| S:11518 E:11532 ||| NNS
.  ||| S:11532 E:11562 ||| .
Overexpression  ||| S:11562 E:11577 ||| NNP
of  ||| S:11577 E:11580 ||| IN
SKP2  ||| S:11580 E:11585 ||| NNP
induces  ||| S:11585 E:11593 ||| VBZ
F-box-dependent  ||| S:11593 E:11609 ||| JJ
p27  ||| S:11609 E:11623 ||| NN
ubiquitylation  ||| S:11623 E:11648 ||| VBZ
Considering  ||| S:11648 E:11660 ||| VBG
the  ||| S:11660 E:11664 ||| DT
inverse  ||| S:11664 E:11672 ||| JJ
correlation  ||| S:11672 E:11684 ||| NN
between  ||| S:11684 E:11692 ||| IN
p27  ||| S:11692 E:11696 ||| NNP
and  ||| S:11696 E:11710 ||| CC
SKP2  ||| S:11710 E:11715 ||| CD
protein  ||| S:11715 E:11723 ||| NN
levels ||| S:11723 E:11729 ||| NNS
,  ||| S:11729 E:11731 ||| ,
we  ||| S:11731 E:11734 ||| PRP
asked  ||| S:11734 E:11740 ||| VBD
whether  ||| S:11740 E:11748 ||| IN
ectopic  ||| S:11748 E:11756 ||| JJ
SKP2  ||| S:11756 E:11761 ||| NN
can  ||| S:11761 E:11775 ||| MD
forge  ||| S:11775 E:11781 ||| VB
p27  ||| S:11781 E:11785 ||| CD
down-regulation  ||| S:11785 E:11801 ||| NN
in  ||| S:11801 E:11804 ||| IN
LNCaP  ||| S:11804 E:11810 ||| JJ
cells ||| S:11810 E:11815 ||| NNS
.  ||| S:11815 E:11817 ||| .
To  ||| S:11817 E:11820 ||| TO
test  ||| S:11820 E:11825 ||| VB
this ||| S:11825 E:11829 ||| DT
,  ||| S:11829 E:11841 ||| ,
we  ||| S:11841 E:11844 ||| PRP
generated  ||| S:11844 E:11854 ||| VBD
recombinant  ||| S:11854 E:11866 ||| JJ
adenoviruses  ||| S:11866 E:11879 ||| NNS
driving  ||| S:11879 E:11887 ||| VBG
the  ||| S:11887 E:11901 ||| DT
expression  ||| S:11901 E:11912 ||| NN
of  ||| S:11912 E:11915 ||| IN
SKP2  ||| S:11915 E:11920 ||| NNP
( ||| S:11920 E:11921 ||| -LRB-
Ad-SKP2 ||| S:11921 E:11928 ||| NNP
)  ||| S:11928 E:11930 ||| -RRB-
or  ||| S:11930 E:11933 ||| CC
a  ||| S:11933 E:11935 ||| DT
mutant  ||| S:11935 E:11942 ||| NN
of  ||| S:11942 E:11945 ||| IN
SKP2  ||| S:11945 E:11950 ||| CD
lacking  ||| S:11950 E:11968 ||| VBG
the  ||| S:11968 E:11972 ||| DT
F-box  ||| S:11972 E:11978 ||| JJ
( ||| S:11978 E:11979 ||| -LRB-
Ad-SKP2-ΔF ||| S:11979 E:11989 ||| NNP
) ||| S:11989 E:11990 ||| -RRB-
.  ||| S:11990 E:11992 ||| .
Infection  ||| S:11992 E:12002 ||| NN
of  ||| S:12002 E:12005 ||| IN
asynchronous  ||| S:12005 E:12018 ||| JJ
LNCaP  ||| S:12018 E:12034 ||| JJ
cells  ||| S:12034 E:12040 ||| NNS
with  ||| S:12040 E:12045 ||| IN
SKP2  ||| S:12045 E:12050 ||| CD
virus  ||| S:12050 E:12056 ||| NN
led  ||| S:12056 E:12060 ||| VBD
to  ||| S:12060 E:12063 ||| TO
time-dependent  ||| S:12063 E:12088 ||| JJ
downregulation  ||| S:12088 E:12103 ||| NN
of  ||| S:12103 E:12106 ||| IN
p27  ||| S:12106 E:12110 ||| NNP
( ||| S:12110 E:12111 ||| -LRB-
Fig.  ||| S:12111 E:12116 ||| NNP
4A ||| S:12116 E:12118 ||| NNP
) ||| S:12118 E:12119 ||| -RRB-
.  ||| S:12119 E:12131 ||| .
To  ||| S:12131 E:12134 ||| TO
determine  ||| S:12134 E:12144 ||| VB
whether  ||| S:12144 E:12152 ||| IN
SKP2  ||| S:12152 E:12157 ||| CD
downregulation  ||| S:12157 E:12172 ||| NN
is  ||| S:12172 E:12175 ||| VBZ
a  ||| S:12175 E:12187 ||| DT
necessary  ||| S:12187 E:12197 ||| JJ
step  ||| S:12197 E:12202 ||| NN
in  ||| S:12202 E:12205 ||| IN
MIB-induced  ||| S:12205 E:12217 ||| JJ
p27  ||| S:12217 E:12221 ||| CD
upregulation ||| S:12221 E:12233 ||| NN
,  ||| S:12233 E:12235 ||| ,
LNCaP  ||| S:12235 E:12251 ||| JJ
cells  ||| S:12251 E:12257 ||| NNS
were  ||| S:12257 E:12262 ||| VBD
blocked  ||| S:12262 E:12270 ||| VBN
with  ||| S:12270 E:12275 ||| IN
MIB  ||| S:12275 E:12279 ||| NNP
for  ||| S:12279 E:12283 ||| IN
72  ||| S:12283 E:12286 ||| CD
h ||| S:12286 E:12287 ||| NN
,  ||| S:12287 E:12289 ||| ,
followed  ||| S:12289 E:12298 ||| VBN
by  ||| S:12298 E:12311 ||| IN
infection  ||| S:12311 E:12321 ||| NN
with  ||| S:12321 E:12326 ||| IN
Ad-SKP2  ||| S:12326 E:12334 ||| NNP
or  ||| S:12334 E:12337 ||| CC
Ad-SKP2-ΔF  ||| S:12337 E:12348 ||| CD
for  ||| S:12348 E:12352 ||| IN
various  ||| S:12352 E:12360 ||| JJ
periods ||| S:12360 E:12367 ||| NNS
.  ||| S:12367 E:12379 ||| .
Immunoblotting  ||| S:12379 E:12394 ||| NNP
revealed  ||| S:12394 E:12403 ||| VBD
that  ||| S:12403 E:12408 ||| IN
SKP2  ||| S:12408 E:12413 ||| CD
overexpression  ||| S:12413 E:12428 ||| NNS
can  ||| S:12428 E:12442 ||| MD
efficiently  ||| S:12442 E:12454 ||| RB
downregulate  ||| S:12454 E:12467 ||| CD
p27  ||| S:12467 E:12471 ||| CD
levels  ||| S:12471 E:12478 ||| NNS
in  ||| S:12478 E:12481 ||| IN
the  ||| S:12481 E:12485 ||| DT
continuous  ||| S:12485 E:12506 ||| JJ
presence  ||| S:12506 E:12515 ||| NN
of  ||| S:12515 E:12518 ||| IN
MIB  ||| S:12518 E:12522 ||| NNP
( ||| S:12522 E:12523 ||| -LRB-
Fig.  ||| S:12523 E:12528 ||| NNP
4B ||| S:12528 E:12530 ||| NNP
) ||| S:12530 E:12531 ||| -RRB-
.  ||| S:12531 E:12533 ||| .
In  ||| S:12533 E:12536 ||| IN
contrast ||| S:12536 E:12544 ||| NN
,  ||| S:12544 E:12546 ||| ,
overexpression  ||| S:12546 E:12561 ||| VBG
of  ||| S:12561 E:12574 ||| IN
F-box  ||| S:12574 E:12580 ||| JJ
deleted  ||| S:12580 E:12588 ||| JJ
SKP2  ||| S:12588 E:12593 ||| NN
did  ||| S:12593 E:12597 ||| VBD
not  ||| S:12597 E:12601 ||| RB
result  ||| S:12601 E:12608 ||| VB
in  ||| S:12608 E:12611 ||| IN
a  ||| S:12611 E:12613 ||| DT
decline  ||| S:12613 E:12621 ||| NN
of  ||| S:12621 E:12624 ||| IN
p27  ||| S:12624 E:12638 ||| NNP
( ||| S:12638 E:12639 ||| -LRB-
Fig.  ||| S:12639 E:12644 ||| NNP
4B ||| S:12644 E:12646 ||| NNP
) ||| S:12646 E:12647 ||| -RRB-
.  ||| S:12647 E:12659 ||| .
To  ||| S:12659 E:12662 ||| TO
determine  ||| S:12662 E:12672 ||| VB
whether  ||| S:12672 E:12680 ||| IN
SKP2  ||| S:12680 E:12685 ||| CD
induces  ||| S:12685 E:12693 ||| CD
p27  ||| S:12693 E:12697 ||| CD
ubiquitylation ||| S:12697 E:12711 ||| NN
,  ||| S:12711 E:12723 ||| ,
cell  ||| S:12723 E:12728 ||| NN
lysate  ||| S:12728 E:12735 ||| NNS
was  ||| S:12735 E:12739 ||| VBD
prepared  ||| S:12739 E:12748 ||| VBN
from  ||| S:12748 E:12753 ||| IN
MIB-exposed  ||| S:12753 E:12765 ||| JJ
cells  ||| S:12765 E:12771 ||| NNS
infected  ||| S:12771 E:12790 ||| VBN
with  ||| S:12790 E:12795 ||| IN
Ad-SKP2  ||| S:12795 E:12803 ||| NNP
and  ||| S:12803 E:12807 ||| CC
Ad-SKP2-ΔF ||| S:12807 E:12817 ||| NNP
,  ||| S:12817 E:12819 ||| ,
and  ||| S:12819 E:12823 ||| CC
supplemented  ||| S:12823 E:12836 ||| NN
with  ||| S:12836 E:12851 ||| IN
phosphorylated  ||| S:12851 E:12866 ||| CD
p27 ||| S:12866 E:12869 ||| CD
,  ||| S:12869 E:12871 ||| ,
ATP ||| S:12871 E:12874 ||| NNP
,  ||| S:12874 E:12876 ||| ,
and  ||| S:12876 E:12880 ||| CC
ubiquitin ||| S:12880 E:12889 ||| NN
.  ||| S:12889 E:12891 ||| .
SKP  ||| S:12891 E:12905 ||| NNP
overexpression  ||| S:12905 E:12920 ||| NN
for  ||| S:12920 E:12924 ||| IN
24  ||| S:12924 E:12927 ||| CD
or  ||| S:12927 E:12930 ||| CC
48  ||| S:12930 E:12933 ||| CD
h  ||| S:12933 E:12935 ||| NNS
dramatically  ||| S:12935 E:12948 ||| RB
increased  ||| S:12948 E:12958 ||| VBD
p27  ||| S:12958 E:12972 ||| CD
ubiquitylation  ||| S:12972 E:12987 ||| JJ
activity  ||| S:12987 E:12996 ||| NN
present  ||| S:12996 E:13004 ||| NN
in  ||| S:13004 E:13007 ||| IN
these  ||| S:13007 E:13013 ||| DT
cell  ||| S:13013 E:13018 ||| NN
lysates  ||| S:13018 E:13036 ||| NNS
( ||| S:13036 E:13037 ||| -LRB-
Fig.  ||| S:13037 E:13042 ||| NNP
4C ||| S:13042 E:13044 ||| NNP
,  ||| S:13044 E:13046 ||| ,
lane  ||| S:13046 E:13051 ||| CD
5  ||| S:13051 E:13053 ||| CD
and  ||| S:13053 E:13057 ||| CC
7 ||| S:13057 E:13058 ||| CD
) ||| S:13058 E:13059 ||| -RRB-
.  ||| S:13059 E:13061 ||| .
This  ||| S:13061 E:13066 ||| DT
increase  ||| S:13066 E:13075 ||| NN
was  ||| S:13075 E:13079 ||| VBD
not  ||| S:13079 E:13083 ||| RB
observed  ||| S:13083 E:13102 ||| VBN
with  ||| S:13102 E:13107 ||| IN
mutant  ||| S:13107 E:13114 ||| JJ
p27T187A  ||| S:13114 E:13123 ||| NN
as  ||| S:13123 E:13126 ||| IN
substrate  ||| S:13126 E:13136 ||| NN
and  ||| S:13136 E:13140 ||| CC
upon  ||| S:13140 E:13145 ||| IN
overexpression  ||| S:13145 E:13170 ||| NN
of  ||| S:13170 E:13173 ||| IN
SKP-ΔF  ||| S:13173 E:13180 ||| NNP
( ||| S:13180 E:13181 ||| -LRB-
Fig.  ||| S:13181 E:13186 ||| NNP
4C ||| S:13186 E:13188 ||| NNP
,  ||| S:13188 E:13190 ||| ,
lanes  ||| S:13190 E:13196 ||| CD
9  ||| S:13196 E:13198 ||| CD
and  ||| S:13198 E:13202 ||| CC
11 ||| S:13202 E:13204 ||| CD
) ||| S:13204 E:13205 ||| -RRB-
.  ||| S:13205 E:13235 ||| .
Overexpression  ||| S:13235 E:13250 ||| NNP
of  ||| S:13250 E:13253 ||| IN
SKP2  ||| S:13253 E:13258 ||| NNP
is  ||| S:13258 E:13261 ||| VBZ
not  ||| S:13261 E:13265 ||| RB
sufficient  ||| S:13265 E:13276 ||| JJ
to  ||| S:13276 E:13289 ||| TO
overcome  ||| S:13289 E:13298 ||| VB
androgen-mediated  ||| S:13298 E:13316 ||| JJ
G1  ||| S:13316 E:13319 ||| CD
arrest  ||| S:13319 E:13336 ||| NN
To  ||| S:13336 E:13339 ||| TO
test  ||| S:13339 E:13344 ||| VB
whether  ||| S:13344 E:13352 ||| IN
SKP2-mediated  ||| S:13352 E:13366 ||| CD
p27  ||| S:13366 E:13370 ||| CD
degradation  ||| S:13370 E:13382 ||| NN
is  ||| S:13382 E:13395 ||| VBZ
sufficient  ||| S:13395 E:13406 ||| JJ
to  ||| S:13406 E:13409 ||| TO
overcome  ||| S:13409 E:13418 ||| VB
the  ||| S:13418 E:13422 ||| DT
MIB-induced  ||| S:13422 E:13434 ||| JJ
G1  ||| S:13434 E:13437 ||| CD
cell  ||| S:13437 E:13442 ||| NN
cycle  ||| S:13442 E:13458 ||| NN
arrest ||| S:13458 E:13464 ||| NN
,  ||| S:13464 E:13466 ||| ,
LNCaP  ||| S:13466 E:13472 ||| JJ
cells  ||| S:13472 E:13478 ||| NNS
were  ||| S:13478 E:13483 ||| VBD
arrested  ||| S:13483 E:13492 ||| VBN
with  ||| S:13492 E:13497 ||| IN
MIB  ||| S:13497 E:13501 ||| NNP
for  ||| S:13501 E:13505 ||| IN
72  ||| S:13505 E:13508 ||| CD
h ||| S:13508 E:13509 ||| NN
,  ||| S:13509 E:13521 ||| ,
followed  ||| S:13521 E:13530 ||| VBN
by  ||| S:13530 E:13533 ||| IN
infection  ||| S:13533 E:13543 ||| NN
with  ||| S:13543 E:13548 ||| IN
SKP2  ||| S:13548 E:13553 ||| CD
adenovirus ||| S:13553 E:13563 ||| NNS
.  ||| S:13563 E:13565 ||| .
Cells  ||| S:13565 E:13571 ||| NNS
were  ||| S:13571 E:13586 ||| VBD
harvested  ||| S:13586 E:13596 ||| VBN
and  ||| S:13596 E:13600 ||| CC
analyzed  ||| S:13600 E:13609 ||| VBD
by  ||| S:13609 E:13612 ||| IN
flow  ||| S:13612 E:13617 ||| NN
cytometry  ||| S:13617 E:13627 ||| NN
after  ||| S:13627 E:13633 ||| IN
various  ||| S:13633 E:13651 ||| JJ
periods ||| S:13651 E:13658 ||| NNS
.  ||| S:13658 E:13660 ||| .
The  ||| S:13660 E:13664 ||| DT
mutant  ||| S:13664 E:13671 ||| JJ
SKP2-ΔF  ||| S:13671 E:13679 ||| NN
was  ||| S:13679 E:13683 ||| VBD
used  ||| S:13683 E:13688 ||| VBN
as  ||| S:13688 E:13691 ||| IN
a  ||| S:13691 E:13693 ||| DT
negative  ||| S:13693 E:13712 ||| JJ
control ||| S:13712 E:13719 ||| NN
.  ||| S:13719 E:13721 ||| .
Although ||| S:13721 E:13729 ||| IN
,  ||| S:13729 E:13731 ||| ,
in  ||| S:13731 E:13734 ||| IN
three  ||| S:13734 E:13740 ||| CD
independent  ||| S:13740 E:13752 ||| JJ
experiments ||| S:13752 E:13763 ||| NNS
,  ||| S:13763 E:13765 ||| ,
the  ||| S:13765 E:13779 ||| DT
fraction  ||| S:13779 E:13788 ||| NN
of  ||| S:13788 E:13791 ||| IN
cells  ||| S:13791 E:13797 ||| NNS
in  ||| S:13797 E:13800 ||| IN
S  ||| S:13800 E:13802 ||| NNP
phase  ||| S:13802 E:13808 ||| NN
was  ||| S:13808 E:13812 ||| VBD
significantly  ||| S:13812 E:13826 ||| RB
( ||| S:13826 E:13827 ||| -LRB-
p  ||| S:13827 E:13829 ||| CD
=  ||| S:13829 E:13841 ||| SYM
0.009 ||| S:13841 E:13846 ||| CD
)  ||| S:13846 E:13848 ||| -RRB-
higher  ||| S:13848 E:13855 ||| JJR
in  ||| S:13855 E:13858 ||| IN
MIB-arrested  ||| S:13858 E:13871 ||| JJ
cells  ||| S:13871 E:13877 ||| NNS
overexpressing  ||| S:13877 E:13892 ||| VBD
SKP2  ||| S:13892 E:13907 ||| CD
( ||| S:13907 E:13908 ||| -LRB-
7.93 ||| S:13908 E:13912 ||| CD
% ||| S:13912 E:13913 ||| NN
,  ||| S:13913 E:13915 ||| ,
+ ||| S:13915 E:13916 ||| CD
/ ||| S:13916 E:13917 ||| CD
-0.32 ||| S:13917 E:13922 ||| CD
)  ||| S:13922 E:13924 ||| -RRB-
than  ||| S:13924 E:13929 ||| IN
in  ||| S:13929 E:13932 ||| IN
SKP2-ΔF  ||| S:13932 E:13940 ||| CD
overexpressing  ||| S:13940 E:13955 ||| CD
cells  ||| S:13955 E:13971 ||| NNS
( ||| S:13971 E:13972 ||| -LRB-
4.02 ||| S:13972 E:13976 ||| NNP
% ||| S:13976 E:13977 ||| NN
,  ||| S:13977 E:13979 ||| ,
+ ||| S:13979 E:13980 ||| CD
/ ||| S:13980 E:13981 ||| CD
-1.41 ||| S:13981 E:13986 ||| CD
)  ||| S:13986 E:13988 ||| -RRB-
at  ||| S:13988 E:13991 ||| IN
a  ||| S:13991 E:13993 ||| DT
time  ||| S:13993 E:13998 ||| NN
when  ||| S:13998 E:14003 ||| WRB
p27  ||| S:14003 E:14007 ||| JJ
downregulation  ||| S:14007 E:14022 ||| NN
was  ||| S:14022 E:14036 ||| VBD
already  ||| S:14036 E:14044 ||| RB
apparent  ||| S:14044 E:14053 ||| JJ
( ||| S:14053 E:14054 ||| -LRB-
24  ||| S:14054 E:14057 ||| CD
h ||| S:14057 E:14058 ||| CD
) ||| S:14058 E:14059 ||| -RRB-
,  ||| S:14059 E:14061 ||| ,
the  ||| S:14061 E:14065 ||| DT
majority  ||| S:14065 E:14074 ||| NN
of  ||| S:14074 E:14077 ||| IN
cells  ||| S:14077 E:14083 ||| NNS
remained  ||| S:14083 E:14102 ||| VBD
tightly  ||| S:14102 E:14110 ||| RB
arrested  ||| S:14110 E:14119 ||| VBN
in  ||| S:14119 E:14122 ||| IN
G1  ||| S:14122 E:14125 ||| CD
over  ||| S:14125 E:14130 ||| IN
the  ||| S:14130 E:14134 ||| DT
entire  ||| S:14134 E:14141 ||| JJ
72  ||| S:14141 E:14144 ||| CD
h  ||| S:14144 E:14146 ||| JJ
course  ||| S:14146 E:14153 ||| NN
of  ||| S:14153 E:14156 ||| IN
the  ||| S:14156 E:14170 ||| DT
experiment  ||| S:14170 E:14181 ||| NN
( ||| S:14181 E:14182 ||| -LRB-
Fig.  ||| S:14182 E:14187 ||| NNP
5A ||| S:14187 E:14189 ||| NNP
) ||| S:14189 E:14190 ||| -RRB-
.  ||| S:14190 E:14202 ||| .
This  ||| S:14202 E:14207 ||| DT
finding  ||| S:14207 E:14215 ||| NN
is  ||| S:14215 E:14218 ||| VBZ
in  ||| S:14218 E:14221 ||| IN
contrast  ||| S:14221 E:14230 ||| NN
to  ||| S:14230 E:14233 ||| TO
serum  ||| S:14233 E:14239 ||| VB
starved  ||| S:14239 E:14247 ||| VBN
rat  ||| S:14247 E:14261 ||| JJ
fibroblasts  ||| S:14261 E:14273 ||| NN
and  ||| S:14273 E:14277 ||| CC
human  ||| S:14277 E:14283 ||| JJ
U87  ||| S:14283 E:14287 ||| CD
cells  ||| S:14287 E:14293 ||| NNS
arrested  ||| S:14293 E:14302 ||| VBN
in  ||| S:14302 E:14305 ||| IN
G1  ||| S:14305 E:14308 ||| CD
by  ||| S:14308 E:14321 ||| IN
overexpression  ||| S:14321 E:14336 ||| NN
of  ||| S:14336 E:14339 ||| IN
PTEN ||| S:14339 E:14343 ||| NNP
,  ||| S:14343 E:14345 ||| ,
in  ||| S:14345 E:14348 ||| IN
which  ||| S:14348 E:14354 ||| WDT
SKP2  ||| S:14354 E:14359 ||| CD
overexpression  ||| S:14359 E:14374 ||| NNS
can  ||| S:14374 E:14388 ||| MD
drive  ||| S:14388 E:14394 ||| VB
S  ||| S:14394 E:14396 ||| NNP
phase  ||| S:14396 E:14402 ||| FW
entry.  ||| S:14402 E:14409 ||| FW
[  ||| S:14409 E:14411 ||| -LRB-
29  ||| S:14411 E:14414 ||| CD
30  ||| S:14414 E:14417 ||| CD
32  ||| S:14417 E:14420 ||| CD
33  ||| S:14420 E:14423 ||| CD
]  ||| S:14423 E:14425 ||| -RRB-
.  ||| S:14425 E:14427 ||| .
In  ||| S:14427 E:14430 ||| IN
both  ||| S:14430 E:14435 ||| DT
cases ||| S:14435 E:14440 ||| NNS
,  ||| S:14440 E:14452 ||| ,
SKP2  ||| S:14452 E:14457 ||| CD
overexpression  ||| S:14457 E:14472 ||| NN
leads  ||| S:14472 E:14478 ||| VBZ
to  ||| S:14478 E:14481 ||| TO
induction  ||| S:14481 E:14491 ||| VB
of  ||| S:14491 E:14494 ||| IN
cyclin  ||| S:14494 E:14501 ||| JJ
A  ||| S:14501 E:14503 ||| NN
and  ||| S:14503 E:14517 ||| CC
CDK2  ||| S:14517 E:14522 ||| CD
kinase  ||| S:14522 E:14529 ||| JJ
activity ||| S:14529 E:14537 ||| NN
.  ||| S:14537 E:14539 ||| .
We  ||| S:14539 E:14542 ||| PRP
therefore  ||| S:14542 E:14552 ||| RB
asked  ||| S:14552 E:14558 ||| VBN
whether  ||| S:14558 E:14576 ||| IN
SKP2-mediated  ||| S:14576 E:14590 ||| CD
p27  ||| S:14590 E:14594 ||| CD
downregulation  ||| S:14594 E:14609 ||| NN
in  ||| S:14609 E:14612 ||| IN
MIB  ||| S:14612 E:14616 ||| NNP
arrested  ||| S:14616 E:14625 ||| VBN
LNCaP  ||| S:14625 E:14641 ||| JJ
cells  ||| S:14641 E:14647 ||| NNS
was  ||| S:14647 E:14651 ||| VBD
able  ||| S:14651 E:14656 ||| JJ
to  ||| S:14656 E:14659 ||| TO
actually  ||| S:14659 E:14668 ||| RB
bring  ||| S:14668 E:14674 ||| VB
about  ||| S:14674 E:14680 ||| IN
CDK2  ||| S:14680 E:14695 ||| CD
activation ||| S:14695 E:14705 ||| NNS
.  ||| S:14705 E:14717 ||| .
We  ||| S:14717 E:14720 ||| PRP
first  ||| S:14720 E:14726 ||| RB
determined  ||| S:14726 E:14737 ||| VBN
the  ||| S:14737 E:14741 ||| DT
effect  ||| S:14741 E:14748 ||| NN
of  ||| S:14748 E:14751 ||| IN
SKP2  ||| S:14751 E:14756 ||| CD
overexpression  ||| S:14756 E:14781 ||| NN
on  ||| S:14781 E:14784 ||| IN
MIB-induced  ||| S:14784 E:14796 ||| JJ
RB1  ||| S:14796 E:14800 ||| CD
downregulation  ||| S:14800 E:14815 ||| NNS
and  ||| S:14815 E:14819 ||| CC
accumulation  ||| S:14819 E:14832 ||| NN
in  ||| S:14832 E:14835 ||| IN
the  ||| S:14835 E:14849 ||| DT
dephosphorylated  ||| S:14849 E:14866 ||| JJ
state  ||| S:14866 E:14872 ||| NN
( ||| S:14872 E:14873 ||| -LRB-
see  ||| S:14873 E:14877 ||| VB
Fig.  ||| S:14877 E:14882 ||| CD
2A ||| S:14882 E:14884 ||| CD
) ||| S:14884 E:14885 ||| -RRB-
,  ||| S:14885 E:14887 ||| ,
which  ||| S:14887 E:14893 ||| WDT
is  ||| S:14893 E:14896 ||| VBZ
carried  ||| S:14896 E:14914 ||| VBN
out  ||| S:14914 E:14918 ||| RP
by  ||| S:14918 E:14921 ||| IN
CDK2  ||| S:14921 E:14937 ||| CD
in  ||| S:14937 E:14940 ||| IN
vivo  ||| S:14940 E:14945 ||| NNS
[  ||| S:14945 E:14947 ||| -LRB-
47  ||| S:14947 E:14950 ||| CD
]  ||| S:14950 E:14952 ||| -RRB-
.  ||| S:14952 E:14954 ||| .
Immunoblotting  ||| S:14954 E:14979 ||| NNP
revealed  ||| S:14979 E:14988 ||| VBD
that  ||| S:14988 E:14993 ||| IN
RB1  ||| S:14993 E:14997 ||| CD
suppression  ||| S:14997 E:15009 ||| NN
in  ||| S:15009 E:15012 ||| IN
the  ||| S:15012 E:15016 ||| DT
hypophosphorylated  ||| S:15016 E:15045 ||| JJ
state  ||| S:15045 E:15051 ||| NN
was  ||| S:15051 E:15055 ||| VBD
efficiently  ||| S:15055 E:15067 ||| RB
reversed  ||| S:15067 E:15076 ||| VBN
by  ||| S:15076 E:15079 ||| IN
SKP2  ||| S:15079 E:15084 ||| CD
overexpression  ||| S:15084 E:15099 ||| NN
for  ||| S:15099 E:15113 ||| IN
24  ||| S:15113 E:15116 ||| CD
or  ||| S:15116 E:15119 ||| CC
48  ||| S:15119 E:15122 ||| CD
h  ||| S:15122 E:15124 ||| NNS
( ||| S:15124 E:15125 ||| -LRB-
Fig.  ||| S:15125 E:15130 ||| NNP
5B ||| S:15130 E:15132 ||| NNP
) ||| S:15132 E:15133 ||| -RRB-
.  ||| S:15133 E:15135 ||| .
In  ||| S:15135 E:15138 ||| IN
addition ||| S:15138 E:15146 ||| NN
,  ||| S:15146 E:15148 ||| ,
cyclin  ||| S:15148 E:15155 ||| VBG
A  ||| S:15155 E:15157 ||| DT
expression  ||| S:15157 E:15178 ||| NN
was  ||| S:15178 E:15182 ||| VBD
partially  ||| S:15182 E:15192 ||| RB
restored  ||| S:15192 E:15201 ||| VBN
( ||| S:15201 E:15202 ||| -LRB-
Fig.  ||| S:15202 E:15207 ||| NNP
5B ||| S:15207 E:15209 ||| NNP
) ||| S:15209 E:15210 ||| -RRB-
.  ||| S:15210 E:15212 ||| .
However ||| S:15212 E:15219 ||| RB
,  ||| S:15219 E:15221 ||| ,
both  ||| S:15221 E:15226 ||| DT
effects  ||| S:15226 E:15244 ||| NNS
were  ||| S:15244 E:15249 ||| VBD
largely  ||| S:15249 E:15257 ||| RB
annihilated  ||| S:15257 E:15269 ||| VBN
after  ||| S:15269 E:15275 ||| IN
72  ||| S:15275 E:15278 ||| CD
h  ||| S:15278 E:15280 ||| NN
of  ||| S:15280 E:15283 ||| IN
SKP2  ||| S:15283 E:15298 ||| CD
overexpression ||| S:15298 E:15312 ||| NNS
.  ||| S:15312 E:15314 ||| .
In  ||| S:15314 E:15317 ||| IN
contrast ||| S:15317 E:15325 ||| NN
,  ||| S:15325 E:15327 ||| ,
cyclin  ||| S:15327 E:15334 ||| JJ
E  ||| S:15334 E:15336 ||| NN
levels ||| S:15336 E:15342 ||| NNS
,  ||| S:15342 E:15344 ||| ,
while  ||| S:15344 E:15350 ||| IN
not  ||| S:15350 E:15364 ||| RB
initially  ||| S:15364 E:15374 ||| RB
affected  ||| S:15374 E:15383 ||| VBN
by  ||| S:15383 E:15386 ||| IN
MIB ||| S:15386 E:15389 ||| NNP
,  ||| S:15389 E:15391 ||| ,
were  ||| S:15391 E:15396 ||| VBD
decreased  ||| S:15396 E:15406 ||| VBN
after  ||| S:15406 E:15412 ||| IN
72  ||| S:15412 E:15415 ||| CD
h  ||| S:15415 E:15417 ||| NN
of  ||| S:15417 E:15430 ||| IN
SKP2  ||| S:15430 E:15435 ||| CD
overexpression  ||| S:15435 E:15450 ||| NNS
( ||| S:15450 E:15451 ||| -LRB-
Fig.  ||| S:15451 E:15456 ||| NNP
5B ||| S:15456 E:15458 ||| NNP
) ||| S:15458 E:15459 ||| -RRB-
.  ||| S:15459 E:15461 ||| .
In  ||| S:15461 E:15464 ||| IN
contrast ||| S:15464 E:15472 ||| NN
,  ||| S:15472 E:15474 ||| ,
CDK2  ||| S:15474 E:15479 ||| NNP
and  ||| S:15479 E:15493 ||| CC
tubulin  ||| S:15493 E:15501 ||| JJ
levels  ||| S:15501 E:15508 ||| NNS
remained  ||| S:15508 E:15517 ||| VBD
stable  ||| S:15517 E:15524 ||| JJ
at  ||| S:15524 E:15527 ||| IN
all  ||| S:15527 E:15531 ||| DT
time  ||| S:15531 E:15536 ||| NN
points  ||| S:15536 E:15543 ||| NNS
of  ||| S:15543 E:15546 ||| IN
SKP2  ||| S:15546 E:15561 ||| CD
overexpression  ||| S:15561 E:15576 ||| NNS
( ||| S:15576 E:15577 ||| -LRB-
Fig.  ||| S:15577 E:15582 ||| NNP
5B ||| S:15582 E:15584 ||| NNP
) ||| S:15584 E:15585 ||| -RRB-
.  ||| S:15585 E:15597 ||| .
A  ||| S:15597 E:15599 ||| DT
parallel  ||| S:15599 E:15608 ||| JJ
experiment ||| S:15608 E:15618 ||| NN
,  ||| S:15618 E:15620 ||| ,
revealed  ||| S:15620 E:15629 ||| VBD
that  ||| S:15629 E:15634 ||| IN
CDK2  ||| S:15634 E:15639 ||| CD
kinase  ||| S:15639 E:15656 ||| JJ
activity  ||| S:15656 E:15665 ||| NN
assayed  ||| S:15665 E:15684 ||| NN
in  ||| S:15684 E:15687 ||| IN
vitro  ||| S:15687 E:15693 ||| NNS
using  ||| S:15693 E:15699 ||| VBG
histone  ||| S:15699 E:15707 ||| CD
1  ||| S:15707 E:15709 ||| CD
as  ||| S:15709 E:15722 ||| IN
substrate  ||| S:15722 E:15732 ||| NN
was  ||| S:15732 E:15736 ||| VBD
suppressed  ||| S:15736 E:15747 ||| VBN
by  ||| S:15747 E:15750 ||| IN
MIB ||| S:15750 E:15753 ||| NNP
,  ||| S:15753 E:15755 ||| ,
but  ||| S:15755 E:15759 ||| CC
partially  ||| S:15759 E:15769 ||| RB
restored  ||| S:15769 E:15788 ||| VBN
by  ||| S:15788 E:15791 ||| IN
overexpression  ||| S:15791 E:15806 ||| NN
of  ||| S:15806 E:15809 ||| IN
SKP2  ||| S:15809 E:15814 ||| CD
for  ||| S:15814 E:15818 ||| IN
24  ||| S:15818 E:15821 ||| CD
and  ||| S:15821 E:15825 ||| CC
48  ||| S:15825 E:15828 ||| CD
h  ||| S:15828 E:15830 ||| NNS
( ||| S:15830 E:15831 ||| -LRB-
Fig.  ||| S:15831 E:15836 ||| NNP
5C ||| S:15836 E:15838 ||| NNP
,  ||| S:15838 E:15840 ||| ,
left  ||| S:15840 E:15855 ||| VBN
panel ||| S:15855 E:15860 ||| NN
) ||| S:15860 E:15861 ||| -RRB-
.  ||| S:15861 E:15863 ||| .
This  ||| S:15863 E:15868 ||| DT
increase  ||| S:15868 E:15877 ||| NN
was  ||| S:15877 E:15881 ||| VBD
paralleled  ||| S:15881 E:15892 ||| VBN
by  ||| S:15892 E:15895 ||| IN
a  ||| S:15895 E:15897 ||| DT
decrease  ||| S:15897 E:15906 ||| NN
in  ||| S:15906 E:15909 ||| IN
the  ||| S:15909 E:15923 ||| DT
amount  ||| S:15923 E:15930 ||| NN
of  ||| S:15930 E:15933 ||| IN
p27  ||| S:15933 E:15937 ||| CD
associated  ||| S:15937 E:15948 ||| VBN
with  ||| S:15948 E:15953 ||| IN
cyclin  ||| S:15953 E:15960 ||| JJ
E  ||| S:15960 E:15962 ||| NN
( ||| S:15962 E:15963 ||| -LRB-
Fig.  ||| S:15963 E:15968 ||| NNP
5C ||| S:15968 E:15970 ||| NNP
,  ||| S:15970 E:15972 ||| ,
right  ||| S:15972 E:15988 ||| JJ
panel ||| S:15988 E:15993 ||| NN
) ||| S:15993 E:15994 ||| -RRB-
.  ||| S:15994 E:15996 ||| .
While  ||| S:15996 E:16002 ||| IN
this  ||| S:16002 E:16007 ||| DT
decrease  ||| S:16007 E:16016 ||| NN
was  ||| S:16016 E:16020 ||| VBD
maintained  ||| S:16020 E:16031 ||| VBN
throughout  ||| S:16031 E:16042 ||| IN
the  ||| S:16042 E:16056 ||| DT
course  ||| S:16056 E:16063 ||| NN
of  ||| S:16063 E:16066 ||| IN
the  ||| S:16066 E:16070 ||| DT
experiment ||| S:16070 E:16080 ||| NN
,  ||| S:16080 E:16082 ||| ,
CDK2  ||| S:16082 E:16087 ||| CD
activation  ||| S:16087 E:16098 ||| NNS
was  ||| S:16098 E:16102 ||| VBD
attenuated  ||| S:16102 E:16123 ||| VBN
again  ||| S:16123 E:16129 ||| RB
at  ||| S:16129 E:16132 ||| IN
72  ||| S:16132 E:16135 ||| CD
h  ||| S:16135 E:16137 ||| NN
of  ||| S:16137 E:16140 ||| IN
SKP2  ||| S:16140 E:16145 ||| CD
overexpression ||| S:16145 E:16159 ||| NNS
.  ||| S:16159 E:16161 ||| .
In  ||| S:16161 E:16164 ||| IN
summary ||| S:16164 E:16171 ||| NN
,  ||| S:16171 E:16173 ||| ,
SKP2  ||| S:16173 E:16188 ||| NNP
overexpression  ||| S:16188 E:16203 ||| VBD
caused  ||| S:16203 E:16210 ||| VBN
transient  ||| S:16210 E:16220 ||| JJ
upregulation  ||| S:16220 E:16233 ||| NN
of  ||| S:16233 E:16236 ||| IN
cyclin  ||| S:16236 E:16243 ||| VBG
A  ||| S:16243 E:16255 ||| DT
expression  ||| S:16255 E:16266 ||| NN
and  ||| S:16266 E:16270 ||| CC
CDK2  ||| S:16270 E:16275 ||| CD
activity ||| S:16275 E:16283 ||| NN
,  ||| S:16283 E:16285 ||| ,
but  ||| S:16285 E:16289 ||| CC
was  ||| S:16289 E:16293 ||| VBD
inefficient  ||| S:16293 E:16305 ||| JJ
in  ||| S:16305 E:16318 ||| IN
promoting  ||| S:16318 E:16328 ||| VBG
S  ||| S:16328 E:16330 ||| NNP
phase  ||| S:16330 E:16336 ||| NN
entry  ||| S:16336 E:16342 ||| NN
of  ||| S:16342 E:16345 ||| IN
MIB-arrested  ||| S:16345 E:16358 ||| JJ
LNCaP  ||| S:16358 E:16364 ||| JJ
cells ||| S:16364 E:16369 ||| NNS
.  ||| S:16369 E:16402 ||| .
Discussion  ||| S:16402 E:16432 ||| NNP
Androgen  ||| S:16432 E:16441 ||| NNP
control  ||| S:16441 E:16449 ||| NN
of  ||| S:16449 E:16452 ||| IN
LNCaP  ||| S:16452 E:16458 ||| JJ
cell  ||| S:16458 E:16463 ||| NN
proliferation  ||| S:16463 E:16487 ||| NN
We  ||| S:16487 E:16490 ||| PRP
have  ||| S:16490 E:16495 ||| VBP
used  ||| S:16495 E:16500 ||| VBN
the  ||| S:16500 E:16504 ||| DT
cell  ||| S:16504 E:16509 ||| NN
line  ||| S:16509 E:16514 ||| NN
LNCaP  ||| S:16514 E:16520 ||| NN
as  ||| S:16520 E:16523 ||| IN
a  ||| S:16523 E:16525 ||| DT
model  ||| S:16525 E:16531 ||| NN
to  ||| S:16531 E:16534 ||| TO
examine  ||| S:16534 E:16552 ||| VB
the  ||| S:16552 E:16556 ||| DT
role  ||| S:16556 E:16561 ||| NN
of  ||| S:16561 E:16564 ||| IN
SKP2  ||| S:16564 E:16569 ||| CD
in  ||| S:16569 E:16572 ||| IN
androgen  ||| S:16572 E:16581 ||| JJ
control  ||| S:16581 E:16589 ||| NN
of  ||| S:16589 E:16592 ||| IN
p27  ||| S:16592 E:16596 ||| CD
expression  ||| S:16596 E:16617 ||| NN
and  ||| S:16617 E:16621 ||| CC
cell  ||| S:16621 E:16626 ||| NN
cycle  ||| S:16626 E:16632 ||| NN
progression  ||| S:16632 E:16644 ||| NN
in  ||| S:16644 E:16647 ||| IN
human  ||| S:16647 E:16653 ||| JJ
prostate  ||| S:16653 E:16662 ||| JJ
cancer  ||| S:16662 E:16679 ||| NN
cells ||| S:16679 E:16684 ||| NNS
.  ||| S:16684 E:16686 ||| .
LNCaP  ||| S:16686 E:16692 ||| JJ
cells  ||| S:16692 E:16698 ||| NNS
exhibit  ||| S:16698 E:16706 ||| VBP
a  ||| S:16706 E:16708 ||| DT
complex ||| S:16708 E:16715 ||| NN
,  ||| S:16715 E:16717 ||| ,
but  ||| S:16717 E:16721 ||| CC
characteristic  ||| S:16721 E:16746 ||| JJ
biphasic  ||| S:16746 E:16755 ||| JJ
response  ||| S:16755 E:16764 ||| NN
to  ||| S:16764 E:16767 ||| TO
androgens ||| S:16767 E:16776 ||| VB
:  ||| S:16776 E:16778 ||| :
( ||| S:16778 E:16779 ||| -LRB-
1 ||| S:16779 E:16780 ||| LS
. ||| S:16780 E:16781 ||| .
)  ||| S:16781 E:16783 ||| -RRB-
Stimulation  ||| S:16783 E:16795 ||| NN
of  ||| S:16795 E:16808 ||| IN
proliferation  ||| S:16808 E:16822 ||| NN
at  ||| S:16822 E:16825 ||| IN
low  ||| S:16825 E:16829 ||| JJ
androgen  ||| S:16829 E:16838 ||| JJ
levels ||| S:16838 E:16844 ||| NNS
,  ||| S:16844 E:16846 ||| ,
and  ||| S:16846 E:16850 ||| CC
( ||| S:16850 E:16851 ||| -LRB-
2. ||| S:16851 E:16853 ||| NNP
)  ||| S:16853 E:16855 ||| -RRB-
inhibition  ||| S:16855 E:16876 ||| NN
of  ||| S:16876 E:16879 ||| IN
proliferation  ||| S:16879 E:16893 ||| NN
at  ||| S:16893 E:16896 ||| IN
higher  ||| S:16896 E:16903 ||| JJR
levels  ||| S:16903 E:16910 ||| NNS
such  ||| S:16910 E:16915 ||| JJ
as  ||| S:16915 E:16918 ||| IN
those  ||| S:16918 E:16924 ||| DT
used  ||| S:16924 E:16929 ||| VBN
in  ||| S:16929 E:16942 ||| IN
this  ||| S:16942 E:16947 ||| DT
study  ||| S:16947 E:16953 ||| NN
[  ||| S:16953 E:16955 ||| -LRB-
41  ||| S:16955 E:16958 ||| CD
]  ||| S:16958 E:16960 ||| -RRB-
.  ||| S:16960 E:16962 ||| .
This  ||| S:16962 E:16967 ||| DT
dichotomy  ||| S:16967 E:16977 ||| NN
was  ||| S:16977 E:16981 ||| VBD
compared  ||| S:16981 E:16990 ||| VBN
[  ||| S:16990 E:16992 ||| -LRB-
43  ||| S:16992 E:16995 ||| CD
]  ||| S:16995 E:16997 ||| -RRB-
to  ||| S:16997 E:17010 ||| TO
the  ||| S:17010 E:17014 ||| DT
situation  ||| S:17014 E:17024 ||| NN
in  ||| S:17024 E:17027 ||| IN
male  ||| S:17027 E:17032 ||| JJ
rodents ||| S:17032 E:17039 ||| NNS
,  ||| S:17039 E:17041 ||| ,
where  ||| S:17041 E:17047 ||| WRB
castration  ||| S:17047 E:17058 ||| JJ
leads  ||| S:17058 E:17064 ||| NNS
to  ||| S:17064 E:17077 ||| TO
atrophy  ||| S:17077 E:17085 ||| VB
of  ||| S:17085 E:17088 ||| IN
the  ||| S:17088 E:17092 ||| DT
prostate  ||| S:17092 E:17101 ||| JJ
due  ||| S:17101 E:17105 ||| JJ
to  ||| S:17105 E:17108 ||| TO
apoptosis ||| S:17108 E:17117 ||| VB
.  ||| S:17117 E:17129 ||| .
Re-administration  ||| S:17129 E:17147 ||| JJ
of  ||| S:17147 E:17150 ||| IN
androgen  ||| S:17150 E:17159 ||| FW
induces  ||| S:17159 E:17167 ||| FW
transient  ||| S:17167 E:17187 ||| FW
epithelial  ||| S:17187 E:17198 ||| FW
cell  ||| S:17198 E:17203 ||| FW
proliferation ||| S:17203 E:17216 ||| FW
,  ||| S:17216 E:17218 ||| ,
presumably  ||| S:17218 E:17229 ||| RB
mediated  ||| S:17229 E:17238 ||| VBN
by  ||| S:17238 E:17251 ||| IN
proteolytic  ||| S:17251 E:17263 ||| JJ
downregulation  ||| S:17263 E:17278 ||| NN
of  ||| S:17278 E:17281 ||| IN
p27 ||| S:17281 E:17284 ||| NNP
,  ||| S:17284 E:17286 ||| ,
until  ||| S:17286 E:17292 ||| IN
pre-castration  ||| S:17292 E:17317 ||| JJ
cell  ||| S:17317 E:17322 ||| NN
numbers  ||| S:17322 E:17330 ||| NNS
have  ||| S:17330 E:17335 ||| VBP
been  ||| S:17335 E:17340 ||| VBN
restored  ||| S:17340 E:17349 ||| VBN
[  ||| S:17349 E:17351 ||| -LRB-
48  ||| S:17351 E:17354 ||| CD
49  ||| S:17354 E:17357 ||| CD
]  ||| S:17357 E:17359 ||| -RRB-
.  ||| S:17359 E:17361 ||| .
No  ||| S:17361 E:17364 ||| DT
further  ||| S:17364 E:17382 ||| JJ
proliferation  ||| S:17382 E:17396 ||| NN
ensues  ||| S:17396 E:17403 ||| NN
beyond  ||| S:17403 E:17410 ||| IN
this  ||| S:17410 E:17415 ||| DT
point ||| S:17415 E:17420 ||| NN
,  ||| S:17420 E:17422 ||| ,
at  ||| S:17422 E:17425 ||| IN
which  ||| S:17425 E:17431 ||| WDT
p27  ||| S:17431 E:17445 ||| CD
levels  ||| S:17445 E:17452 ||| NNS
are  ||| S:17452 E:17456 ||| VBP
increased  ||| S:17456 E:17466 ||| VBN
again ||| S:17466 E:17471 ||| RB
,  ||| S:17471 E:17473 ||| ,
despite  ||| S:17473 E:17481 ||| IN
the  ||| S:17481 E:17485 ||| DT
continuous  ||| S:17485 E:17506 ||| JJ
presence  ||| S:17506 E:17515 ||| NN
of  ||| S:17515 E:17518 ||| IN
androgen ||| S:17518 E:17526 ||| NN
.  ||| S:17526 E:17528 ||| .
This  ||| S:17528 E:17533 ||| DT
may  ||| S:17533 E:17537 ||| MD
reflect  ||| S:17537 E:17545 ||| VB
androgen  ||| S:17545 E:17554 ||| JJ
activity  ||| S:17554 E:17573 ||| NN
in  ||| S:17573 E:17576 ||| IN
restoring  ||| S:17576 E:17586 ||| VBG
the  ||| S:17586 E:17590 ||| DT
glandular  ||| S:17590 E:17600 ||| JJ
structure  ||| S:17600 E:17610 ||| NN
by  ||| S:17610 E:17613 ||| IN
promoting  ||| S:17613 E:17633 ||| VBG
postmitotic  ||| S:17633 E:17645 ||| JJ
differentiation  ||| S:17645 E:17661 ||| NNS
[  ||| S:17661 E:17663 ||| -LRB-
48  ||| S:17663 E:17666 ||| CD
49  ||| S:17666 E:17669 ||| CD
]  ||| S:17669 E:17671 ||| -RRB-
.  ||| S:17671 E:17673 ||| .
Consistent  ||| S:17673 E:17684 ||| JJ
with  ||| S:17684 E:17699 ||| IN
this  ||| S:17699 E:17704 ||| DT
view ||| S:17704 E:17708 ||| NN
,  ||| S:17708 E:17710 ||| ,
androgen  ||| S:17710 E:17719 ||| JJ
administration  ||| S:17719 E:17734 ||| NN
to  ||| S:17734 E:17737 ||| TO
intact  ||| S:17737 E:17744 ||| JJ
rats  ||| S:17744 E:17759 ||| NNS
resulted  ||| S:17759 E:17768 ||| VBD
in  ||| S:17768 E:17771 ||| IN
suppression  ||| S:17771 E:17783 ||| NN
of  ||| S:17783 E:17786 ||| IN
prostate  ||| S:17786 E:17795 ||| JJ
epithelial  ||| S:17795 E:17806 ||| JJ
cell  ||| S:17806 E:17821 ||| NN
proliferation  ||| S:17821 E:17835 ||| NN
and  ||| S:17835 E:17839 ||| CC
maintenance  ||| S:17839 E:17851 ||| NN
of  ||| S:17851 E:17854 ||| IN
morphological  ||| S:17854 E:17868 ||| JJ
gland  ||| S:17868 E:17884 ||| JJ
integrity  ||| S:17884 E:17894 ||| NN
[  ||| S:17894 E:17896 ||| -LRB-
50  ||| S:17896 E:17899 ||| CD
]  ||| S:17899 E:17901 ||| -RRB-
.  ||| S:17901 E:17903 ||| .
Based  ||| S:17903 E:17909 ||| VBN
on  ||| S:17909 E:17912 ||| IN
these  ||| S:17912 E:17918 ||| DT
findings ||| S:17918 E:17926 ||| NNS
,  ||| S:17926 E:17928 ||| ,
we  ||| S:17928 E:17931 ||| PRP
propose  ||| S:17931 E:17949 ||| VBP
that  ||| S:17949 E:17954 ||| IN
the  ||| S:17954 E:17958 ||| DT
effects  ||| S:17958 E:17966 ||| NNS
of  ||| S:17966 E:17969 ||| IN
high  ||| S:17969 E:17974 ||| JJ
doses  ||| S:17974 E:17980 ||| NNS
of  ||| S:17980 E:17983 ||| IN
androgens  ||| S:17983 E:17993 ||| NN
on  ||| S:17993 E:17996 ||| IN
SKP2  ||| S:17996 E:18001 ||| NNP
and  ||| S:18001 E:18015 ||| CC
p27  ||| S:18015 E:18019 ||| CD
in  ||| S:18019 E:18022 ||| IN
LNCaP  ||| S:18022 E:18028 ||| JJ
cells  ||| S:18028 E:18034 ||| NNS
described  ||| S:18034 E:18044 ||| VBD
here  ||| S:18044 E:18049 ||| RB
reflect  ||| S:18049 E:18057 ||| VB
a  ||| S:18057 E:18069 ||| DT
differentiation  ||| S:18069 E:18085 ||| NN
and  ||| S:18085 E:18089 ||| CC
consolidation  ||| S:18089 E:18103 ||| NN
effect  ||| S:18103 E:18121 ||| NN
in  ||| S:18121 E:18124 ||| IN
vitro  ||| S:18124 E:18130 ||| NN
.  ||| S:18130 E:18132 ||| .
If  ||| S:18132 E:18135 ||| IN
this  ||| S:18135 E:18140 ||| DT
is  ||| S:18140 E:18143 ||| VBZ
the  ||| S:18143 E:18147 ||| DT
case ||| S:18147 E:18151 ||| NN
,  ||| S:18151 E:18163 ||| ,
LNCaP  ||| S:18163 E:18169 ||| JJ
cells ||| S:18169 E:18174 ||| NNS
,  ||| S:18174 E:18176 ||| ,
despite  ||| S:18176 E:18184 ||| IN
being  ||| S:18184 E:18190 ||| VBG
highly  ||| S:18190 E:18197 ||| RB
aneuploid  ||| S:18197 E:18207 ||| JJ
derivatives  ||| S:18207 E:18229 ||| NNS
of  ||| S:18229 E:18232 ||| IN
a  ||| S:18232 E:18234 ||| DT
metastatic  ||| S:18234 E:18245 ||| JJ
lesion  ||| S:18245 E:18252 ||| NN
of  ||| S:18252 E:18255 ||| IN
an  ||| S:18255 E:18258 ||| DT
advanced  ||| S:18258 E:18267 ||| JJ
cancer  ||| S:18267 E:18274 ||| NN
[  ||| S:18274 E:18276 ||| -LRB-
39  ||| S:18276 E:18279 ||| CD
]  ||| S:18279 E:18281 ||| -RRB-
,  ||| S:18281 E:18283 ||| ,
may  ||| S:18283 E:18297 ||| MD
have  ||| S:18297 E:18302 ||| VB
retained  ||| S:18302 E:18311 ||| VBN
some  ||| S:18311 E:18316 ||| DT
aspects  ||| S:18316 E:18324 ||| NNS
of  ||| S:18324 E:18327 ||| IN
the  ||| S:18327 E:18331 ||| DT
normal  ||| S:18331 E:18338 ||| JJ
biphasic  ||| S:18338 E:18357 ||| JJ
mechanism  ||| S:18357 E:18367 ||| NN
of  ||| S:18367 E:18370 ||| IN
androgen  ||| S:18370 E:18379 ||| JJ
control  ||| S:18379 E:18387 ||| NN
observed  ||| S:18387 E:18396 ||| VBD
in  ||| S:18396 E:18399 ||| IN
castrated  ||| S:18399 E:18419 ||| JJ
rodents ||| S:18419 E:18426 ||| NNS
.  ||| S:18426 E:18428 ||| .
This  ||| S:18428 E:18433 ||| DT
mechanism  ||| S:18433 E:18443 ||| NN
may  ||| S:18443 E:18447 ||| MD
also  ||| S:18447 E:18452 ||| RB
be  ||| S:18452 E:18455 ||| VB
retained  ||| S:18455 E:18464 ||| VBN
in  ||| S:18464 E:18467 ||| IN
other  ||| S:18467 E:18483 ||| JJ
prostate  ||| S:18483 E:18492 ||| NN
cancers ||| S:18492 E:18499 ||| NNS
,  ||| S:18499 E:18501 ||| ,
thereby  ||| S:18501 E:18509 ||| RB
representing  ||| S:18509 E:18522 ||| VBG
a  ||| S:18522 E:18524 ||| DT
potential  ||| S:18524 E:18534 ||| JJ
target  ||| S:18534 E:18551 ||| NN
for  ||| S:18551 E:18555 ||| IN
intervention ||| S:18555 E:18567 ||| NN
.  ||| S:18567 E:18597 ||| .
Role  ||| S:18597 E:18602 ||| NN
of  ||| S:18602 E:18605 ||| IN
SKP2  ||| S:18605 E:18610 ||| CD
in  ||| S:18610 E:18613 ||| IN
androgen  ||| S:18613 E:18622 ||| JJ
control  ||| S:18622 E:18630 ||| NN
of  ||| S:18630 E:18633 ||| IN
p27  ||| S:18633 E:18647 ||| CD
stability  ||| S:18647 E:18667 ||| NN
Our  ||| S:18667 E:18671 ||| PRP$
data  ||| S:18671 E:18676 ||| NNS
indicate  ||| S:18676 E:18685 ||| VBP
that  ||| S:18685 E:18690 ||| IN
SKP2  ||| S:18690 E:18695 ||| NNP
is  ||| S:18695 E:18698 ||| VBZ
an  ||| S:18698 E:18701 ||| DT
integral  ||| S:18701 E:18710 ||| JJ
component  ||| S:18710 E:18730 ||| NN
of  ||| S:18730 E:18733 ||| IN
androgen  ||| S:18733 E:18742 ||| JJ
control  ||| S:18742 E:18750 ||| NN
in  ||| S:18750 E:18753 ||| IN
LNCaP  ||| S:18753 E:18759 ||| JJ
cells ||| S:18759 E:18764 ||| NNS
,  ||| S:18764 E:18766 ||| ,
as  ||| S:18766 E:18769 ||| IN
it  ||| S:18769 E:18772 ||| PRP
is  ||| S:18772 E:18785 ||| VBZ
down-regulated  ||| S:18785 E:18800 ||| JJ
in  ||| S:18800 E:18803 ||| IN
an  ||| S:18803 E:18806 ||| DT
AR-mediated  ||| S:18806 E:18818 ||| JJ
manner  ||| S:18818 E:18825 ||| NN
( ||| S:18825 E:18826 ||| -LRB-
Fig.  ||| S:18826 E:18831 ||| CD
2Band  ||| S:18831 E:18837 ||| CD
2C ||| S:18837 E:18839 ||| CD
) ||| S:18839 E:18840 ||| -RRB-
.  ||| S:18840 E:18852 ||| .
In  ||| S:18852 E:18855 ||| IN
contrast ||| S:18855 E:18863 ||| NN
,  ||| S:18863 E:18865 ||| ,
all  ||| S:18865 E:18869 ||| DT
other  ||| S:18869 E:18875 ||| JJ
known  ||| S:18875 E:18881 ||| VBN
SCF  ||| S:18881 E:18885 ||| NNP
SKP2subunits  ||| S:18885 E:18898 ||| NNP
examined  ||| S:18898 E:18917 ||| NN
were  ||| S:18917 E:18922 ||| VBD
largely  ||| S:18922 E:18930 ||| RB
unresponsive  ||| S:18930 E:18943 ||| VBN
to  ||| S:18943 E:18946 ||| TO
androgen  ||| S:18946 E:18955 ||| VB
( ||| S:18955 E:18956 ||| -LRB-
Fig.  ||| S:18956 E:18961 ||| NNP
2A ||| S:18961 E:18963 ||| NNP
) ||| S:18963 E:18964 ||| -RRB-
.  ||| S:18964 E:18976 ||| .
Importantly ||| S:18976 E:18987 ||| RB
,  ||| S:18987 E:18989 ||| ,
SKP2  ||| S:18989 E:18994 ||| CD
overexpression  ||| S:18994 E:19009 ||| NN
is  ||| S:19009 E:19012 ||| VBZ
sufficient  ||| S:19012 E:19023 ||| JJ
to  ||| S:19023 E:19026 ||| TO
reverse  ||| S:19026 E:19044 ||| VB
androgen-mediated  ||| S:19044 E:19062 ||| JJ
p27  ||| S:19062 E:19066 ||| CD
accumulation  ||| S:19066 E:19079 ||| NN
and  ||| S:19079 E:19083 ||| CC
induce  ||| S:19083 E:19090 ||| VB
p27  ||| S:19090 E:19104 ||| CD
ubiquitylation  ||| S:19104 E:19119 ||| NNS
( ||| S:19119 E:19120 ||| -LRB-
Fig.  ||| S:19120 E:19125 ||| CD
4Band  ||| S:19125 E:19131 ||| CD
4D ||| S:19131 E:19133 ||| CD
) ||| S:19133 E:19134 ||| -RRB-
.  ||| S:19134 E:19136 ||| .
Based  ||| S:19136 E:19142 ||| VBN
on  ||| S:19142 E:19145 ||| IN
the  ||| S:19145 E:19149 ||| DT
F-box  ||| S:19149 E:19165 ||| JJ
dependency  ||| S:19165 E:19176 ||| NN
of  ||| S:19176 E:19179 ||| IN
these  ||| S:19179 E:19185 ||| DT
processes  ||| S:19185 E:19195 ||| NNS
( ||| S:19195 E:19196 ||| -LRB-
Fig.  ||| S:19196 E:19201 ||| NNP
4C ||| S:19201 E:19203 ||| NNP
) ||| S:19203 E:19204 ||| -RRB-
,  ||| S:19204 E:19206 ||| ,
we  ||| S:19206 E:19209 ||| PRP
conclude  ||| S:19209 E:19218 ||| VBP
that  ||| S:19218 E:19233 ||| IN
SKP2  ||| S:19233 E:19238 ||| NNP
directly  ||| S:19238 E:19247 ||| RB
triggers  ||| S:19247 E:19256 ||| VBZ
the  ||| S:19256 E:19260 ||| DT
ubiquitylation  ||| S:19260 E:19275 ||| NN
and  ||| S:19275 E:19279 ||| CC
degradation  ||| S:19279 E:19301 ||| NN
of  ||| S:19301 E:19304 ||| IN
p27  ||| S:19304 E:19308 ||| CD
in  ||| S:19308 E:19311 ||| IN
LNCaP  ||| S:19311 E:19317 ||| JJ
cells ||| S:19317 E:19322 ||| NNS
,  ||| S:19322 E:19324 ||| ,
a  ||| S:19324 E:19326 ||| DT
process  ||| S:19326 E:19334 ||| NN
which  ||| S:19334 E:19340 ||| WDT
is  ||| S:19340 E:19343 ||| VBZ
attenuated  ||| S:19343 E:19354 ||| VBN
by  ||| S:19354 E:19367 ||| IN
androgen-mediated  ||| S:19367 E:19385 ||| JJ
SKP2  ||| S:19385 E:19390 ||| CD
downregulation ||| S:19390 E:19404 ||| NNS
.  ||| S:19404 E:19406 ||| .
This  ||| S:19406 E:19421 ||| DT
interpretation  ||| S:19421 E:19436 ||| NN
is  ||| S:19436 E:19439 ||| VBZ
consistent  ||| S:19439 E:19450 ||| JJ
with  ||| S:19450 E:19455 ||| IN
SKP2  ||| S:19455 E:19460 ||| CD
being  ||| S:19460 E:19466 ||| VBG
a  ||| S:19466 E:19468 ||| DT
proximal  ||| S:19468 E:19487 ||| JJ
element  ||| S:19487 E:19495 ||| NN
in  ||| S:19495 E:19498 ||| IN
the  ||| S:19498 E:19502 ||| DT
previously  ||| S:19502 E:19513 ||| RB
identified  ||| S:19513 E:19524 ||| VBN
androgen-mediated  ||| S:19524 E:19552 ||| JJ
pathway  ||| S:19552 E:19560 ||| NN
of  ||| S:19560 E:19563 ||| IN
cell  ||| S:19563 E:19568 ||| NN
cycle  ||| S:19568 E:19574 ||| NN
inhibition  ||| S:19574 E:19585 ||| NN
in  ||| S:19585 E:19588 ||| IN
LNCaP  ||| S:19588 E:19594 ||| JJ
cells ||| S:19594 E:19599 ||| NNS
.  ||| S:19599 E:19601 ||| .
As  ||| S:19601 E:19604 ||| IN
a  ||| S:19604 E:19616 ||| DT
direct  ||| S:19616 E:19623 ||| JJ
consequence  ||| S:19623 E:19635 ||| NN
of  ||| S:19635 E:19638 ||| IN
SKP2  ||| S:19638 E:19643 ||| CD
downregulation ||| S:19643 E:19657 ||| NN
,  ||| S:19657 E:19659 ||| ,
p27  ||| S:19659 E:19663 ||| NNP
is  ||| S:19663 E:19676 ||| VBZ
upregulated  ||| S:19676 E:19688 ||| VBN
and  ||| S:19688 E:19692 ||| CC
cyclin  ||| S:19692 E:19699 ||| VBG
A  ||| S:19699 E:19701 ||| DT
is  ||| S:19701 E:19704 ||| VBZ
downregulated ||| S:19704 E:19717 ||| VBN
.  ||| S:19717 E:19719 ||| .
This  ||| S:19719 E:19724 ||| DT
results  ||| S:19724 E:19742 ||| NNS
in  ||| S:19742 E:19745 ||| IN
inhibition  ||| S:19745 E:19756 ||| NN
of  ||| S:19756 E:19759 ||| IN
CDK2  ||| S:19759 E:19764 ||| CD
activity ||| S:19764 E:19772 ||| NN
,  ||| S:19772 E:19774 ||| ,
accumulation  ||| S:19774 E:19787 ||| NN
of  ||| S:19787 E:19800 ||| IN
hypophosphorylated  ||| S:19800 E:19819 ||| CD
RB1 ||| S:19819 E:19822 ||| CD
,  ||| S:19822 E:19824 ||| ,
inactivation  ||| S:19824 E:19837 ||| NN
of  ||| S:19837 E:19840 ||| IN
E2F1  ||| S:19840 E:19845 ||| NNP
[  ||| S:19845 E:19847 ||| -LRB-
45  ||| S:19847 E:19850 ||| CD
]  ||| S:19850 E:19852 ||| -RRB-
,  ||| S:19852 E:19854 ||| ,
and  ||| S:19854 E:19868 ||| CC
cell  ||| S:19868 E:19873 ||| NN
cycle  ||| S:19873 E:19879 ||| NN
arrest ||| S:19879 E:19885 ||| NN
.  ||| S:19885 E:19897 ||| .
While  ||| S:19897 E:19903 ||| IN
it  ||| S:19903 E:19906 ||| PRP
may  ||| S:19906 E:19910 ||| MD
surprise  ||| S:19910 E:19919 ||| VB
that  ||| S:19919 E:19924 ||| IN
SKP2  ||| S:19924 E:19929 ||| CD
overexpression  ||| S:19929 E:19944 ||| NNS
alone  ||| S:19944 E:19960 ||| RB
is  ||| S:19960 E:19963 ||| VBZ
sufficient  ||| S:19963 E:19974 ||| JJ
to  ||| S:19974 E:19977 ||| TO
mediate  ||| S:19977 E:19985 ||| VB
p27  ||| S:19985 E:19989 ||| CD
degradation  ||| S:19989 E:20001 ||| NN
in  ||| S:20001 E:20004 ||| IN
LNCaP  ||| S:20004 E:20010 ||| JJ
cells ||| S:20010 E:20015 ||| NNS
,  ||| S:20015 E:20027 ||| ,
given  ||| S:20027 E:20033 ||| VBN
the  ||| S:20033 E:20037 ||| DT
known  ||| S:20037 E:20043 ||| JJ
requirement  ||| S:20043 E:20055 ||| NN
for  ||| S:20055 E:20059 ||| IN
p27  ||| S:20059 E:20063 ||| CD
phosphorylation  ||| S:20063 E:20079 ||| NNS
[  ||| S:20079 E:20081 ||| -LRB-
24  ||| S:20081 E:20094 ||| CD
]  ||| S:20094 E:20096 ||| -RRB-
,  ||| S:20096 E:20098 ||| ,
similar  ||| S:20098 E:20106 ||| JJ
observations  ||| S:20106 E:20119 ||| NNS
were  ||| S:20119 E:20124 ||| VBD
made  ||| S:20124 E:20129 ||| VBN
in  ||| S:20129 E:20132 ||| IN
rat  ||| S:20132 E:20136 ||| JJ
fibroblasts ||| S:20136 E:20147 ||| NN
,  ||| S:20147 E:20159 ||| ,
human  ||| S:20159 E:20165 ||| JJ
U87  ||| S:20165 E:20169 ||| CD
cells ||| S:20169 E:20174 ||| NNS
,  ||| S:20174 E:20176 ||| ,
and  ||| S:20176 E:20180 ||| CC
primary  ||| S:20180 E:20188 ||| JJ
rat  ||| S:20188 E:20192 ||| NN
hepatocytes  ||| S:20192 E:20204 ||| NNS
[  ||| S:20204 E:20206 ||| -LRB-
29  ||| S:20206 E:20209 ||| CD
30  ||| S:20209 E:20212 ||| CD
31  ||| S:20212 E:20225 ||| CD
32  ||| S:20225 E:20228 ||| CD
]  ||| S:20228 E:20230 ||| -RRB-
.  ||| S:20230 E:20232 ||| .
In  ||| S:20232 E:20235 ||| IN
rat  ||| S:20235 E:20239 ||| JJ
fibroblasts ||| S:20239 E:20250 ||| NN
,  ||| S:20250 E:20252 ||| ,
these  ||| S:20252 E:20258 ||| DT
findings  ||| S:20258 E:20267 ||| NNS
correlate  ||| S:20267 E:20277 ||| VBN
with  ||| S:20277 E:20292 ||| IN
SKP2-induced  ||| S:20292 E:20305 ||| CD
upregulation  ||| S:20305 E:20318 ||| NN
of  ||| S:20318 E:20321 ||| IN
cyclin  ||| S:20321 E:20328 ||| JJ
A  ||| S:20328 E:20330 ||| NN
and  ||| S:20330 E:20334 ||| CC
CDK2  ||| S:20334 E:20339 ||| CD
kinase  ||| S:20339 E:20356 ||| JJ
activity  ||| S:20356 E:20365 ||| NN
[  ||| S:20365 E:20367 ||| -LRB-
29  ||| S:20367 E:20370 ||| CD
32  ||| S:20370 E:20373 ||| CD
]  ||| S:20373 E:20375 ||| -RRB-
,  ||| S:20375 E:20377 ||| ,
which  ||| S:20377 E:20383 ||| WDT
could  ||| S:20383 E:20389 ||| MD
further  ||| S:20389 E:20397 ||| RB
augment  ||| S:20397 E:20405 ||| VB
p27  ||| S:20405 E:20419 ||| CD
phosphorylation  ||| S:20419 E:20435 ||| NNS
and  ||| S:20435 E:20439 ||| CC
degradation ||| S:20439 E:20450 ||| NN
,  ||| S:20450 E:20452 ||| ,
ultimately  ||| S:20452 E:20463 ||| RB
stimulating  ||| S:20463 E:20485 ||| VBG
cells  ||| S:20485 E:20491 ||| NNS
to  ||| S:20491 E:20494 ||| TO
enter  ||| S:20494 E:20500 ||| VB
S  ||| S:20500 E:20502 ||| NNP
phase ||| S:20502 E:20507 ||| NN
.  ||| S:20507 E:20519 ||| .
Unlike  ||| S:20519 E:20526 ||| IN
in  ||| S:20526 E:20529 ||| IN
rat  ||| S:20529 E:20533 ||| JJ
fibroblasts  ||| S:20533 E:20545 ||| NN
and  ||| S:20545 E:20549 ||| CC
human  ||| S:20549 E:20555 ||| JJ
U87  ||| S:20555 E:20559 ||| CD
cells  ||| S:20559 E:20565 ||| NNS
[  ||| S:20565 E:20567 ||| -LRB-
29  ||| S:20567 E:20570 ||| CD
30  ||| S:20570 E:20583 ||| CD
32  ||| S:20583 E:20586 ||| CD
]  ||| S:20586 E:20588 ||| -RRB-
,  ||| S:20588 E:20590 ||| ,
SKP2  ||| S:20590 E:20595 ||| CD
overexpression  ||| S:20595 E:20610 ||| NN
is  ||| S:20610 E:20613 ||| VBZ
not  ||| S:20613 E:20617 ||| RB
sufficient  ||| S:20617 E:20628 ||| JJ
to  ||| S:20628 E:20631 ||| TO
override  ||| S:20631 E:20650 ||| VB
androgen-induced  ||| S:20650 E:20667 ||| JJ
G1  ||| S:20667 E:20670 ||| CD
arrest  ||| S:20670 E:20677 ||| NN
in  ||| S:20677 E:20680 ||| IN
LNCaP  ||| S:20680 E:20686 ||| JJ
cells ||| S:20686 E:20691 ||| NNS
,  ||| S:20691 E:20693 ||| ,
despite  ||| S:20693 E:20701 ||| IN
a  ||| S:20701 E:20713 ||| DT
profound  ||| S:20713 E:20722 ||| JJ
effect  ||| S:20722 E:20729 ||| NN
on  ||| S:20729 E:20732 ||| IN
p27  ||| S:20732 E:20736 ||| CD
levels  ||| S:20736 E:20743 ||| NNS
( ||| S:20743 E:20744 ||| -LRB-
Fig.  ||| S:20744 E:20749 ||| CD
5 ||| S:20749 E:20750 ||| CD
) ||| S:20750 E:20751 ||| -RRB-
.  ||| S:20751 E:20753 ||| .
Consistent  ||| S:20753 E:20764 ||| JJ
with  ||| S:20764 E:20779 ||| IN
this  ||| S:20779 E:20784 ||| DT
finding ||| S:20784 E:20791 ||| NN
,  ||| S:20791 E:20793 ||| ,
ectopic  ||| S:20793 E:20801 ||| CD
SKP2  ||| S:20801 E:20806 ||| CD
expression  ||| S:20806 E:20817 ||| NN
was  ||| S:20817 E:20821 ||| VBD
not  ||| S:20821 E:20825 ||| RB
sufficient  ||| S:20825 E:20846 ||| JJ
to  ||| S:20846 E:20849 ||| TO
maintain  ||| S:20849 E:20858 ||| VB
high  ||| S:20858 E:20863 ||| JJ
cyclin  ||| S:20863 E:20870 ||| NNS
A  ||| S:20870 E:20872 ||| DT
levels ||| S:20872 E:20878 ||| NNS
,  ||| S:20878 E:20880 ||| ,
CDK2  ||| S:20880 E:20885 ||| CD
activation ||| S:20885 E:20895 ||| NN
,  ||| S:20895 E:20897 ||| ,
and  ||| S:20897 E:20911 ||| CC
RB1  ||| S:20911 E:20915 ||| CD
phosphorylation  ||| S:20915 E:20931 ||| NN
for  ||| S:20931 E:20935 ||| IN
prolonged  ||| S:20935 E:20945 ||| JJ
periods  ||| S:20945 E:20953 ||| NNS
( ||| S:20953 E:20954 ||| -LRB-
Fig.  ||| S:20954 E:20959 ||| CD
5Band  ||| S:20959 E:20975 ||| CD
5C ||| S:20975 E:20977 ||| CD
) ||| S:20977 E:20978 ||| -RRB-
.  ||| S:20978 E:20980 ||| .
The  ||| S:20980 E:20984 ||| DT
transient  ||| S:20984 E:20994 ||| JJ
character  ||| S:20994 E:21004 ||| NN
of  ||| S:21004 E:21007 ||| IN
these  ||| S:21007 E:21013 ||| DT
responses  ||| S:21013 E:21023 ||| NNS
may  ||| S:21023 E:21037 ||| MD
explain  ||| S:21037 E:21045 ||| VB
the  ||| S:21045 E:21049 ||| DT
failure  ||| S:21049 E:21057 ||| NN
to  ||| S:21057 E:21060 ||| TO
cause  ||| S:21060 E:21066 ||| VB
efficient  ||| S:21066 E:21076 ||| JJ
S  ||| S:21076 E:21078 ||| NNP
phase  ||| S:21078 E:21084 ||| NN
entry  ||| S:21084 E:21090 ||| NN
in  ||| S:21090 E:21103 ||| IN
the  ||| S:21103 E:21107 ||| DT
presence  ||| S:21107 E:21116 ||| NN
of  ||| S:21116 E:21119 ||| IN
MIB ||| S:21119 E:21122 ||| NNP
,  ||| S:21122 E:21124 ||| ,
in  ||| S:21124 E:21127 ||| IN
particular  ||| S:21127 E:21138 ||| JJ
as  ||| S:21138 E:21141 ||| IN
co-expression  ||| S:21141 E:21155 ||| JJ
of  ||| S:21155 E:21168 ||| IN
cyclins  ||| S:21168 E:21176 ||| NN
was  ||| S:21176 E:21180 ||| VBD
previously  ||| S:21180 E:21191 ||| RB
shown  ||| S:21191 E:21197 ||| VBN
to  ||| S:21197 E:21200 ||| TO
synergize  ||| S:21200 E:21210 ||| VB
with  ||| S:21210 E:21215 ||| IN
SKP2  ||| S:21215 E:21220 ||| CD
in  ||| S:21220 E:21233 ||| IN
stimulating  ||| S:21233 E:21245 ||| VBG
CDK2  ||| S:21245 E:21250 ||| CD
activity  ||| S:21250 E:21259 ||| NN
and  ||| S:21259 E:21263 ||| CC
S  ||| S:21263 E:21265 ||| NNP
phase  ||| S:21265 E:21271 ||| NN
entry  ||| S:21271 E:21277 ||| NN
[  ||| S:21277 E:21279 ||| -LRB-
30  ||| S:21279 E:21282 ||| CD
31  ||| S:21282 E:21285 ||| CD
]  ||| S:21285 E:21287 ||| -RRB-
.  ||| S:21287 E:21299 ||| .
In  ||| S:21299 E:21302 ||| IN
addition ||| S:21302 E:21310 ||| NN
,  ||| S:21310 E:21312 ||| ,
cyclin  ||| S:21312 E:21319 ||| VBG
A  ||| S:21319 E:21321 ||| DT
is  ||| S:21321 E:21324 ||| VBZ
frequently  ||| S:21324 E:21335 ||| RB
overexpressed  ||| S:21335 E:21349 ||| VBN
in  ||| S:21349 E:21362 ||| IN
prostate  ||| S:21362 E:21371 ||| JJ
cancers  ||| S:21371 E:21379 ||| NNS
[  ||| S:21379 E:21381 ||| -LRB-
51  ||| S:21381 E:21384 ||| CD
]  ||| S:21384 E:21386 ||| -RRB-
.  ||| S:21386 E:21388 ||| .
In  ||| S:21388 E:21391 ||| IN
future  ||| S:21391 E:21398 ||| JJ
experiments ||| S:21398 E:21409 ||| NNS
,  ||| S:21409 E:21411 ||| ,
it  ||| S:21411 E:21414 ||| PRP
will  ||| S:21414 E:21429 ||| MD
be  ||| S:21429 E:21432 ||| VB
interesting  ||| S:21432 E:21444 ||| JJ
to  ||| S:21444 E:21447 ||| TO
determine  ||| S:21447 E:21457 ||| VB
the  ||| S:21457 E:21461 ||| DT
effect  ||| S:21461 E:21468 ||| NN
of  ||| S:21468 E:21471 ||| IN
combined  ||| S:21471 E:21490 ||| JJ
overexpression  ||| S:21490 E:21505 ||| NN
of  ||| S:21505 E:21508 ||| IN
SKP2  ||| S:21508 E:21513 ||| NNP
and  ||| S:21513 E:21517 ||| CC
cyclin  ||| S:21517 E:21524 ||| JJ
A  ||| S:21524 E:21526 ||| NN
and  ||| S:21526 E:21530 ||| CC
cyclin  ||| S:21530 E:21537 ||| JJ
E  ||| S:21537 E:21539 ||| NN
on  ||| S:21539 E:21542 ||| IN
cell  ||| S:21542 E:21557 ||| NN
cycle  ||| S:21557 E:21563 ||| NN
progression  ||| S:21563 E:21575 ||| NN
of  ||| S:21575 E:21578 ||| IN
MIB-arrested  ||| S:21578 E:21591 ||| JJ
cells ||| S:21591 E:21596 ||| NNS
.  ||| S:21596 E:21608 ||| .
Regardless  ||| S:21608 E:21619 ||| RB
of  ||| S:21619 E:21622 ||| IN
the  ||| S:21622 E:21626 ||| DT
outcome  ||| S:21626 E:21634 ||| NN
of  ||| S:21634 E:21637 ||| IN
such  ||| S:21637 E:21642 ||| JJ
experiments ||| S:21642 E:21653 ||| NNS
,  ||| S:21653 E:21655 ||| ,
our  ||| S:21655 E:21669 ||| PRP$
data  ||| S:21669 E:21674 ||| NNS
firmly  ||| S:21674 E:21681 ||| RB
suggest  ||| S:21681 E:21689 ||| VB
that  ||| S:21689 E:21694 ||| IN
SKP2  ||| S:21694 E:21699 ||| NNP
is  ||| S:21699 E:21702 ||| VBZ
a  ||| S:21702 E:21704 ||| DT
central  ||| S:21704 E:21712 ||| JJ
mediator  ||| S:21712 E:21721 ||| NN
of  ||| S:21721 E:21734 ||| IN
the  ||| S:21734 E:21738 ||| DT
androgen  ||| S:21738 E:21747 ||| JJ
response  ||| S:21747 E:21756 ||| NN
mechanism  ||| S:21756 E:21766 ||| NN
of  ||| S:21766 E:21769 ||| IN
LNCaP  ||| S:21769 E:21775 ||| JJ
cells ||| S:21775 E:21780 ||| NNS
.  ||| S:21780 E:21782 ||| .
However ||| S:21782 E:21789 ||| RB
,  ||| S:21789 E:21801 ||| ,
we  ||| S:21801 E:21804 ||| PRP
do  ||| S:21804 E:21807 ||| VBP
not  ||| S:21807 E:21811 ||| RB
believe  ||| S:21811 E:21819 ||| VB
that  ||| S:21819 E:21824 ||| IN
SKP2  ||| S:21824 E:21829 ||| NNP
is  ||| S:21829 E:21832 ||| VBZ
a  ||| S:21832 E:21834 ||| DT
direct  ||| S:21834 E:21841 ||| JJ
transcriptional  ||| S:21841 E:21867 ||| JJ
target  ||| S:21867 E:21874 ||| NN
of  ||| S:21874 E:21877 ||| IN
the  ||| S:21877 E:21881 ||| DT
AR ||| S:21881 E:21883 ||| NNP
,  ||| S:21883 E:21885 ||| ,
as  ||| S:21885 E:21888 ||| IN
the  ||| S:21888 E:21892 ||| DT
kinetics  ||| S:21892 E:21901 ||| NN
of  ||| S:21901 E:21904 ||| IN
its  ||| S:21904 E:21908 ||| PRP$
downregulation  ||| S:21908 E:21933 ||| NN
were  ||| S:21933 E:21938 ||| VBD
rather  ||| S:21938 E:21945 ||| RB
slow  ||| S:21945 E:21950 ||| VB
( ||| S:21950 E:21951 ||| -LRB-
Fig.  ||| S:21951 E:21956 ||| NNP
2A ||| S:21956 E:21958 ||| NNP
) ||| S:21958 E:21959 ||| -RRB-
,  ||| S:21959 E:21961 ||| ,
suggesting  ||| S:21961 E:21972 ||| VBG
several  ||| S:21972 E:21990 ||| JJ
intermediate  ||| S:21990 E:22003 ||| JJ
steps  ||| S:22003 E:22009 ||| NNS
culminating  ||| S:22009 E:22021 ||| VBG
in  ||| S:22021 E:22024 ||| IN
this  ||| S:22024 E:22029 ||| DT
event ||| S:22029 E:22034 ||| NN
.  ||| S:22034 E:22036 ||| .
Such  ||| S:22036 E:22041 ||| PDT
a  ||| S:22041 E:22053 ||| DT
mediator  ||| S:22053 E:22062 ||| NN
could  ||| S:22062 E:22068 ||| MD
be  ||| S:22068 E:22071 ||| VB
AS3 ||| S:22071 E:22074 ||| CD
,  ||| S:22074 E:22076 ||| ,
a  ||| S:22076 E:22078 ||| DT
gene  ||| S:22078 E:22083 ||| NN
induced  ||| S:22083 E:22091 ||| NN
by  ||| S:22091 E:22094 ||| IN
growth  ||| S:22094 E:22111 ||| NN
inhibiting  ||| S:22111 E:22122 ||| NN
levels  ||| S:22122 E:22129 ||| NNS
of  ||| S:22129 E:22132 ||| IN
androgen  ||| S:22132 E:22141 ||| NN
with  ||| S:22141 E:22146 ||| IN
kinetics  ||| S:22146 E:22155 ||| NN
that  ||| S:22155 E:22160 ||| IN
precede  ||| S:22160 E:22178 ||| JJ
cell  ||| S:22178 E:22183 ||| NN
cycle  ||| S:22183 E:22189 ||| NN
arrest  ||| S:22189 E:22196 ||| NN
[  ||| S:22196 E:22198 ||| -LRB-
52  ||| S:22198 E:22201 ||| CD
]  ||| S:22201 E:22203 ||| -RRB-
.  ||| S:22203 E:22205 ||| .
In  ||| S:22205 E:22208 ||| IN
addition ||| S:22208 E:22216 ||| NN
,  ||| S:22216 E:22218 ||| ,
AS3  ||| S:22218 E:22232 ||| FW
overexpression  ||| S:22232 E:22247 ||| FW
mimics  ||| S:22247 E:22254 ||| FW
androgen-mediated  ||| S:22254 E:22272 ||| FW
cell  ||| S:22272 E:22277 ||| FW
cycle  ||| S:22277 E:22283 ||| FW
arrest  ||| S:22283 E:22300 ||| FW
in  ||| S:22300 E:22303 ||| FW
MCF7  ||| S:22303 E:22308 ||| FW
cells  ||| S:22308 E:22314 ||| FW
stably  ||| S:22314 E:22321 ||| FW
expressing  ||| S:22321 E:22332 ||| FW
exogenous  ||| S:22332 E:22342 ||| FW
AR ||| S:22342 E:22344 ||| NNP
,  ||| S:22344 E:22346 ||| ,
while  ||| S:22346 E:22362 ||| IN
anti-sense  ||| S:22362 E:22373 ||| NNP
AS3  ||| S:22373 E:22377 ||| NNP
confers  ||| S:22377 E:22385 ||| VBZ
resistance  ||| S:22385 E:22396 ||| NN
to  ||| S:22396 E:22399 ||| TO
androgen-induced  ||| S:22399 E:22426 ||| JJ
growth  ||| S:22426 E:22433 ||| NN
arrest  ||| S:22433 E:22440 ||| NN
[  ||| S:22440 E:22442 ||| -LRB-
53  ||| S:22442 E:22445 ||| CD
]  ||| S:22445 E:22447 ||| -RRB-
.  ||| S:22447 E:22449 ||| .
The  ||| S:22449 E:22453 ||| DT
function  ||| S:22453 E:22462 ||| NN
of  ||| S:22462 E:22465 ||| IN
AS3  ||| S:22465 E:22469 ||| NNP
is  ||| S:22469 E:22472 ||| VBZ
still  ||| S:22472 E:22488 ||| RB
unknown ||| S:22488 E:22495 ||| JJ
,  ||| S:22495 E:22497 ||| ,
but  ||| S:22497 E:22501 ||| CC
the  ||| S:22501 E:22505 ||| DT
encoded  ||| S:22505 E:22513 ||| JJ
protein  ||| S:22513 E:22521 ||| NN
has  ||| S:22521 E:22525 ||| VBZ
features  ||| S:22525 E:22534 ||| NNS
of  ||| S:22534 E:22537 ||| IN
a  ||| S:22537 E:22549 ||| DT
potential  ||| S:22549 E:22559 ||| JJ
transcription  ||| S:22559 E:22573 ||| JJ
factor  ||| S:22573 E:22580 ||| NN
[  ||| S:22580 E:22582 ||| -LRB-
53  ||| S:22582 E:22585 ||| CD
]  ||| S:22585 E:22587 ||| -RRB-
.  ||| S:22587 E:22599 ||| .
While  ||| S:22599 E:22605 ||| IN
our  ||| S:22605 E:22609 ||| PRP$
study  ||| S:22609 E:22615 ||| NN
suggests  ||| S:22615 E:22624 ||| VBZ
that  ||| S:22624 E:22629 ||| IN
SKP2  ||| S:22629 E:22634 ||| NNP
is  ||| S:22634 E:22637 ||| VBZ
an  ||| S:22637 E:22640 ||| DT
important  ||| S:22640 E:22660 ||| JJ
player  ||| S:22660 E:22667 ||| NN
in  ||| S:22667 E:22670 ||| IN
p27  ||| S:22670 E:22674 ||| CD
regulation  ||| S:22674 E:22685 ||| NN
in  ||| S:22685 E:22688 ||| IN
prostate  ||| S:22688 E:22697 ||| JJ
cancer  ||| S:22697 E:22704 ||| NN
cells ||| S:22704 E:22709 ||| NNS
,  ||| S:22709 E:22711 ||| ,
recent  ||| S:22711 E:22728 ||| JJ
studies  ||| S:22728 E:22736 ||| NNS
have  ||| S:22736 E:22741 ||| VBP
also  ||| S:22741 E:22746 ||| RB
implicated  ||| S:22746 E:22757 ||| VBN
another  ||| S:22757 E:22765 ||| DT
protein ||| S:22765 E:22772 ||| NN
,  ||| S:22772 E:22774 ||| ,
CSN5 ||| S:22774 E:22778 ||| NNP
/ ||| S:22778 E:22779 ||| NNP
JAB1 ||| S:22779 E:22783 ||| NNP
,  ||| S:22783 E:22795 ||| ,
in  ||| S:22795 E:22798 ||| IN
p27  ||| S:22798 E:22802 ||| CD
regulation  ||| S:22802 E:22813 ||| NN
[  ||| S:22813 E:22815 ||| -LRB-
54  ||| S:22815 E:22818 ||| CD
55  ||| S:22818 E:22821 ||| CD
]  ||| S:22821 E:22823 ||| -RRB-
.  ||| S:22823 E:22825 ||| .
CSN5  ||| S:22825 E:22830 ||| NNP
is  ||| S:22830 E:22833 ||| VBZ
a  ||| S:22833 E:22835 ||| DT
subunit  ||| S:22835 E:22843 ||| NN
of  ||| S:22843 E:22846 ||| IN
the  ||| S:22846 E:22860 ||| DT
COP9 ||| S:22860 E:22864 ||| CD
/ ||| S:22864 E:22865 ||| CD
signalosome  ||| S:22865 E:22877 ||| NNS
( ||| S:22877 E:22878 ||| -LRB-
CSN ||| S:22878 E:22881 ||| NNP
)  ||| S:22881 E:22883 ||| -RRB-
complex  ||| S:22883 E:22891 ||| NN
[  ||| S:22891 E:22893 ||| -LRB-
56  ||| S:22893 E:22896 ||| CD
57  ||| S:22896 E:22899 ||| CD
58  ||| S:22899 E:22902 ||| CD
59  ||| S:22902 E:22905 ||| CD
]  ||| S:22905 E:22907 ||| -RRB-
,  ||| S:22907 E:22909 ||| ,
but  ||| S:22909 E:22913 ||| CC
also  ||| S:22913 E:22928 ||| RB
forms  ||| S:22928 E:22934 ||| VBZ
distinct  ||| S:22934 E:22943 ||| JJ
complexes  ||| S:22943 E:22953 ||| NNS
apparently  ||| S:22953 E:22964 ||| RB
lacking  ||| S:22964 E:22972 ||| VBG
CSN  ||| S:22972 E:22976 ||| NNP
subunits  ||| S:22976 E:22995 ||| NNS
[  ||| S:22995 E:22997 ||| -LRB-
55  ||| S:22997 E:23000 ||| CD
60  ||| S:23000 E:23003 ||| CD
61  ||| S:23003 E:23006 ||| CD
62  ||| S:23006 E:23009 ||| CD
]  ||| S:23009 E:23011 ||| -RRB-
.  ||| S:23011 E:23013 ||| .
Overexpression  ||| S:23013 E:23028 ||| NNP
of  ||| S:23028 E:23031 ||| IN
CSN5  ||| S:23031 E:23036 ||| CD
in  ||| S:23036 E:23039 ||| IN
NIH3T3  ||| S:23039 E:23046 ||| CD
cells  ||| S:23046 E:23062 ||| NNS
causes  ||| S:23062 E:23069 ||| VBZ
p27  ||| S:23069 E:23073 ||| CD
export  ||| S:23073 E:23080 ||| NN
from  ||| S:23080 E:23085 ||| IN
the  ||| S:23085 E:23089 ||| DT
nucleus  ||| S:23089 E:23097 ||| NN
and  ||| S:23097 E:23101 ||| CC
ectopic  ||| S:23101 E:23119 ||| JJ
degradation  ||| S:23119 E:23131 ||| NNS
[  ||| S:23131 E:23133 ||| -LRB-
54  ||| S:23133 E:23136 ||| CD
]  ||| S:23136 E:23138 ||| -RRB-
.  ||| S:23138 E:23140 ||| .
Notably ||| S:23140 E:23147 ||| RB
,  ||| S:23147 E:23149 ||| ,
like  ||| S:23149 E:23154 ||| IN
SKP2  ||| S:23154 E:23159 ||| NNP
[  ||| S:23159 E:23161 ||| -LRB-
33  ||| S:23161 E:23164 ||| CD
36  ||| S:23164 E:23167 ||| CD
37  ||| S:23167 E:23170 ||| CD
38  ||| S:23170 E:23173 ||| CD
]  ||| S:23173 E:23175 ||| -RRB-
,  ||| S:23175 E:23187 ||| ,
CSN5  ||| S:23187 E:23192 ||| NNP
was  ||| S:23192 E:23196 ||| VBD
found  ||| S:23196 E:23202 ||| VBN
to  ||| S:23202 E:23205 ||| TO
be  ||| S:23205 E:23208 ||| VB
overexpressed  ||| S:23208 E:23222 ||| VBN
in  ||| S:23222 E:23225 ||| IN
cancers  ||| S:23225 E:23233 ||| JJ
devoid  ||| S:23233 E:23240 ||| NN
of  ||| S:23240 E:23253 ||| IN
p27  ||| S:23253 E:23257 ||| NNP
[  ||| S:23257 E:23259 ||| -LRB-
63  ||| S:23259 E:23262 ||| CD
]  ||| S:23262 E:23264 ||| -RRB-
.  ||| S:23264 E:23266 ||| .
However ||| S:23266 E:23273 ||| RB
,  ||| S:23273 E:23275 ||| ,
our  ||| S:23275 E:23279 ||| PRP$
studies  ||| S:23279 E:23287 ||| NNS
did  ||| S:23287 E:23291 ||| VBD
not  ||| S:23291 E:23295 ||| RB
reveal  ||| S:23295 E:23302 ||| VB
any  ||| S:23302 E:23316 ||| DT
effect  ||| S:23316 E:23323 ||| NN
of  ||| S:23323 E:23326 ||| IN
MIB  ||| S:23326 E:23330 ||| NNP
on  ||| S:23330 E:23333 ||| IN
CSN5  ||| S:23333 E:23338 ||| CD
expression ||| S:23338 E:23348 ||| NN
.  ||| S:23348 E:23350 ||| .
Future  ||| S:23350 E:23357 ||| JJ
studies  ||| S:23357 E:23365 ||| NNS
aimed  ||| S:23365 E:23371 ||| VBN
at  ||| S:23371 E:23384 ||| IN
eliminating  ||| S:23384 E:23396 ||| VBG
CSN5  ||| S:23396 E:23401 ||| CD
activity  ||| S:23401 E:23410 ||| NN
will  ||| S:23410 E:23415 ||| MD
show  ||| S:23415 E:23420 ||| VB
whether  ||| S:23420 E:23428 ||| IN
it  ||| S:23428 E:23431 ||| PRP
is  ||| S:23431 E:23444 ||| VBZ
involved  ||| S:23444 E:23453 ||| VBN
in  ||| S:23453 E:23456 ||| IN
androgen-mediated  ||| S:23456 E:23474 ||| JJ
p27  ||| S:23474 E:23478 ||| CD
control ||| S:23478 E:23485 ||| NN
.  ||| S:23485 E:23497 ||| .
Finally ||| S:23497 E:23504 ||| RB
,  ||| S:23504 E:23506 ||| ,
a  ||| S:23506 E:23508 ||| DT
recent  ||| S:23508 E:23515 ||| JJ
report  ||| S:23515 E:23522 ||| NN
demonstrated  ||| S:23522 E:23535 ||| VBD
SKP2-independent  ||| S:23535 E:23562 ||| CD
proteolysis  ||| S:23562 E:23574 ||| NN
of  ||| S:23574 E:23577 ||| IN
p27  ||| S:23577 E:23581 ||| CD
in  ||| S:23581 E:23584 ||| IN
lymphocytes  ||| S:23584 E:23596 ||| VBG
derived  ||| S:23596 E:23604 ||| VBN
from  ||| S:23604 E:23609 ||| IN
SKP2  ||| S:23609 E:23624 ||| CD
knockout  ||| S:23624 E:23633 ||| CD
mice  ||| S:23633 E:23638 ||| NNS
[  ||| S:23638 E:23640 ||| -LRB-
64  ||| S:23640 E:23643 ||| CD
]  ||| S:23643 E:23645 ||| -RRB-
.  ||| S:23645 E:23647 ||| .
It  ||| S:23647 E:23650 ||| PRP
is  ||| S:23650 E:23653 ||| VBZ
thus  ||| S:23653 E:23658 ||| RB
possible  ||| S:23658 E:23667 ||| JJ
that  ||| S:23667 E:23672 ||| IN
p27  ||| S:23672 E:23686 ||| CD
proteolysis  ||| S:23686 E:23698 ||| NN
is  ||| S:23698 E:23701 ||| VBZ
subject  ||| S:23701 E:23709 ||| JJ
to  ||| S:23709 E:23712 ||| TO
tissue-specific  ||| S:23712 E:23728 ||| JJ
regulation ||| S:23728 E:23738 ||| NN
.  ||| S:23738 E:23740 ||| .
In  ||| S:23740 E:23753 ||| IN
prostate  ||| S:23753 E:23762 ||| JJ
cells ||| S:23762 E:23767 ||| NNS
,  ||| S:23767 E:23769 ||| ,
however ||| S:23769 E:23776 ||| RB
,  ||| S:23776 E:23778 ||| ,
SKP2  ||| S:23778 E:23783 ||| NNP
seems  ||| S:23783 E:23789 ||| VBZ
to  ||| S:23789 E:23792 ||| TO
be  ||| S:23792 E:23795 ||| VB
a  ||| S:23795 E:23797 ||| DT
major  ||| S:23797 E:23813 ||| JJ
determinant  ||| S:23813 E:23825 ||| NN
of  ||| S:23825 E:23828 ||| IN
p27  ||| S:23828 E:23832 ||| CD
degradation ||| S:23832 E:23843 ||| NN
,  ||| S:23843 E:23845 ||| ,
as  ||| S:23845 E:23848 ||| IN
it  ||| S:23848 E:23851 ||| PRP
is  ||| S:23851 E:23854 ||| VBZ
down-regulated  ||| S:23854 E:23879 ||| JJ
by  ||| S:23879 E:23882 ||| IN
androgen  ||| S:23882 E:23891 ||| NN
and  ||| S:23891 E:23895 ||| CC
its  ||| S:23895 E:23899 ||| PRP$
overexpression  ||| S:23899 E:23914 ||| NN
is  ||| S:23914 E:23917 ||| VBZ
sufficient  ||| S:23917 E:23928 ||| JJ
to  ||| S:23928 E:23941 ||| TO
mediate  ||| S:23941 E:23949 ||| VB
p27  ||| S:23949 E:23953 ||| CD
ubiquitylation  ||| S:23953 E:23968 ||| NNS
and  ||| S:23968 E:23972 ||| CC
degradation ||| S:23972 E:23983 ||| NN
.  ||| S:23983 E:23985 ||| .
Recent  ||| S:23985 E:24002 ||| JJ
studies  ||| S:24002 E:24010 ||| NNS
involving  ||| S:24010 E:24020 ||| VBG
androgen  ||| S:24020 E:24029 ||| JJ
administration  ||| S:24029 E:24044 ||| NN
to  ||| S:24044 E:24047 ||| TO
castrated  ||| S:24047 E:24067 ||| VB
rats  ||| S:24067 E:24072 ||| NNS
have  ||| S:24072 E:24077 ||| VBP
come  ||| S:24077 E:24082 ||| VBN
to  ||| S:24082 E:24085 ||| TO
similar  ||| S:24085 E:24093 ||| JJ
conclusions  ||| S:24093 E:24105 ||| NNS
[  ||| S:24105 E:24107 ||| -LRB-
49  ||| S:24107 E:24110 ||| CD
]  ||| S:24110 E:24112 ||| -RRB-
.  ||| S:24112 E:24145 ||| .
Conclusions  ||| S:24145 E:24165 ||| VBG
Our  ||| S:24165 E:24169 ||| PRP$
data  ||| S:24169 E:24174 ||| NNS
suggest  ||| S:24174 E:24182 ||| VBP
that  ||| S:24182 E:24187 ||| IN
androgen-mediated  ||| S:24187 E:24205 ||| JJ
SKP2  ||| S:24205 E:24218 ||| CD
downregulation  ||| S:24218 E:24233 ||| NN
is  ||| S:24233 E:24236 ||| VBZ
responsible  ||| S:24236 E:24248 ||| JJ
for  ||| S:24248 E:24252 ||| IN
decreased  ||| S:24252 E:24262 ||| JJ
ubiquitylation  ||| S:24262 E:24285 ||| NN
and  ||| S:24285 E:24289 ||| CC
accumulation  ||| S:24289 E:24302 ||| NN
of  ||| S:24302 E:24305 ||| IN
p27  ||| S:24305 E:24309 ||| CD
in  ||| S:24309 E:24312 ||| IN
LNCaP  ||| S:24312 E:24318 ||| JJ
cells ||| S:24318 E:24323 ||| NNS
,  ||| S:24323 E:24325 ||| ,
an  ||| S:24325 E:24328 ||| DT
effect  ||| S:24328 E:24335 ||| NN
that  ||| S:24335 E:24340 ||| WDT
is  ||| S:24340 E:24351 ||| VBZ
readily  ||| S:24351 E:24359 ||| RB
overcome  ||| S:24359 E:24368 ||| VB
by  ||| S:24368 E:24371 ||| IN
overexpression  ||| S:24371 E:24386 ||| NN
of  ||| S:24386 E:24389 ||| IN
SKP2 ||| S:24389 E:24393 ||| CD
.  ||| S:24393 E:24395 ||| .
We  ||| S:24395 E:24398 ||| PRP
propose  ||| S:24398 E:24406 ||| VBP
that  ||| S:24406 E:24419 ||| IN
frequent  ||| S:24419 E:24428 ||| JJ
p27  ||| S:24428 E:24432 ||| CD
downregulation  ||| S:24432 E:24447 ||| NN
in  ||| S:24447 E:24450 ||| IN
prostate  ||| S:24450 E:24459 ||| JJ
cancer  ||| S:24459 E:24466 ||| NN
may  ||| S:24466 E:24470 ||| MD
be  ||| S:24470 E:24481 ||| VB
caused  ||| S:24481 E:24488 ||| VBN
by  ||| S:24488 E:24491 ||| IN
SKP2  ||| S:24491 E:24496 ||| CD
overexpression  ||| S:24496 E:24511 ||| NNS
thus  ||| S:24511 E:24516 ||| RB
enabling  ||| S:24516 E:24525 ||| VBG
escape  ||| S:24525 E:24532 ||| NN
from  ||| S:24532 E:24545 ||| IN
normal  ||| S:24545 E:24552 ||| JJ
androgen  ||| S:24552 E:24561 ||| JJ
control ||| S:24561 E:24568 ||| NN
.  ||| S:24568 E:24570 ||| .
Finally ||| S:24570 E:24577 ||| RB
,  ||| S:24577 E:24579 ||| ,
our  ||| S:24579 E:24592 ||| VBG
in  ||| S:24592 E:24595 ||| IN
vitro  ||| S:24595 E:24601 ||| JJ
studies  ||| S:24601 E:24609 ||| NNS
validate  ||| S:24609 E:24618 ||| VBP
the  ||| S:24618 E:24622 ||| DT
SKP2  ||| S:24622 E:24635 ||| JJ
pathway  ||| S:24635 E:24643 ||| NN
as  ||| S:24643 E:24646 ||| IN
a  ||| S:24646 E:24648 ||| DT
potential  ||| S:24648 E:24658 ||| JJ
target  ||| S:24658 E:24665 ||| NN
for  ||| S:24665 E:24669 ||| IN
therapeutic  ||| S:24669 E:24681 ||| JJ
intervention  ||| S:24681 E:24702 ||| NN
in  ||| S:24702 E:24705 ||| IN
cancers  ||| S:24705 E:24713 ||| JJ
devoid  ||| S:24713 E:24720 ||| NN
of  ||| S:24720 E:24723 ||| IN
p27 ||| S:24723 E:24726 ||| CD
.  ||| S:24726 E:24750 ||| .
Materials  ||| S:24750 E:24760 ||| NNS
and  ||| S:24760 E:24764 ||| CC
methods  ||| S:24764 E:24791 ||| NNS
Plasmids  ||| S:24791 E:24800 ||| NNP
and  ||| S:24800 E:24804 ||| CC
reagents  ||| S:24804 E:24823 ||| JJ
Human  ||| S:24823 E:24829 ||| NNP
SKP2  ||| S:24829 E:24834 ||| NNP
and  ||| S:24834 E:24838 ||| CC
p27  ||| S:24838 E:24842 ||| NNP
cDNAs  ||| S:24842 E:24848 ||| NNP
were  ||| S:24848 E:24853 ||| VBD
kindly  ||| S:24853 E:24860 ||| RB
provided  ||| S:24860 E:24869 ||| VBN
by  ||| S:24869 E:24872 ||| IN
H.  ||| S:24872 E:24885 ||| NNP
Zhang  ||| S:24885 E:24891 ||| NNP
( ||| S:24891 E:24892 ||| -LRB-
Yale  ||| S:24892 E:24897 ||| NNP
University ||| S:24897 E:24907 ||| NNP
)  ||| S:24907 E:24909 ||| -RRB-
and  ||| S:24909 E:24913 ||| CC
P.  ||| S:24913 E:24916 ||| NNP
Jackson  ||| S:24916 E:24924 ||| NNP
( ||| S:24924 E:24925 ||| -LRB-
Stanford  ||| S:24925 E:24944 ||| NNP
University ||| S:24944 E:24954 ||| NNP
) ||| S:24954 E:24955 ||| -RRB-
.  ||| S:24955 E:24957 ||| .
The  ||| S:24957 E:24961 ||| DT
genes  ||| S:24961 E:24967 ||| NNS
were  ||| S:24967 E:24972 ||| VBD
amplified  ||| S:24972 E:24982 ||| VBN
by  ||| S:24982 E:24985 ||| IN
PCR  ||| S:24985 E:24989 ||| NNP
and  ||| S:24989 E:24993 ||| CC
cloned  ||| S:24993 E:25010 ||| VBN
into  ||| S:25010 E:25015 ||| IN
pcDNA3  ||| S:25015 E:25022 ||| CD
enabling  ||| S:25022 E:25042 ||| NN
in  ||| S:25042 E:25045 ||| IN
vitro  ||| S:25045 E:25051 ||| JJ
transcription ||| S:25051 E:25064 ||| NN
.  ||| S:25064 E:25066 ||| .
The  ||| S:25066 E:25070 ||| DT
SKP2  ||| S:25070 E:25085 ||| NNP
mutant  ||| S:25085 E:25092 ||| VBZ
lacking  ||| S:25092 E:25100 ||| VBG
the  ||| S:25100 E:25104 ||| DT
F-box  ||| S:25104 E:25110 ||| NN
was  ||| S:25110 E:25114 ||| VBD
constructed  ||| S:25114 E:25126 ||| VBN
using  ||| S:25126 E:25132 ||| VBG
the  ||| S:25132 E:25146 ||| DT
Quickchange  ||| S:25146 E:25158 ||| NNP
kit  ||| S:25158 E:25162 ||| VBD
purchased  ||| S:25162 E:25172 ||| VBN
from  ||| S:25172 E:25177 ||| IN
Stratagene ||| S:25177 E:25187 ||| NNP
.  ||| S:25187 E:25189 ||| .
Probes  ||| S:25189 E:25196 ||| NNS
for  ||| S:25196 E:25210 ||| IN
Northern  ||| S:25210 E:25219 ||| JJ
blotting  ||| S:25219 E:25228 ||| NN
were  ||| S:25228 E:25233 ||| VBD
generated  ||| S:25233 E:25243 ||| VBN
by  ||| S:25243 E:25246 ||| IN
PCR ||| S:25246 E:25249 ||| NNP
.  ||| S:25249 E:25251 ||| .
The  ||| S:25251 E:25255 ||| DT
GAPDH  ||| S:25255 E:25261 ||| NNP
probe  ||| S:25261 E:25277 ||| NN
was  ||| S:25277 E:25281 ||| VBD
generated  ||| S:25281 E:25291 ||| VBN
by  ||| S:25291 E:25294 ||| IN
reverse  ||| S:25294 E:25302 ||| JJ
transcription  ||| S:25302 E:25316 ||| NN
and  ||| S:25316 E:25320 ||| CC
PCR  ||| S:25320 E:25324 ||| NNP
from  ||| S:25324 E:25329 ||| IN
LNCaP  ||| S:25329 E:25345 ||| JJ
m  ||| S:25345 E:25347 ||| JJ
RNA ||| S:25347 E:25350 ||| NNP
.  ||| S:25350 E:25362 ||| .
The  ||| S:25362 E:25366 ||| DT
synthetic  ||| S:25366 E:25376 ||| JJ
androgen  ||| S:25376 E:25385 ||| JJ
mibolerone  ||| S:25385 E:25406 ||| NNS
( ||| S:25406 E:25407 ||| -LRB-
7α-17α-dimethyl-19-nortestosterone ||| S:25407 E:25441 ||| NNP
)  ||| S:25441 E:25443 ||| -RRB-
was  ||| S:25443 E:25447 ||| VBD
purchased  ||| S:25447 E:25457 ||| VBN
from  ||| S:25457 E:25472 ||| IN
Perkin  ||| S:25472 E:25479 ||| NNP
Elmer  ||| S:25479 E:25485 ||| NNP
Life  ||| S:25485 E:25490 ||| NNP
Sciences ||| S:25490 E:25498 ||| NNPS
.  ||| S:25498 E:25500 ||| .
The  ||| S:25500 E:25504 ||| DT
antiandrogen  ||| S:25504 E:25517 ||| JJ
cyproterone  ||| S:25517 E:25539 ||| JJ
acetate  ||| S:25539 E:25547 ||| NN
was  ||| S:25547 E:25551 ||| VBD
a  ||| S:25551 E:25553 ||| DT
gift  ||| S:25553 E:25558 ||| NN
from  ||| S:25558 E:25563 ||| IN
C.  ||| S:25563 E:25566 ||| NNP
Sonnenschein  ||| S:25566 E:25579 ||| NNP
( ||| S:25579 E:25580 ||| -LRB-
Tufts  ||| S:25580 E:25596 ||| NNP
University ||| S:25596 E:25606 ||| NNP
) ||| S:25606 E:25607 ||| -RRB-
.  ||| S:25607 E:25609 ||| .
The  ||| S:25609 E:25613 ||| DT
reagents  ||| S:25613 E:25622 ||| NN
were  ||| S:25622 E:25627 ||| VBD
dissolved  ||| S:25627 E:25637 ||| VBN
in  ||| S:25637 E:25640 ||| IN
absolute  ||| S:25640 E:25659 ||| JJ
ethanol ||| S:25659 E:25666 ||| NN
.  ||| S:25666 E:25678 ||| .
Antibodies ||| S:25678 E:25688 ||| NNS
:  ||| S:25688 E:25690 ||| :
SKP2  ||| S:25690 E:25695 ||| CD
( ||| S:25695 E:25696 ||| -LRB-
Zymed  ||| S:25696 E:25702 ||| NNP
32-3300 ||| S:25702 E:25709 ||| NNP
,  ||| S:25709 E:25711 ||| ,
1 ||| S:25711 E:25712 ||| CD
: ||| S:25712 E:25713 ||| :
250  ||| S:25713 E:25717 ||| CD
for  ||| S:25717 E:25731 ||| IN
immunoblotting ||| S:25731 E:25745 ||| CD
) ||| S:25745 E:25746 ||| -RRB-
,  ||| S:25746 E:25748 ||| ,
SKP2  ||| S:25748 E:25753 ||| NNP
( ||| S:25753 E:25754 ||| -LRB-
Santa  ||| S:25754 E:25760 ||| NNP
Cruz  ||| S:25760 E:25765 ||| NNP
sc-7164 ||| S:25765 E:25772 ||| NNP
,  ||| S:25772 E:25774 ||| ,
1 ||| S:25774 E:25775 ||| CD
: ||| S:25775 E:25776 ||| :
500  ||| S:25776 E:25780 ||| CD
for  ||| S:25780 E:25794 ||| IN
immunofluorescence  ||| S:25794 E:25813 ||| JJ
staining ||| S:25813 E:25821 ||| NN
) ||| S:25821 E:25822 ||| -RRB-
,  ||| S:25822 E:25824 ||| ,
p27  ||| S:25824 E:25828 ||| NNP
( ||| S:25828 E:25829 ||| -LRB-
Transduction  ||| S:25829 E:25852 ||| NNP
Laboratories  ||| S:25852 E:25865 ||| NNPS
K25030 ||| S:25865 E:25871 ||| NNP
,  ||| S:25871 E:25873 ||| ,
1 ||| S:25873 E:25874 ||| CD
: ||| S:25874 E:25875 ||| :
5000  ||| S:25875 E:25880 ||| CD
for  ||| S:25880 E:25884 ||| IN
immunoblotting ||| S:25884 E:25898 ||| NN
,  ||| S:25898 E:25900 ||| ,
1 ||| S:25900 E:25901 ||| CD
: ||| S:25901 E:25902 ||| :
1000  ||| S:25902 E:25917 ||| CD
for  ||| S:25917 E:25921 ||| IN
immunofluorescence  ||| S:25921 E:25940 ||| JJ
staining ||| S:25940 E:25948 ||| NN
) ||| S:25948 E:25949 ||| -RRB-
,  ||| S:25949 E:25951 ||| ,
cyclin  ||| S:25951 E:25958 ||| VBG
A  ||| S:25958 E:25960 ||| DT
( ||| S:25960 E:25961 ||| -LRB-
Neomarkers  ||| S:25961 E:25982 ||| NNP
Ab-6 ||| S:25982 E:25986 ||| NNP
,  ||| S:25986 E:25988 ||| ,
MS-1061 ||| S:25988 E:25995 ||| NNP
,  ||| S:25995 E:25997 ||| ,
1 ||| S:25997 E:25998 ||| CD
: ||| S:25998 E:25999 ||| :
100  ||| S:25999 E:26003 ||| CD
for  ||| S:26003 E:26007 ||| IN
immunoblotting ||| S:26007 E:26021 ||| CD
) ||| S:26021 E:26022 ||| -RRB-
,  ||| S:26022 E:26024 ||| ,
cyclin  ||| S:26024 E:26031 ||| JJ
E  ||| S:26031 E:26043 ||| NN
( ||| S:26043 E:26044 ||| -LRB-
Neomarkers  ||| S:26044 E:26055 ||| NNP
Ab-1 ||| S:26055 E:26059 ||| NNP
,  ||| S:26059 E:26061 ||| ,
RB-012 ||| S:26061 E:26067 ||| NNP
,  ||| S:26067 E:26069 ||| ,
2  ||| S:26069 E:26071 ||| CD
ug  ||| S:26071 E:26074 ||| FW
per  ||| S:26074 E:26078 ||| FW
immunoprecipitation ||| S:26078 E:26097 ||| FW
)  ||| S:26097 E:26109 ||| -RRB-
cyclin  ||| S:26109 E:26116 ||| JJ
E  ||| S:26116 E:26118 ||| NN
( ||| S:26118 E:26119 ||| -LRB-
Neomarkers  ||| S:26119 E:26130 ||| NNP
Ab-2 ||| S:26130 E:26134 ||| NNP
,  ||| S:26134 E:26136 ||| ,
MS-870 ||| S:26136 E:26142 ||| NNP
,  ||| S:26142 E:26144 ||| ,
1 ||| S:26144 E:26145 ||| CD
: ||| S:26145 E:26146 ||| :
200  ||| S:26146 E:26150 ||| CD
for  ||| S:26150 E:26164 ||| IN
immunoblotting ||| S:26164 E:26178 ||| CD
) ||| S:26178 E:26179 ||| -RRB-
,  ||| S:26179 E:26181 ||| ,
HRT1  ||| S:26181 E:26186 ||| NNP
( ||| S:26186 E:26187 ||| -LRB-
affinity-purified  ||| S:26187 E:26205 ||| FW
rabbit  ||| S:26205 E:26222 ||| FW
polyclonal ||| S:26222 E:26232 ||| FW
,  ||| S:26232 E:26234 ||| ,
gift  ||| S:26234 E:26239 ||| NN
from  ||| S:26239 E:26244 ||| IN
R.  ||| S:26244 E:26247 ||| NNP
Deshaies ||| S:26247 E:26255 ||| NNP
,  ||| S:26255 E:26257 ||| ,
1 ||| S:26257 E:26258 ||| CD
: ||| S:26258 E:26259 ||| :
1000  ||| S:26259 E:26264 ||| CD
for  ||| S:26264 E:26278 ||| IN
immunoblotting ||| S:26278 E:26292 ||| CD
) ||| S:26292 E:26293 ||| -RRB-
,  ||| S:26293 E:26295 ||| ,
CUL1  ||| S:26295 E:26300 ||| NNP
( ||| S:26300 E:26301 ||| -LRB-
Zymed  ||| S:26301 E:26307 ||| NNP
71-8700 ||| S:26307 E:26314 ||| NNP
,  ||| S:26314 E:26316 ||| ,
1 ||| S:26316 E:26317 ||| CD
: ||| S:26317 E:26318 ||| :
250  ||| S:26318 E:26322 ||| CD
for  ||| S:26322 E:26336 ||| IN
immunoblotting ||| S:26336 E:26350 ||| CD
) ||| S:26350 E:26351 ||| -RRB-
,  ||| S:26351 E:26353 ||| ,
SKP1  ||| S:26353 E:26358 ||| NNP
( ||| S:26358 E:26359 ||| -LRB-
Transduction  ||| S:26359 E:26372 ||| NNP
laboratories  ||| S:26372 E:26385 ||| VBD
610530 ||| S:26385 E:26391 ||| CD
,  ||| S:26391 E:26403 ||| ,
1 ||| S:26403 E:26404 ||| CD
: ||| S:26404 E:26405 ||| :
5000  ||| S:26405 E:26410 ||| CD
for  ||| S:26410 E:26414 ||| IN
immunoblotting ||| S:26414 E:26428 ||| CD
) ||| S:26428 E:26429 ||| -RRB-
,  ||| S:26429 E:26431 ||| ,
JAB1 ||| S:26431 E:26435 ||| NNP
/ ||| S:26435 E:26436 ||| NNP
CSN5  ||| S:26436 E:26441 ||| NNP
( ||| S:26441 E:26442 ||| -LRB-
GeneTex  ||| S:26442 E:26460 ||| NNP
MS-Jab11-PX1 ||| S:26460 E:26472 ||| NNP
,  ||| S:26472 E:26474 ||| ,
1 ||| S:26474 E:26475 ||| CD
: ||| S:26475 E:26476 ||| :
1000  ||| S:26476 E:26481 ||| CD
for  ||| S:26481 E:26485 ||| IN
immunoblotting ||| S:26485 E:26499 ||| CD
) ||| S:26499 E:26500 ||| -RRB-
,  ||| S:26500 E:26502 ||| ,
RB1  ||| S:26502 E:26506 ||| NNP
( ||| S:26506 E:26507 ||| -LRB-
Pharmingen  ||| S:26507 E:26528 ||| NNP
554136 ||| S:26528 E:26534 ||| CD
,  ||| S:26534 E:26536 ||| ,
1 ||| S:26536 E:26537 ||| CD
: ||| S:26537 E:26538 ||| :
500  ||| S:26538 E:26542 ||| CD
for  ||| S:26542 E:26546 ||| IN
immunoblotting ||| S:26546 E:26560 ||| CD
) ||| S:26560 E:26561 ||| -RRB-
,  ||| S:26561 E:26563 ||| ,
CDK2  ||| S:26563 E:26568 ||| NNP
( ||| S:26568 E:26569 ||| -LRB-
Santo  ||| S:26569 E:26575 ||| NNP
Cruz  ||| S:26575 E:26590 ||| NNP
Biotechnology  ||| S:26590 E:26604 ||| NNP
sc-163 ||| S:26604 E:26610 ||| NNP
,  ||| S:26610 E:26612 ||| ,
2  ||| S:26612 E:26614 ||| CD
ug  ||| S:26614 E:26617 ||| NN
per  ||| S:26617 E:26621 ||| IN
immunoprecipitation ||| S:26621 E:26640 ||| NN
,  ||| S:26640 E:26642 ||| ,
1 ||| S:26642 E:26643 ||| CD
: ||| S:26643 E:26644 ||| :
500  ||| S:26644 E:26658 ||| CD
for  ||| S:26658 E:26662 ||| IN
immunoblotting ||| S:26662 E:26676 ||| CD
) ||| S:26676 E:26677 ||| -RRB-
,  ||| S:26677 E:26679 ||| ,
Tubulin  ||| S:26679 E:26687 ||| NNP
( ||| S:26687 E:26688 ||| -LRB-
Sigma  ||| S:26688 E:26694 ||| NNP
T5168 ||| S:26694 E:26699 ||| NNP
,  ||| S:26699 E:26701 ||| ,
1 ||| S:26701 E:26702 ||| CD
: ||| S:26702 E:26703 ||| :
2000  ||| S:26703 E:26708 ||| CD
for  ||| S:26708 E:26722 ||| IN
immunoblotting ||| S:26722 E:26736 ||| CD
) ||| S:26736 E:26737 ||| -RRB-
.  ||| S:26737 E:26767 ||| .
Tissue  ||| S:26767 E:26774 ||| NN
culture  ||| S:26774 E:26792 ||| NN
LNCaP-FGC  ||| S:26792 E:26802 ||| JJ
cells  ||| S:26802 E:26808 ||| NNS
were  ||| S:26808 E:26813 ||| VBD
obtained  ||| S:26813 E:26822 ||| VBN
from  ||| S:26822 E:26827 ||| IN
ATCC  ||| S:26827 E:26832 ||| NNP
( ||| S:26832 E:26833 ||| -LRB-
order  ||| S:26833 E:26839 ||| NN
number  ||| S:26839 E:26856 ||| NN
CRL-10995 ||| S:26856 E:26865 ||| CD
)  ||| S:26865 E:26867 ||| -RRB-
and  ||| S:26867 E:26871 ||| CC
maintained  ||| S:26871 E:26882 ||| VBN
in  ||| S:26882 E:26885 ||| IN
RPMI  ||| S:26885 E:26890 ||| NNP
supplemented  ||| S:26890 E:26903 ||| NN
with  ||| S:26903 E:26908 ||| IN
10 ||| S:26908 E:26910 ||| CD
%  ||| S:26910 E:26922 ||| NN
FBS  ||| S:26922 E:26926 ||| NNP
as  ||| S:26926 E:26929 ||| RB
described  ||| S:26929 E:26939 ||| VBN
[  ||| S:26939 E:26941 ||| -LRB-
46  ||| S:26941 E:26944 ||| CD
]  ||| S:26944 E:26946 ||| -RRB-
.  ||| S:26946 E:26948 ||| .
We  ||| S:26948 E:26951 ||| PRP
noticed  ||| S:26951 E:26959 ||| VBD
that  ||| S:26959 E:26964 ||| DT
LNCaP  ||| S:26964 E:26970 ||| JJ
cells  ||| S:26970 E:26976 ||| NNS
at  ||| S:26976 E:26989 ||| IN
low  ||| S:26989 E:26993 ||| JJ
density  ||| S:26993 E:27001 ||| NNS
grow  ||| S:27001 E:27006 ||| VBP
best  ||| S:27006 E:27011 ||| RB
on  ||| S:27011 E:27014 ||| IN
15  ||| S:27014 E:27017 ||| CD
cm  ||| S:27017 E:27020 ||| JJ
Falcon  ||| S:27020 E:27027 ||| NNP
3025  ||| S:27027 E:27032 ||| CD
tissue  ||| S:27032 E:27039 ||| NN
culture  ||| S:27039 E:27057 ||| NN
dishes  ||| S:27057 E:27064 ||| NNS
and  ||| S:27064 E:27068 ||| CC
that  ||| S:27068 E:27073 ||| IN
the  ||| S:27073 E:27077 ||| DT
effects  ||| S:27077 E:27085 ||| NNS
of  ||| S:27085 E:27088 ||| IN
SKP2  ||| S:27088 E:27093 ||| CD
overexpression  ||| S:27093 E:27108 ||| NNS
were  ||| S:27108 E:27123 ||| VBD
most  ||| S:27123 E:27128 ||| RBS
pronounced  ||| S:27128 E:27139 ||| JJ
when  ||| S:27139 E:27144 ||| WRB
cells  ||| S:27144 E:27150 ||| NNS
were  ||| S:27150 E:27155 ||| VBD
cultured  ||| S:27155 E:27164 ||| VBN
on  ||| S:27164 E:27167 ||| IN
these  ||| S:27167 E:27173 ||| DT
dishes  ||| S:27173 E:27190 ||| NNS
( ||| S:27190 E:27191 ||| -LRB-
data  ||| S:27191 E:27196 ||| NNS
not  ||| S:27196 E:27200 ||| RB
shown ||| S:27200 E:27205 ||| VBN
) ||| S:27205 E:27206 ||| -RRB-
.  ||| S:27206 E:27236 ||| .
Adenoviruses  ||| S:27236 E:27259 ||| NNP
For  ||| S:27259 E:27263 ||| IN
production  ||| S:27263 E:27274 ||| NN
of  ||| S:27274 E:27277 ||| IN
adenoviruses ||| S:27277 E:27289 ||| NN
,  ||| S:27289 E:27291 ||| ,
the  ||| S:27291 E:27295 ||| DT
ADEASY  ||| S:27295 E:27302 ||| NNP
system  ||| S:27302 E:27309 ||| NN
was  ||| S:27309 E:27323 ||| VBD
used  ||| S:27323 E:27328 ||| VBN
( ||| S:27328 E:27329 ||| -LRB-
generously  ||| S:27329 E:27340 ||| RB
provided  ||| S:27340 E:27349 ||| VBN
by  ||| S:27349 E:27352 ||| IN
B.  ||| S:27352 E:27355 ||| NNP
Vogelstein ||| S:27355 E:27365 ||| NNP
) ||| S:27365 E:27366 ||| -RRB-
.  ||| S:27366 E:27368 ||| .
The  ||| S:27368 E:27372 ||| DT
complete  ||| S:27372 E:27391 ||| JJ
SKP2  ||| S:27391 E:27396 ||| NNP
cDNA  ||| S:27396 E:27401 ||| NNP
or  ||| S:27401 E:27404 ||| CC
a  ||| S:27404 E:27406 ||| DT
mutant  ||| S:27406 E:27413 ||| NN
lacking  ||| S:27413 E:27421 ||| VBG
the  ||| S:27421 E:27425 ||| DT
F-box  ||| S:27425 E:27431 ||| JJ
( ||| S:27431 E:27432 ||| -LRB-
SKP2-ΔF ||| S:27432 E:27439 ||| NNP
)  ||| S:27439 E:27441 ||| -RRB-
were  ||| S:27441 E:27456 ||| VBD
cloned  ||| S:27456 E:27463 ||| VBN
into  ||| S:27463 E:27468 ||| IN
a  ||| S:27468 E:27470 ||| DT
modified  ||| S:27470 E:27479 ||| JJ
pcDNA3  ||| S:27479 E:27486 ||| NN
plasmid  ||| S:27486 E:27494 ||| VBZ
providing  ||| S:27494 E:27504 ||| VBG
an  ||| S:27504 E:27517 ||| DT
N-terminal  ||| S:27517 E:27528 ||| JJ
Myc  ||| S:27528 E:27532 ||| JJ
epitope  ||| S:27532 E:27540 ||| JJ
tag  ||| S:27540 E:27544 ||| NN
and  ||| S:27544 E:27548 ||| CC
the  ||| S:27548 E:27552 ||| DT
human  ||| S:27552 E:27558 ||| JJ
lamin  ||| S:27558 E:27564 ||| JJ
B  ||| S:27564 E:27566 ||| NN
leader  ||| S:27566 E:27583 ||| NN
sequence ||| S:27583 E:27591 ||| NN
.  ||| S:27591 E:27593 ||| .
The  ||| S:27593 E:27597 ||| DT
lamin  ||| S:27597 E:27603 ||| JJ
B-SKP2  ||| S:27603 E:27610 ||| CD
cassette  ||| S:27610 E:27619 ||| NN
was  ||| S:27619 E:27623 ||| VBD
removed  ||| S:27623 E:27631 ||| VBN
and  ||| S:27631 E:27645 ||| CC
cloned  ||| S:27645 E:27652 ||| VBN
into  ||| S:27652 E:27657 ||| IN
the  ||| S:27657 E:27661 ||| DT
pADTRACK1  ||| S:27661 E:27671 ||| JJ
shuttle  ||| S:27671 E:27679 ||| NN
vector ||| S:27679 E:27685 ||| NN
.  ||| S:27685 E:27687 ||| .
The  ||| S:27687 E:27691 ||| DT
resulting  ||| S:27691 E:27711 ||| VBG
plasmid  ||| S:27711 E:27719 ||| NNS
was  ||| S:27719 E:27723 ||| VBD
transformed  ||| S:27723 E:27735 ||| VBN
into  ||| S:27735 E:27740 ||| IN
BJ-ADEASY  ||| S:27740 E:27750 ||| JJ
cells  ||| S:27750 E:27756 ||| NNS
by  ||| S:27756 E:27769 ||| IN
electroporation ||| S:27769 E:27784 ||| NN
.  ||| S:27784 E:27786 ||| .
Adenoviral  ||| S:27786 E:27797 ||| NNP
DNA  ||| S:27797 E:27801 ||| NNP
generated  ||| S:27801 E:27811 ||| VBD
by  ||| S:27811 E:27824 ||| IN
recombination  ||| S:27824 E:27838 ||| NN
in  ||| S:27838 E:27841 ||| IN
BJ-ADEASY  ||| S:27841 E:27851 ||| JJ
cells  ||| S:27851 E:27857 ||| NNS
was  ||| S:27857 E:27861 ||| VBD
isolated ||| S:27861 E:27869 ||| VBN
.  ||| S:27869 E:27881 ||| .
Recombinant  ||| S:27881 E:27893 ||| JJ
adenoviral  ||| S:27893 E:27904 ||| JJ
DNA  ||| S:27904 E:27908 ||| NN
was  ||| S:27908 E:27912 ||| VBD
transfected  ||| S:27912 E:27924 ||| VBN
into  ||| S:27924 E:27929 ||| IN
293  ||| S:27929 E:27933 ||| CD
cells  ||| S:27933 E:27949 ||| NNS
using  ||| S:27949 E:27955 ||| VBG
standard  ||| S:27955 E:27964 ||| JJ
calcium  ||| S:27964 E:27972 ||| NN
phosphate  ||| S:27972 E:27982 ||| NN
procedures ||| S:27982 E:27992 ||| NNS
.  ||| S:27992 E:27994 ||| .
Virus  ||| S:27994 E:28000 ||| NN
was  ||| S:28000 E:28014 ||| VBD
harvested  ||| S:28014 E:28024 ||| VBN
from  ||| S:28024 E:28029 ||| IN
cells  ||| S:28029 E:28035 ||| NNS
and  ||| S:28035 E:28039 ||| CC
amplified  ||| S:28039 E:28049 ||| VBN
by  ||| S:28049 E:28052 ||| IN
infection  ||| S:28052 E:28062 ||| NN
of  ||| S:28062 E:28065 ||| IN
293  ||| S:28065 E:28079 ||| CD
cells ||| S:28079 E:28084 ||| NNS
.  ||| S:28084 E:28086 ||| .
Amplified  ||| S:28086 E:28096 ||| JJ
virus  ||| S:28096 E:28102 ||| NN
was  ||| S:28102 E:28106 ||| VBD
purified  ||| S:28106 E:28115 ||| VBN
by  ||| S:28115 E:28118 ||| IN
cesium  ||| S:28118 E:28125 ||| FW
chloride  ||| S:28125 E:28144 ||| FW
gradient  ||| S:28144 E:28153 ||| FW
centrifugation  ||| S:28153 E:28168 ||| FW
and  ||| S:28168 E:28172 ||| CC
tittered ||| S:28172 E:28180 ||| NN
.  ||| S:28180 E:28182 ||| .
An  ||| S:28182 E:28185 ||| DT
approximate  ||| S:28185 E:28207 ||| JJ
multiplicity  ||| S:28207 E:28220 ||| NN
of  ||| S:28220 E:28223 ||| IN
infection  ||| S:28223 E:28233 ||| NN
of  ||| S:28233 E:28236 ||| IN
100  ||| S:28236 E:28240 ||| CD
was  ||| S:28240 E:28244 ||| VBD
used  ||| S:28244 E:28249 ||| VBN
throughout ||| S:28249 E:28259 ||| IN
.  ||| S:28259 E:28289 ||| .
Immunological  ||| S:28289 E:28303 ||| JJ
techniques  ||| S:28303 E:28324 ||| NNS
Cell  ||| S:28324 E:28329 ||| JJ
lysates  ||| S:28329 E:28337 ||| NN
for  ||| S:28337 E:28341 ||| IN
immunoblotting  ||| S:28341 E:28356 ||| NN
were  ||| S:28356 E:28361 ||| VBD
prepared  ||| S:28361 E:28370 ||| VBN
by  ||| S:28370 E:28383 ||| IN
scraping  ||| S:28383 E:28392 ||| JJ
cells  ||| S:28392 E:28398 ||| NNS
into  ||| S:28398 E:28403 ||| IN
heated  ||| S:28403 E:28410 ||| JJ
2  ||| S:28410 E:28412 ||| CD
×  ||| S:28412 E:28414 ||| CD
SDS  ||| S:28414 E:28418 ||| JJ
sample  ||| S:28418 E:28425 ||| NN
buffer ||| S:28425 E:28431 ||| NN
.  ||| S:28431 E:28433 ||| .
Samples  ||| S:28433 E:28451 ||| NNS
were  ||| S:28451 E:28456 ||| VBD
boiled  ||| S:28456 E:28463 ||| VBN
for  ||| S:28463 E:28467 ||| IN
10  ||| S:28467 E:28470 ||| CD
min ||| S:28470 E:28473 ||| NN
,  ||| S:28473 E:28475 ||| ,
centrifuged ||| S:28475 E:28486 ||| NN
,  ||| S:28486 E:28488 ||| ,
and  ||| S:28488 E:28492 ||| CC
separated  ||| S:28492 E:28502 ||| VBN
by  ||| S:28502 E:28505 ||| IN
SDS  ||| S:28505 E:28519 ||| NNP
gel  ||| S:28519 E:28523 ||| FW
electrophoresis ||| S:28523 E:28538 ||| FW
.  ||| S:28538 E:28540 ||| .
Proteins  ||| S:28540 E:28549 ||| NNS
were  ||| S:28549 E:28554 ||| VBD
transferred  ||| S:28554 E:28566 ||| VBN
onto  ||| S:28566 E:28581 ||| IN
Immobilon  ||| S:28581 E:28591 ||| NNP
P  ||| S:28591 E:28593 ||| NN
membrane  ||| S:28593 E:28602 ||| NNS
( ||| S:28602 E:28603 ||| -LRB-
Millipore ||| S:28603 E:28612 ||| NNP
) ||| S:28612 E:28613 ||| -RRB-
,  ||| S:28613 E:28615 ||| ,
blocked  ||| S:28615 E:28623 ||| VBN
in  ||| S:28623 E:28626 ||| IN
5  ||| S:28626 E:28628 ||| CD
%  ||| S:28628 E:28630 ||| NN
nonfat  ||| S:28630 E:28647 ||| VBZ
dry  ||| S:28647 E:28651 ||| JJ
milk  ||| S:28651 E:28656 ||| NN
dissolved  ||| S:28656 E:28666 ||| VBN
in  ||| S:28666 E:28669 ||| IN
tris-buffered  ||| S:28669 E:28683 ||| JJ
saline  ||| S:28683 E:28690 ||| NN
/  ||| S:28690 E:28692 ||| CD
0.1  ||| S:28692 E:28696 ||| CD
%  ||| S:28696 E:28698 ||| NN
Tween  ||| S:28698 E:28714 ||| NNP
and  ||| S:28714 E:28718 ||| CC
probed  ||| S:28718 E:28725 ||| NN
with  ||| S:28725 E:28730 ||| IN
the  ||| S:28730 E:28734 ||| DT
various  ||| S:28734 E:28742 ||| JJ
antibodies ||| S:28742 E:28752 ||| NNS
.  ||| S:28752 E:28764 ||| .
Cell  ||| S:28764 E:28769 ||| NN
lysates  ||| S:28769 E:28777 ||| NN
for  ||| S:28777 E:28781 ||| IN
immunoprecipitation  ||| S:28781 E:28801 ||| NN
were  ||| S:28801 E:28806 ||| VBD
prepared  ||| S:28806 E:28815 ||| VBN
in  ||| S:28815 E:28828 ||| IN
IP-LB  ||| S:28828 E:28834 ||| NNP
( ||| S:28834 E:28835 ||| -LRB-
25  ||| S:28835 E:28838 ||| CD
mM  ||| S:28838 E:28841 ||| JJ
Tris ||| S:28841 E:28845 ||| NNP
,  ||| S:28845 E:28847 ||| ,
pH  ||| S:28847 E:28850 ||| JJ
7.4 ||| S:28850 E:28853 ||| CD
,  ||| S:28853 E:28855 ||| ,
150  ||| S:28855 E:28859 ||| CD
mM  ||| S:28859 E:28862 ||| JJ
NaCl ||| S:28862 E:28866 ||| NN
,  ||| S:28866 E:28868 ||| ,
0.5  ||| S:28868 E:28872 ||| CD
%  ||| S:28872 E:28874 ||| NN
Triton  ||| S:28874 E:28891 ||| NNP
X100 ||| S:28891 E:28895 ||| NNP
,  ||| S:28895 E:28897 ||| ,
10  ||| S:28897 E:28900 ||| CD
μg ||| S:28900 E:28902 ||| CD
/ ||| S:28902 E:28903 ||| CD
ml  ||| S:28903 E:28906 ||| JJ
leupeptin ||| S:28906 E:28915 ||| NN
,  ||| S:28915 E:28917 ||| ,
10  ||| S:28917 E:28920 ||| CD
μg ||| S:28920 E:28922 ||| CD
/ ||| S:28922 E:28923 ||| CD
ml  ||| S:28923 E:28926 ||| JJ
pepstatin ||| S:28926 E:28935 ||| NN
,  ||| S:28935 E:28937 ||| ,
1  ||| S:28937 E:28939 ||| CD
mM  ||| S:28939 E:28942 ||| JJ
PMSF ||| S:28942 E:28946 ||| NNP
,  ||| S:28946 E:28958 ||| ,
17  ||| S:28958 E:28961 ||| CD
μg ||| S:28961 E:28963 ||| CD
/ ||| S:28963 E:28964 ||| CD
ml  ||| S:28964 E:28967 ||| CD
aprotinin ||| S:28967 E:28976 ||| CD
) ||| S:28976 E:28977 ||| -RRB-
.  ||| S:28977 E:28979 ||| .
Cells  ||| S:28979 E:28985 ||| NNS
were  ||| S:28985 E:28990 ||| VBD
scraped  ||| S:28990 E:28998 ||| VBN
into  ||| S:28998 E:29003 ||| IN
IP-LB  ||| S:29003 E:29009 ||| JJ
and  ||| S:29009 E:29023 ||| CC
incubated  ||| S:29023 E:29033 ||| NN
on  ||| S:29033 E:29036 ||| IN
ice  ||| S:29036 E:29040 ||| NN
for  ||| S:29040 E:29044 ||| IN
30  ||| S:29044 E:29047 ||| CD
min ||| S:29047 E:29050 ||| NNS
.  ||| S:29050 E:29052 ||| .
Cell  ||| S:29052 E:29057 ||| NN
lysate  ||| S:29057 E:29064 ||| NNS
was  ||| S:29064 E:29068 ||| VBD
cleared  ||| S:29068 E:29076 ||| VBN
by  ||| S:29076 E:29089 ||| IN
centrifugation  ||| S:29089 E:29104 ||| NN
and  ||| S:29104 E:29108 ||| CC
the  ||| S:29108 E:29112 ||| DT
supernatant  ||| S:29112 E:29124 ||| NN
was  ||| S:29124 E:29128 ||| VBD
incubated  ||| S:29128 E:29138 ||| VBN
with  ||| S:29138 E:29153 ||| IN
various  ||| S:29153 E:29161 ||| JJ
antibodies  ||| S:29161 E:29172 ||| NNS
( ||| S:29172 E:29173 ||| -LRB-
see  ||| S:29173 E:29177 ||| VB
plasmid  ||| S:29177 E:29185 ||| NNS
and  ||| S:29185 E:29189 ||| CC
reagents  ||| S:29189 E:29198 ||| JJ
section  ||| S:29198 E:29216 ||| NN
above ||| S:29216 E:29221 ||| IN
) ||| S:29221 E:29222 ||| -RRB-
.  ||| S:29222 E:29224 ||| .
Immunocomplexes  ||| S:29224 E:29240 ||| NNP
were  ||| S:29240 E:29245 ||| VBD
collected  ||| S:29245 E:29255 ||| VBN
on  ||| S:29255 E:29258 ||| IN
protein  ||| S:29258 E:29266 ||| NN
A  ||| S:29266 E:29268 ||| NN
or  ||| S:29268 E:29271 ||| CC
G  ||| S:29271 E:29283 ||| NNP
beads ||| S:29283 E:29288 ||| NN
,  ||| S:29288 E:29290 ||| ,
washed  ||| S:29290 E:29297 ||| VBD
five  ||| S:29297 E:29302 ||| CD
times  ||| S:29302 E:29308 ||| NNS
in  ||| S:29308 E:29311 ||| IN
IP-LB  ||| S:29311 E:29317 ||| JJ
for  ||| S:29317 E:29321 ||| IN
5  ||| S:29321 E:29323 ||| CD
minutes  ||| S:29323 E:29331 ||| NNS
each ||| S:29331 E:29335 ||| DT
,  ||| S:29335 E:29347 ||| ,
dissolved  ||| S:29347 E:29357 ||| VBN
in  ||| S:29357 E:29360 ||| IN
2  ||| S:29360 E:29362 ||| CD
×  ||| S:29362 E:29364 ||| CD
SDS  ||| S:29364 E:29368 ||| JJ
sample  ||| S:29368 E:29375 ||| NN
buffer ||| S:29375 E:29381 ||| NN
,  ||| S:29381 E:29383 ||| ,
and  ||| S:29383 E:29387 ||| CC
separated  ||| S:29387 E:29397 ||| VBN
by  ||| S:29397 E:29400 ||| IN
SDS  ||| S:29400 E:29414 ||| NNP
gel  ||| S:29414 E:29418 ||| FW
electrophoresis ||| S:29418 E:29433 ||| FW
.  ||| S:29433 E:29445 ||| .
For  ||| S:29445 E:29449 ||| IN
immunofluorescence  ||| S:29449 E:29468 ||| JJ
staining ||| S:29468 E:29476 ||| NN
,  ||| S:29476 E:29478 ||| ,
LNCaP  ||| S:29478 E:29484 ||| JJ
cells  ||| S:29484 E:29490 ||| NNS
were  ||| S:29490 E:29505 ||| VBD
plated  ||| S:29505 E:29512 ||| VBN
onto  ||| S:29512 E:29517 ||| IN
poly-lysine  ||| S:29517 E:29529 ||| JJ
coated  ||| S:29529 E:29536 ||| JJ
glass  ||| S:29536 E:29542 ||| NN
coverslips ||| S:29542 E:29552 ||| NN
.  ||| S:29552 E:29554 ||| .
Cells  ||| S:29554 E:29570 ||| NNS
were  ||| S:29570 E:29575 ||| VBD
fixed  ||| S:29575 E:29581 ||| VBN
in  ||| S:29581 E:29584 ||| IN
4  ||| S:29584 E:29586 ||| CD
%  ||| S:29586 E:29588 ||| NN
para-formaldehyde  ||| S:29588 E:29606 ||| NN
in  ||| S:29606 E:29609 ||| IN
PBS  ||| S:29609 E:29613 ||| NNP
and  ||| S:29613 E:29627 ||| CC
permeabilized  ||| S:29627 E:29641 ||| NN
by  ||| S:29641 E:29644 ||| IN
washing  ||| S:29644 E:29652 ||| VBG
in  ||| S:29652 E:29655 ||| IN
PBS  ||| S:29655 E:29659 ||| NNP
/  ||| S:29659 E:29661 ||| CD
0.1  ||| S:29661 E:29665 ||| CD
%  ||| S:29665 E:29667 ||| NN
Triton  ||| S:29667 E:29674 ||| NNP
X100 ||| S:29674 E:29678 ||| NNP
.  ||| S:29678 E:29690 ||| .
Coverslips  ||| S:29690 E:29701 ||| NNP
were  ||| S:29701 E:29706 ||| VBD
blocked  ||| S:29706 E:29714 ||| VBN
in  ||| S:29714 E:29717 ||| IN
PBS  ||| S:29717 E:29721 ||| NNP
/  ||| S:29721 E:29723 ||| CD
0.1  ||| S:29723 E:29727 ||| CD
%  ||| S:29727 E:29729 ||| NN
Triton  ||| S:29729 E:29736 ||| NNP
X100  ||| S:29736 E:29751 ||| NNP
containing  ||| S:29751 E:29762 ||| VBG
5  ||| S:29762 E:29764 ||| CD
%  ||| S:29764 E:29766 ||| NN
nonfat  ||| S:29766 E:29773 ||| VBZ
dry  ||| S:29773 E:29777 ||| JJ
milk  ||| S:29777 E:29782 ||| NN
for  ||| S:29782 E:29786 ||| IN
45  ||| S:29786 E:29789 ||| CD
min ||| S:29789 E:29792 ||| NNS
.  ||| S:29792 E:29794 ||| .
Incubation  ||| S:29794 E:29815 ||| NNP
with  ||| S:29815 E:29820 ||| IN
primary  ||| S:29820 E:29828 ||| JJ
and  ||| S:29828 E:29832 ||| CC
secondary  ||| S:29832 E:29842 ||| JJ
antibodies  ||| S:29842 E:29853 ||| NNS
was  ||| S:29853 E:29857 ||| VBD
in  ||| S:29857 E:29860 ||| IN
the  ||| S:29860 E:29864 ||| DT
same  ||| S:29864 E:29879 ||| JJ
buffer  ||| S:29879 E:29886 ||| NN
for  ||| S:29886 E:29890 ||| IN
45  ||| S:29890 E:29893 ||| CD
min  ||| S:29893 E:29897 ||| CD
each ||| S:29897 E:29901 ||| DT
.  ||| S:29901 E:29903 ||| .
After  ||| S:29903 E:29909 ||| IN
antibody  ||| S:29909 E:29918 ||| NN
incubations ||| S:29918 E:29929 ||| NN
,  ||| S:29929 E:29941 ||| ,
coverslips  ||| S:29941 E:29952 ||| NN
were  ||| S:29952 E:29957 ||| VBD
washed  ||| S:29957 E:29964 ||| VBN
five  ||| S:29964 E:29969 ||| CD
times  ||| S:29969 E:29975 ||| NNS
in  ||| S:29975 E:29978 ||| IN
PBS  ||| S:29978 E:29982 ||| NNP
/  ||| S:29982 E:29984 ||| CD
0.1  ||| S:29984 E:29988 ||| CD
%  ||| S:29988 E:29990 ||| NN
Triton  ||| S:29990 E:30007 ||| NNP
X100 ||| S:30007 E:30011 ||| NNP
,  ||| S:30011 E:30013 ||| ,
followed  ||| S:30013 E:30022 ||| VBN
by  ||| S:30022 E:30025 ||| IN
mounting  ||| S:30025 E:30034 ||| VBG
on  ||| S:30034 E:30037 ||| IN
microscopy  ||| S:30037 E:30048 ||| JJ
slides ||| S:30048 E:30054 ||| NNS
.  ||| S:30054 E:30066 ||| .
Micrographs  ||| S:30066 E:30078 ||| NNP
were  ||| S:30078 E:30083 ||| VBD
taken  ||| S:30083 E:30089 ||| VBN
with  ||| S:30089 E:30094 ||| IN
a  ||| S:30094 E:30096 ||| DT
Spot  ||| S:30096 E:30101 ||| NNP
CCD  ||| S:30101 E:30105 ||| NNP
camera  ||| S:30105 E:30112 ||| NN
mounted  ||| S:30112 E:30120 ||| VBD
on  ||| S:30120 E:30133 ||| IN
a  ||| S:30133 E:30135 ||| DT
Nikon  ||| S:30135 E:30141 ||| NNP
E600  ||| S:30141 E:30146 ||| NNP
epifluorescence  ||| S:30146 E:30162 ||| JJ
microscope ||| S:30162 E:30172 ||| NN
.  ||| S:30172 E:30174 ||| .
Brightness  ||| S:30174 E:30185 ||| NNP
and  ||| S:30185 E:30199 ||| CC
contrast  ||| S:30199 E:30208 ||| NN
of  ||| S:30208 E:30211 ||| IN
the  ||| S:30211 E:30215 ||| DT
images  ||| S:30215 E:30222 ||| NNS
was  ||| S:30222 E:30226 ||| VBD
adjusted  ||| S:30226 E:30235 ||| VBN
in  ||| S:30235 E:30238 ||| IN
Adobe  ||| S:30238 E:30244 ||| NNP
Photoshop  ||| S:30244 E:30264 ||| NNP
5.0 ||| S:30264 E:30267 ||| NNP
.  ||| S:30267 E:30297 ||| .
Northern  ||| S:30297 E:30306 ||| NNP
blotting  ||| S:30306 E:30325 ||| VBD
Isolation  ||| S:30325 E:30335 ||| NNP
of  ||| S:30335 E:30338 ||| IN
total  ||| S:30338 E:30344 ||| JJ
cellular  ||| S:30344 E:30353 ||| JJ
RNA  ||| S:30353 E:30357 ||| NNP
using  ||| S:30357 E:30363 ||| VBG
a  ||| S:30363 E:30365 ||| DT
urea ||| S:30365 E:30369 ||| JJ
/ ||| S:30369 E:30370 ||| CD
LiCl  ||| S:30370 E:30385 ||| JJ
protocol  ||| S:30385 E:30394 ||| NN
and  ||| S:30394 E:30398 ||| CC
gel  ||| S:30398 E:30402 ||| JJ
electrophoresis  ||| S:30402 E:30418 ||| NN
was  ||| S:30418 E:30422 ||| VBD
performed  ||| S:30422 E:30432 ||| VBN
as  ||| S:30432 E:30445 ||| RB
described  ||| S:30445 E:30455 ||| VBN
previously  ||| S:30455 E:30466 ||| RB
[  ||| S:30466 E:30468 ||| -LRB-
65  ||| S:30468 E:30471 ||| CD
]  ||| S:30471 E:30473 ||| -RRB-
.  ||| S:30473 E:30475 ||| .
Gels  ||| S:30475 E:30480 ||| NNP
were  ||| S:30480 E:30485 ||| VBD
transferred  ||| S:30485 E:30497 ||| VBN
onto  ||| S:30497 E:30512 ||| IN
Amersham  ||| S:30512 E:30521 ||| NNP
Hybond  ||| S:30521 E:30528 ||| NNP
N+  ||| S:30528 E:30531 ||| NNP
nylon  ||| S:30531 E:30537 ||| VBD
membranes  ||| S:30537 E:30547 ||| VBN
in  ||| S:30547 E:30550 ||| IN
20  ||| S:30550 E:30553 ||| CD
×  ||| S:30553 E:30555 ||| CD
SSC  ||| S:30555 E:30559 ||| NNP
and  ||| S:30559 E:30573 ||| CC
prehybridized  ||| S:30573 E:30587 ||| NN
in  ||| S:30587 E:30590 ||| IN
4  ||| S:30590 E:30592 ||| CD
×  ||| S:30592 E:30594 ||| CD
SSC ||| S:30594 E:30597 ||| NNP
,  ||| S:30597 E:30599 ||| ,
1  ||| S:30599 E:30601 ||| CD
×  ||| S:30601 E:30603 ||| CD
Denhardt ||| S:30603 E:30611 ||| NNP
's  ||| S:30611 E:30614 ||| POS
solution ||| S:30614 E:30622 ||| NN
,  ||| S:30622 E:30624 ||| ,
0.5 ||| S:30624 E:30627 ||| CD
%  ||| S:30627 E:30639 ||| NN
SDS  ||| S:30639 E:30643 ||| NN
for  ||| S:30643 E:30647 ||| IN
2  ||| S:30647 E:30649 ||| CD
h  ||| S:30649 E:30651 ||| NN
at  ||| S:30651 E:30654 ||| IN
68°C ||| S:30654 E:30658 ||| CD
.  ||| S:30658 E:30660 ||| .
Complementary  ||| S:30660 E:30674 ||| JJ
DNA  ||| S:30674 E:30678 ||| NN
fragments  ||| S:30678 E:30688 ||| NNS
for  ||| S:30688 E:30702 ||| IN
SKP2 ||| S:30702 E:30706 ||| NNP
,  ||| S:30706 E:30708 ||| ,
p27 ||| S:30708 E:30711 ||| NNP
,  ||| S:30711 E:30713 ||| ,
and  ||| S:30713 E:30717 ||| CC
GAPDH  ||| S:30717 E:30723 ||| NNP
were  ||| S:30723 E:30728 ||| VBD
amplified  ||| S:30728 E:30738 ||| VBN
by  ||| S:30738 E:30741 ||| IN
PCR  ||| S:30741 E:30745 ||| NNP
and  ||| S:30745 E:30759 ||| CC
radiolabeled  ||| S:30759 E:30772 ||| NN
by  ||| S:30772 E:30775 ||| IN
random  ||| S:30775 E:30782 ||| JJ
priming ||| S:30782 E:30789 ||| NN
.  ||| S:30789 E:30791 ||| .
Filters  ||| S:30791 E:30799 ||| NNS
were  ||| S:30799 E:30804 ||| VBD
hybridized  ||| S:30804 E:30825 ||| VBN
for  ||| S:30825 E:30829 ||| IN
16  ||| S:30829 E:30832 ||| CD
h  ||| S:30832 E:30834 ||| NN
at  ||| S:30834 E:30837 ||| IN
68°C  ||| S:30837 E:30842 ||| NNP
followed  ||| S:30842 E:30851 ||| VBD
by  ||| S:30851 E:30854 ||| IN
washing  ||| S:30854 E:30862 ||| VBG
in  ||| S:30862 E:30865 ||| IN
2  ||| S:30865 E:30867 ||| CD
×  ||| S:30867 E:30869 ||| CD
SSC  ||| S:30869 E:30873 ||| NN
at  ||| S:30873 E:30876 ||| IN
68°C ||| S:30876 E:30880 ||| CD
.  ||| S:30880 E:30892 ||| .
Membranes  ||| S:30892 E:30902 ||| NNP
were  ||| S:30902 E:30907 ||| VBD
exposed  ||| S:30907 E:30915 ||| VBN
to  ||| S:30915 E:30918 ||| TO
X-ray  ||| S:30918 E:30924 ||| NN
film  ||| S:30924 E:30929 ||| NN
for  ||| S:30929 E:30933 ||| IN
2  ||| S:30933 E:30935 ||| CD
to  ||| S:30935 E:30938 ||| TO
12  ||| S:30938 E:30941 ||| CD
h  ||| S:30941 E:30943 ||| NNS
and  ||| S:30943 E:30957 ||| CC
scanned  ||| S:30957 E:30965 ||| NN
with  ||| S:30965 E:30970 ||| IN
a  ||| S:30970 E:30972 ||| DT
phosphoimager  ||| S:30972 E:30986 ||| NN
for  ||| S:30986 E:30990 ||| IN
signal  ||| S:30990 E:30997 ||| NN
quantitation ||| S:30997 E:31009 ||| NN
.  ||| S:31009 E:31039 ||| .
H1  ||| S:31039 E:31042 ||| FW
kinase  ||| S:31042 E:31049 ||| FW
assay  ||| S:31049 E:31065 ||| FW
Histone  ||| S:31065 E:31073 ||| NNP
1  ||| S:31073 E:31075 ||| CD
kinase  ||| S:31075 E:31082 ||| JJ
assays  ||| S:31082 E:31089 ||| NN
with  ||| S:31089 E:31094 ||| IN
cyclin  ||| S:31094 E:31101 ||| JJ
E  ||| S:31101 E:31103 ||| NN
or  ||| S:31103 E:31106 ||| CC
CDK2  ||| S:31106 E:31121 ||| CD
immunoprecipitates  ||| S:31121 E:31140 ||| NNS
were  ||| S:31140 E:31145 ||| VBD
performed  ||| S:31145 E:31155 ||| VBN
as  ||| S:31155 E:31158 ||| RB
described  ||| S:31158 E:31168 ||| VBN
[  ||| S:31168 E:31170 ||| -LRB-
65  ||| S:31170 E:31173 ||| CD
]  ||| S:31173 E:31185 ||| -RRB-
.  ||| S:31185 E:31215 ||| .
In  ||| S:31215 E:31218 ||| IN
vitroubiquitylation  ||| S:31218 E:31238 ||| FW
assay  ||| S:31238 E:31254 ||| FW
Cell  ||| S:31254 E:31259 ||| FW
lysates  ||| S:31259 E:31267 ||| FW
for  ||| S:31267 E:31271 ||| IN
ubiquitylation  ||| S:31271 E:31286 ||| JJ
assays  ||| S:31286 E:31293 ||| NN
were  ||| S:31293 E:31298 ||| VBD
prepared  ||| S:31298 E:31317 ||| VBN
by  ||| S:31317 E:31320 ||| IN
hypotonic  ||| S:31320 E:31330 ||| JJ
lysis  ||| S:31330 E:31336 ||| NN
on  ||| S:31336 E:31339 ||| IN
ice  ||| S:31339 E:31343 ||| NN
in  ||| S:31343 E:31346 ||| IN
20  ||| S:31346 E:31349 ||| CD
mM  ||| S:31349 E:31352 ||| JJ
Hepes  ||| S:31352 E:31358 ||| NNP
pH  ||| S:31358 E:31361 ||| NNP
7.5 ||| S:31361 E:31364 ||| CD
,  ||| S:31364 E:31366 ||| ,
15  ||| S:31366 E:31369 ||| CD
mM  ||| S:31369 E:31382 ||| JJ
MgCl  ||| S:31382 E:31398 ||| JJ
2  ||| S:31398 E:31400 ||| CD
,  ||| S:31400 E:31402 ||| ,
5  ||| S:31402 E:31404 ||| CD
mM  ||| S:31404 E:31407 ||| JJ
KCl ||| S:31407 E:31410 ||| NN
,  ||| S:31410 E:31412 ||| ,
1  ||| S:31412 E:31414 ||| CD
mM  ||| S:31414 E:31417 ||| JJ
DTT ||| S:31417 E:31420 ||| NNP
,  ||| S:31420 E:31422 ||| ,
10  ||| S:31422 E:31425 ||| CD
μg ||| S:31425 E:31427 ||| CD
/ ||| S:31427 E:31428 ||| CD
ml  ||| S:31428 E:31441 ||| JJ
leupeptin ||| S:31441 E:31450 ||| NN
,  ||| S:31450 E:31452 ||| ,
10  ||| S:31452 E:31455 ||| CD
μg ||| S:31455 E:31457 ||| CD
/ ||| S:31457 E:31458 ||| CD
ml  ||| S:31458 E:31461 ||| JJ
pepstatin ||| S:31461 E:31470 ||| NN
,  ||| S:31470 E:31472 ||| ,
1  ||| S:31472 E:31474 ||| CD
mM  ||| S:31474 E:31477 ||| JJ
PMSF ||| S:31477 E:31481 ||| NNP
,  ||| S:31481 E:31483 ||| ,
17  ||| S:31483 E:31486 ||| CD
μg ||| S:31486 E:31488 ||| CD
/ ||| S:31488 E:31489 ||| CD
ml  ||| S:31489 E:31502 ||| NNS
aprotinin  ||| S:31502 E:31512 ||| VBP
as  ||| S:31512 E:31515 ||| RB
described  ||| S:31515 E:31525 ||| VBN
previously  ||| S:31525 E:31536 ||| RB
[  ||| S:31536 E:31538 ||| -LRB-
30  ||| S:31538 E:31541 ||| CD
]  ||| S:31541 E:31543 ||| -RRB-
.  ||| S:31543 E:31545 ||| .
Lysates  ||| S:31545 E:31553 ||| NNP
were  ||| S:31553 E:31568 ||| VBD
cleared  ||| S:31568 E:31576 ||| VBN
by  ||| S:31576 E:31579 ||| IN
centrifugation  ||| S:31579 E:31594 ||| NN
and  ||| S:31594 E:31598 ||| CC
used  ||| S:31598 E:31603 ||| VBN
without  ||| S:31603 E:31611 ||| IN
prior  ||| S:31611 E:31627 ||| JJ
freezing ||| S:31627 E:31635 ||| NN
.  ||| S:31635 E:31637 ||| .
Radiolabeled  ||| S:31637 E:31650 ||| JJ
wildtype  ||| S:31650 E:31659 ||| NN
and  ||| S:31659 E:31663 ||| CC
T178A  ||| S:31663 E:31669 ||| CD
point  ||| S:31669 E:31675 ||| NN
mutant  ||| S:31675 E:31692 ||| VBD
p27  ||| S:31692 E:31696 ||| NNP
were  ||| S:31696 E:31701 ||| VBD
produced  ||| S:31701 E:31710 ||| VBN
by  ||| S:31710 E:31713 ||| IN
combined  ||| S:31713 E:31733 ||| VBN
in  ||| S:31733 E:31736 ||| IN
vitro  ||| S:31736 E:31742 ||| JJ
transcription  ||| S:31742 E:31756 ||| NN
and  ||| S:31756 E:31770 ||| CC
translation  ||| S:31770 E:31782 ||| NN
in  ||| S:31782 E:31785 ||| IN
rabbit  ||| S:31785 E:31792 ||| FW
reticulocyte  ||| S:31792 E:31805 ||| FW
lysate  ||| S:31805 E:31812 ||| FW
containing  ||| S:31812 E:31833 ||| FW
35S-methionine ||| S:31833 E:31847 ||| FW
.  ||| S:31847 E:31849 ||| .
The  ||| S:31849 E:31864 ||| DT
in  ||| S:31864 E:31867 ||| IN
vitro  ||| S:31867 E:31873 ||| JJ
translated  ||| S:31873 E:31884 ||| JJ
proteins  ||| S:31884 E:31893 ||| NNS
were  ||| S:31893 E:31908 ||| VBD
incubated  ||| S:31908 E:31918 ||| CD
2  ||| S:31918 E:31920 ||| CD
h  ||| S:31920 E:31922 ||| NN
at  ||| S:31922 E:31925 ||| IN
30°C  ||| S:31925 E:31930 ||| CD
in  ||| S:31930 E:31933 ||| IN
the  ||| S:31933 E:31937 ||| DT
presence  ||| S:31937 E:31946 ||| NN
of  ||| S:31946 E:31949 ||| IN
1  ||| S:31949 E:31951 ||| CD
mM  ||| S:31951 E:31954 ||| JJ
ATP  ||| S:31954 E:31958 ||| NN
with  ||| S:31958 E:31973 ||| IN
recombinant  ||| S:31973 E:31985 ||| JJ
cyclin  ||| S:31985 E:31992 ||| JJ
E  ||| S:31992 E:31994 ||| NN
/  ||| S:31994 E:31996 ||| CD
CDK2  ||| S:31996 E:32001 ||| CD
complexes  ||| S:32001 E:32011 ||| NNS
produced  ||| S:32011 E:32020 ||| VBN
from  ||| S:32020 E:32035 ||| IN
baculoviruses  ||| S:32035 E:32049 ||| NN
in  ||| S:32049 E:32052 ||| IN
insect  ||| S:32052 E:32059 ||| JJ
cells ||| S:32059 E:32064 ||| NNS
.  ||| S:32064 E:32066 ||| .
Aliquots  ||| S:32066 E:32075 ||| NNP
of  ||| S:32075 E:32078 ||| IN
phosphorylated  ||| S:32078 E:32103 ||| JJ
proteins  ||| S:32103 E:32112 ||| NNS
were  ||| S:32112 E:32117 ||| VBD
added  ||| S:32117 E:32123 ||| VBN
to  ||| S:32123 E:32126 ||| TO
a  ||| S:32126 E:32128 ||| DT
reaction  ||| S:32128 E:32137 ||| NN
containing  ||| S:32137 E:32148 ||| VBG
120  ||| S:32148 E:32152 ||| CD
μg  ||| S:32152 E:32155 ||| JJ
cell  ||| S:32155 E:32170 ||| NN
lysate ||| S:32170 E:32176 ||| NN
,  ||| S:32176 E:32178 ||| ,
recombinant  ||| S:32178 E:32190 ||| JJ
human  ||| S:32190 E:32196 ||| JJ
E1 ||| S:32196 E:32198 ||| NN
,  ||| S:32198 E:32200 ||| ,
0.25  ||| S:32200 E:32205 ||| CD
mg ||| S:32205 E:32207 ||| CD
/ ||| S:32207 E:32208 ||| CD
ml  ||| S:32208 E:32211 ||| JJ
ubiquitin ||| S:32211 E:32220 ||| NN
,  ||| S:32220 E:32222 ||| ,
1  ||| S:32222 E:32224 ||| CD
μM  ||| S:32224 E:32237 ||| JJ
ubiquitin  ||| S:32237 E:32247 ||| JJ
aldehyde ||| S:32247 E:32255 ||| NN
,  ||| S:32255 E:32257 ||| ,
1  ||| S:32257 E:32259 ||| CD
μM  ||| S:32259 E:32262 ||| JJ
okadaic  ||| S:32262 E:32270 ||| JJ
acid ||| S:32270 E:32274 ||| NN
,  ||| S:32274 E:32276 ||| ,
20  ||| S:32276 E:32279 ||| CD
μM  ||| S:32279 E:32282 ||| JJ
MG132 ||| S:32282 E:32287 ||| NN
,  ||| S:32287 E:32289 ||| ,
and  ||| S:32289 E:32303 ||| CC
ATP  ||| S:32303 E:32307 ||| NNP
regenerating  ||| S:32307 E:32320 ||| JJ
system  ||| S:32320 E:32327 ||| NN
( ||| S:32327 E:32328 ||| -LRB-
20  ||| S:32328 E:32331 ||| CD
mM  ||| S:32331 E:32334 ||| JJ
ATP ||| S:32334 E:32337 ||| NNP
,  ||| S:32337 E:32339 ||| ,
10  ||| S:32339 E:32342 ||| CD
mM  ||| S:32342 E:32345 ||| JJ
creatine  ||| S:32345 E:32364 ||| JJ
phosphate ||| S:32364 E:32373 ||| NN
,  ||| S:32373 E:32375 ||| ,
0.1  ||| S:32375 E:32379 ||| FW
μg ||| S:32379 E:32381 ||| FW
/ ||| S:32381 E:32382 ||| FW
ml  ||| S:32382 E:32385 ||| FW
creatine  ||| S:32385 E:32394 ||| FW
kinase ||| S:32394 E:32400 ||| FW
) ||| S:32400 E:32401 ||| -RRB-
.  ||| S:32401 E:32403 ||| .
After  ||| S:32403 E:32409 ||| IN
90  ||| S:32409 E:32412 ||| CD
min ||| S:32412 E:32415 ||| NN
,  ||| S:32415 E:32417 ||| ,
the  ||| S:32417 E:32431 ||| DT
reactions  ||| S:32431 E:32441 ||| NNS
were  ||| S:32441 E:32446 ||| VBD
stopped  ||| S:32446 E:32454 ||| VBN
by  ||| S:32454 E:32457 ||| IN
addition  ||| S:32457 E:32466 ||| NN
of  ||| S:32466 E:32469 ||| IN
SDS  ||| S:32469 E:32473 ||| NNP
sample  ||| S:32473 E:32480 ||| NN
buffer ||| S:32480 E:32486 ||| NN
,  ||| S:32486 E:32498 ||| ,
and  ||| S:32498 E:32502 ||| CC
reaction  ||| S:32502 E:32511 ||| NN
products  ||| S:32511 E:32520 ||| NNS
were  ||| S:32520 E:32525 ||| VBD
separated  ||| S:32525 E:32535 ||| VBN
by  ||| S:32535 E:32538 ||| IN
SDS  ||| S:32538 E:32542 ||| NNP
gel  ||| S:32542 E:32556 ||| NN
electrophoresis  ||| S:32556 E:32572 ||| NNS
and  ||| S:32572 E:32576 ||| CC
detected  ||| S:32576 E:32585 ||| VBN
by  ||| S:32585 E:32588 ||| IN
autoradiography ||| S:32588 E:32603 ||| NN
.  ||| S:32603 E:32636 ||| .
Abbreviations  ||| S:32636 E:32658 ||| NNP
SCF  ||| S:32658 E:32662 ||| NNP
=  ||| S:32662 E:32664 ||| SYM
SKP1 ||| S:32664 E:32668 ||| FW
/ ||| S:32668 E:32669 ||| FW
Cullin ||| S:32669 E:32675 ||| FW
/ ||| S:32675 E:32676 ||| FW
F-box  ||| S:32676 E:32682 ||| FW
protein  ||| S:32682 E:32690 ||| FW
complex  ||| S:32690 E:32706 ||| FW
UBC  ||| S:32706 E:32710 ||| FW
=  ||| S:32710 E:32712 ||| FW
Ubiquitin  ||| S:32712 E:32722 ||| FW
conjugating  ||| S:32722 E:32734 ||| FW
enzyme  ||| S:32734 E:32749 ||| FW
MIB  ||| S:32749 E:32753 ||| FW
=  ||| S:32753 E:32755 ||| FW
Mibolerone  ||| S:32755 E:32774 ||| FW
( ||| S:32774 E:32775 ||| -LRB-
7α-17α-dimethyl-19-nortestosterone ||| S:32775 E:32809 ||| NNP
)  ||| S:32809 E:32819 ||| -RRB-
SKP2  ||| S:32819 E:32824 ||| NNP
=  ||| S:32824 E:32826 ||| NNP
S  ||| S:32826 E:32828 ||| NNP
phase  ||| S:32828 E:32834 ||| NN
kinase  ||| S:32834 E:32841 ||| VBZ
associated  ||| S:32841 E:32852 ||| VBN
protein  ||| S:32852 E:32860 ||| NN
2  ||| S:32860 E:32870 ||| CD
CDK2  ||| S:32870 E:32875 ||| CD
=  ||| S:32875 E:32877 ||| SYM
cyclin-dependent  ||| S:32877 E:32894 ||| JJ
kinase  ||| S:32894 E:32901 ||| NN
2  ||| S:32901 E:32925 ||| CD
Authors ||| S:32925 E:32932 ||| NNP
'  ||| S:32932 E:32934 ||| POS
contributions  ||| S:32934 E:32956 ||| NNS
All  ||| S:32956 E:32960 ||| DT
experiments  ||| S:32960 E:32972 ||| NNS
reported  ||| S:32972 E:32981 ||| VBD
in  ||| S:32981 E:32984 ||| IN
this  ||| S:32984 E:32989 ||| DT
study  ||| S:32989 E:32995 ||| NN
were  ||| S:32995 E:33000 ||| VBD
performed  ||| S:33000 E:33010 ||| VBN
by  ||| S:33010 E:33021 ||| IN
L-F ||| S:33021 E:33024 ||| JJ
.  ||| S:33024 E:33026 ||| .
L.  ||| S:33026 E:33029 ||| NNP
with  ||| S:33029 E:33034 ||| IN
the  ||| S:33034 E:33038 ||| DT
following  ||| S:33038 E:33048 ||| JJ
exceptions ||| S:33048 E:33058 ||| NNS
:  ||| S:33058 E:33060 ||| :
H.S.  ||| S:33060 E:33065 ||| NNP
prepared  ||| S:33065 E:33074 ||| VBD
the  ||| S:33074 E:33086 ||| DT
SKP2-ΔF  ||| S:33086 E:33094 ||| JJ
mutant ||| S:33094 E:33100 ||| NN
,  ||| S:33100 E:33102 ||| ,
SKP2  ||| S:33102 E:33107 ||| CD
adenoviruses ||| S:33107 E:33119 ||| NN
,  ||| S:33119 E:33121 ||| ,
and  ||| S:33121 E:33125 ||| CC
provided  ||| S:33125 E:33134 ||| VBD
initial  ||| S:33134 E:33150 ||| JJ
evidence  ||| S:33150 E:33159 ||| NN
for  ||| S:33159 E:33163 ||| IN
p27  ||| S:33163 E:33167 ||| CD
upregulation  ||| S:33167 E:33180 ||| NN
by  ||| S:33180 E:33183 ||| IN
MIB ||| S:33183 E:33186 ||| NNP
.  ||| S:33186 E:33188 ||| .
D.A.W.  ||| S:33188 E:33195 ||| NNP
performed  ||| S:33195 E:33205 ||| VBD
the  ||| S:33205 E:33217 ||| DT
experiments  ||| S:33217 E:33229 ||| NNS
shown  ||| S:33229 E:33235 ||| VBN
in  ||| S:33235 E:33238 ||| IN
Fig.  ||| S:33238 E:33243 ||| CD
5Band  ||| S:33243 E:33249 ||| CD
5C ||| S:33249 E:33251 ||| CD
,  ||| S:33251 E:33253 ||| ,
conceived  ||| S:33253 E:33263 ||| VBD
the  ||| S:33263 E:33267 ||| DT
study ||| S:33267 E:33272 ||| NN
,  ||| S:33272 E:33282 ||| ,
and  ||| S:33282 E:33286 ||| CC
participated  ||| S:33286 E:33299 ||| VBD
in  ||| S:33299 E:33302 ||| IN
its  ||| S:33302 E:33306 ||| PRP$
design  ||| S:33306 E:33313 ||| NN
and  ||| S:33313 E:33317 ||| CC
coordination ||| S:33317 E:33329 ||| NN
.  ||| S:33329 E:33331 ||| .
All  ||| S:33331 E:33343 ||| DT
authors  ||| S:33343 E:33351 ||| NNS
read  ||| S:33351 E:33356 ||| VBP
and  ||| S:33356 E:33360 ||| CC
approved  ||| S:33360 E:33369 ||| VBD
the  ||| S:33369 E:33373 ||| DT
final  ||| S:33373 E:33379 ||| JJ
manuscript ||| S:33379 E:33389 ||| NN
.  ||| S:33389 E:33406 ||| .
